<SEC-DOCUMENT>0001171843-21-002394.txt : 20210408
<SEC-HEADER>0001171843-21-002394.hdr.sgml : 20210408
<ACCEPTANCE-DATETIME>20210408165010
ACCESSION NUMBER:		0001171843-21-002394
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20210518
FILED AS OF DATE:		20210408
DATE AS OF CHANGE:		20210408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARVARD BIOSCIENCE INC
		CENTRAL INDEX KEY:			0001123494
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				043306140
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33957
		FILM NUMBER:		21815365

	BUSINESS ADDRESS:	
		STREET 1:		84 OCTOBER HILL RD
		CITY:			HOLLISTON
		STATE:			MA
		ZIP:			01746
		BUSINESS PHONE:		5088938999

	MAIL ADDRESS:	
		STREET 1:		84 OCTOBER HILL ROAD
		CITY:			HOLLISTON
		STATE:			MA
		ZIP:			01746
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>def14a_040521.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 14pt"><B>SCHEDULE 14A</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Rule 14a-101)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Information Required in Proxy Statement</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Schedule 14a Information</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Proxy Statement Pursuant to Section 14(a) of the Securities Exchange
Act of 1934</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Filed by the Registrant &#9746;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Filed by a Party other than the Registrant &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary Proxy Statement</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential, for Use of the
Commission Only (as permitted by Rule 14a-6(e)(2))</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional Materials</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material Under Rule
14a-12</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><B>Harvard Bioscience, Inc.</B></P>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No fee required.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fee computed on table below
per Exchange Act Rules 14a-6(i)(1) and 0-11.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title of each class
of securities to which transaction applies:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate number of
securities to which transaction applies:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"> (3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposed maximum aggregate
value of transaction:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fee paid:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fee
paid previously with preliminary materials:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of
its filing.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amount previously paid:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form, Schedule or Registration
Statement No.:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filing Party:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date Filed:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><img src="logo.jpg" alt=""></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center">HARVARD BIOSCIENCE, INC.<BR>
84 October Hill Road<BR>
Holliston, Massachusetts 01746-1371</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: right">April 8, 2021</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Dear Stockholder:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">You are cordially invited to attend the 2021
Annual Meeting of Stockholders of Harvard Bioscience, Inc. (the &ldquo;Annual Meeting&rdquo;) to be held on Tuesday, May 18, 2021
at 11:00 a.m. EDT. Due to the public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being
of our stockholders, the Annual Meeting will be held by virtual meeting only. You will not be able to attend the Annual Meeting
in person. To be admitted to the Annual Meeting at http://www.virtualshareholdermeeting.com/HBIO2021, you must enter the control
number found on your proxy card, voting instruction form or notice you previously received. You may vote during the Annual Meeting
by following the instructions available on the meeting website during the meeting. At the meeting, we will be voting on the matters
described in the accompanying proxy statement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We are using the Internet as our primary means
of furnishing the proxy materials to our stockholders. This process expedites the delivery of proxy materials, ensures materials
remain easily accessible to stockholders, and allows stockholders to receive clear instructions for receiving materials and voting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We are mailing the Notice of Internet Availability
of Proxy Materials to stockholders on or about April 8, 2021. The proxy statement and our Annual Report on Form 10-K for the year
ended December 31, 2020, are available at www.proxyvote.com.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Notice of Internet Availability of Proxy
Materials contains instructions for our stockholders&rsquo; use of this process, including how to access or receive copies of our
proxy statement and 2020 Annual Report and how to vote by Internet or mail. To the extent you receive a proxy card, such proxy
card will also contain instructions on how to vote, including the option to vote by telephone.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If you are unable to attend the meeting virtually,
it is still important that your shares be represented and voted. Therefore, regardless of the number of shares you own, PLEASE
VOTE THROUGH THE INTERNET, BY TELEPHONE OR BY MAIL. Any stockholder who attends the meeting virtually may vote through the meeting
website, even if he or she has already voted through the Internet, by telephone or by mail.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has fixed the close of
business on March 24, 2021 as the record date for determination of stockholders entitled to notice of, and to vote at, the Annual
Meeting and any adjournments or postponements thereof.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">YOUR VOTE IS IMPORTANT. OUR ANNUAL MEETING WILL
BE HELD AS A VIRTUAL MEETING. WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING VIRTUALLY, PLEASE CAST YOUR VOTE ONLINE, BY
TELEPHONE OR BY COMPLETING, DATING, SIGNING AND PROMPTLY RETURNING YOUR PROXY CARD OR VOTING INSTRUCTION CARD IN THE POSTAGE-PAID
ENVELOPE (WHICH WILL BE PROVIDED TO THOSE STOCKHOLDERS WHO REQUEST TO RECEIVE PAPER COPIES OF THESE MATERIALS BY MAIL) BEFORE THE
ANNUAL MEETING SO THAT YOUR SHARES ARE REPRESENTED AT THE ANNUAL MEETING.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 56%">&nbsp;</TD>
    <TD STYLE="width: 44%">Sincerely,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td><img src="green.jpg" alt=""></td></tr>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>James Green</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><I>Chairman of the Board, President and Chief Executive Officer</I></TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"><img src="logo.jpg" alt=""></p>

<p style="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</p>

<p style="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center">HARVARD BIOSCIENCE, INC.<BR>
84 October Hill Road<BR>
Holliston, Massachusetts 01746-1371<BR>
(508) 893-8999<BR>
<BR>
______________________<BR>
<BR>
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS<BR>
To Be Held on Tuesday, May 18, 2021<BR>
<BR>
_____________________</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">NOTICE IS HEREBY GIVEN that the 2021 Annual
Meeting of Stockholders (the &ldquo;Annual Meeting&rdquo;) of Harvard Bioscience, Inc. (the &ldquo;Company&rdquo;) will be held
on Tuesday, May 18, 2021, at 11:00 a.m. EDT. Due to the public health impact of the coronavirus outbreak (COVID-19) and to support
the health and well-being of our stockholders, the Annual Meeting will be held by virtual meeting only. You will not be able to
attend the Annual Meeting in person. To be admitted to the Annual Meeting at http://www.virtualshareholdermeeting.com/HBIO2021,
you must enter the control number found on your proxy card, voting instruction form or notice you previously received. You may
vote during the Annual Meeting by following the instructions available on the meeting website during the meeting. The Annual Meeting
will be held for the following purposes:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The election of one Class III Director named in the accompanying proxy statement, nominated by
the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2024 and until
such Director&rsquo;s successor is duly elected and qualified or until his earlier resignation or removal;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The ratification of the appointment of Grant Thornton LLP as the Company&rsquo;s independent registered
public accounting firm for the fiscal year ending December 31, 2021;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Adoption and approval of the Harvard Bioscience, Inc. 2021 Incentive Plan;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">Such other business as may properly come before the Annual Meeting and any adjournments or postponements
thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has fixed the close of
business on March 24, 2021 as the record date for determination of stockholders entitled to notice of, and to vote at, the Annual
Meeting and any adjournments or postponements thereof. Only holders of Common Stock of record at the close of business on that
date will be entitled to notice of, and to vote at, the Annual Meeting and any adjournments or postponements thereof. Each of the
items of business listed above is more fully described in the proxy statement that accompanies this notice.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors of Harvard Bioscience,
Inc. recommends that you vote &ldquo;FOR&rdquo; the election of the nominee of the Board of Directors as Director of Harvard Bioscience,
Inc., &ldquo;FOR&rdquo; the proposal to ratify the appointment of Grant Thornton LLP as the Company&rsquo;s independent registered
public accounting firm, &ldquo;FOR&rdquo; the proposal to adopt and approve the Harvard Bioscience, Inc. 2021 Incentive Plan, and
&ldquo;FOR&rdquo; the proposal to approve, by a non-binding advisory vote, of the compensation of our named executive officers.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>Important Notice Regarding the Availability
of Proxy Materials for the Annual Meeting to be Held on May 18, 2021: The proxy statement and the Annual Report on Form 10-K for
the year ended December 31, 2020 are available at www.proxyvote.com. The Annual Report, however, is not part of the proxy solicitation
material</B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 56%">&nbsp;</TD>
    <TD STYLE="width: 44%">By Order of the Board of Directors,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td><img src="green.jpg" alt=""></td></tr>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>James Green</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><I>Chairman of the Board, President and Chief Executive Officer</I></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 3.5in; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Holliston, Massachusetts<BR>
April 8, 2021</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>YOUR VOTE IS IMPORTANT. OUR ANNUAL MEETING
WILL BE HELD AS A VIRTUAL MEETING. WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING VIRTUALLY, PLEASE CAST YOUR VOTE ONLINE,
BY TELEPHONE OR BY COMPLETING, DATING, SIGNING AND PROMPTLY RETURNING YOUR PROXY CARD OR VOTING INSTRUCTIONS CARD IN THE POSTAGE-PAID
ENVELOPE (WHICH WILL BE PROVIDED TO THOSE STOCKHOLDERS WHO REQUEST TO RECEIVE PAPER COPIES OF THESE MATERIALS BY MAIL) BEFORE THE
ANNUAL MEETING SO THAT YOUR SHARES ARE REPRESENTED AT THE ANNUAL MEETING.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">Harvard Bioscience, Inc.<BR>
Proxy Statement<BR>
<BR>
Contents</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: right; margin: 0pt 0">Page</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: right; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Proxy Statement</TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 5pt">1</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Proposal 1 Election Of Directors</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">4</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Information Regarding Directors</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">5</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Information Regarding The Board Of Directors And Its Committees</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">7</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Code Of Business Conduct And Ethics</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Report Of The Audit Committee</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">12</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Director Compensation</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">13</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Information About Our Executive Officers</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">15</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Compensation Discussion &amp; Analysis</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">16</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">2020 Summary Compensation Table</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">21</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Outstanding Equity Awards At Fiscal Year-End&mdash;2020</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">23</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Security Ownership Of Certain Beneficial Owners And Management</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">26</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Equity Compensation Plan Information</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">28</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Transactions With Related Persons</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">28</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Delinquent Section 16(A) Reports</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">28</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Stockholder Communications With The Board Of Directors</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">29</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Independent Registered Public Accounting Firm</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">29</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Proposal 2 Ratification Of Appointment Of Independent Registered Public Accounting Firm</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">30</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Proposal 3 Adoption and approval Of The Harvard Bioscience, Inc. 2021 Incentive Plan</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">31</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Proposal 4 Advisory Vote On The Compensation Of Our Named Executive Officers</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">38</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Submission Of Stockholder Proposals For The 2022 Annual Meeting</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">39</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Multiple Stockholders Sharing The Same Address</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">39</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Other Matters</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">39</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">Annex A</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">A-1</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center"><B></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center">HARVARD BIOSCIENCE, INC.<BR>
84 October Hill Road<BR>
Holliston, Massachusetts 01746-1371<BR>
(508) 893-8999<BR>
_______________</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Proxy
Statement</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">_______________<BR>
<BR>
Annual Meeting of Stockholders to Be Held on Tuesday, May 18, 2021</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">This proxy statement is furnished in connection
with the solicitation of proxies by the Board of Directors of Harvard Bioscience, Inc. (the &ldquo;Company&rdquo; or &ldquo;we&rdquo;)
for use at the 2021 Annual Meeting of Stockholders of the Company (the &ldquo;Annual Meeting&rdquo;) to be held on Tuesday, May
18, 2021, at 11:00 a.m. EDT, and any adjournments or postponements thereof. Due to the public health impact of the coronavirus
outbreak (COVID-19) and to support the health and well-being of our stockholders, the Annual Meeting will be held by virtual meeting
only. You will not be able to attend the Annual Meeting in person. To be admitted to the Annual Meeting at http://www.virtualshareholdermeeting.com/HBIO2021,
you must enter the control number found on your proxy card, voting instruction form or notice you previously received. You may
vote during the Annual Meeting by following the instructions available on the meeting website during the meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">At the Annual Meeting, the stockholders of the
Company will be asked to consider and vote upon:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
election of one Class III Director named in this proxy statement, nominated by the Board of Directors (or the &ldquo;Board&rdquo;)
for a three-year term, such term to continue until the annual meeting of stockholders in 2024 and until such Director&rsquo;s successor
is duly elected and qualified or until his earlier resignation or removal;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Grant Thornton LLP as the Company&rsquo;s independent registered public accounting firm for
the fiscal year ending December 31, 2021;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adoption
and approval of the Harvard Bioscience, Inc. 2021 Incentive Plan;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval,
by a non-binding advisory vote, of the compensation of our named executive officers; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We are furnishing proxy materials, which include
our proxy statement and our Annual Report on Form 10-K for the year ended December 31, 2020 (the &ldquo;Annual Report&rdquo;),
to our stockholders over the Internet, and providing a Notice of Internet Availability of Proxy Materials (the &ldquo;Notice&rdquo;)
by mail. We believe that this e-proxy process expedites stockholders&rsquo; receipt of proxy materials, including our proxy statement
and Annual Report, while lowering the costs and reducing the environmental impact of our annual meeting. The Notice is first being
mailed to stockholders of the Company on or about April 8, 2021, in connection with the solicitation of proxies for the Annual
Meeting. The Board of Directors has fixed the close of business on March 24, 2021 as the record date for the determination of stockholders
entitled to notice of, and to vote at, the Annual Meeting (the &ldquo;Record Date&rdquo;). Only holders of Common Stock, par value
$0.01 per share, of the Company (the &ldquo;Common Stock&rdquo;) of record at the close of business on the Record Date will be
entitled to notice of, and to vote at, the Annual Meeting. As of the Record Date, there were 39,927,257 shares of Common Stock
outstanding and entitled to vote at the Annual Meeting. Each holder of a share of Common Stock outstanding as of the close of business
on the Record Date will be entitled to one vote for each share held of record with respect to each matter properly submitted at
the Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The presence, virtually online or by proxy,
of holders of at least a majority of the total number of outstanding shares of Common Stock entitled to vote is necessary to constitute
a quorum for the transaction of business at the Annual Meeting. Shares held of record by stockholders or their nominees who do
not return a signed and dated proxy, properly deliver proxies via the Internet or telephone, or attend the Annual Meeting virtually
will not be considered present or represented at the Annual Meeting and will not be counted in determining the presence of a quorum.
Consistent with applicable law, we intend to count abstentions and broker non-votes only for the purpose of determining the presence
or absence of a quorum for the transaction of business.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A broker &ldquo;non-vote&rdquo; refers to shares
held by a broker or nominee that does not have the authority, either express or discretionary, to vote on a particular matter.
If the beneficial owner does not provide voting instructions, the broker or nominee can still vote the shares with respect to matters
that are considered to be &ldquo;routine,&rdquo; but not with respect to &ldquo;non-routine&rdquo; matters. Proposal No. 2, the
ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year
ending December 31, 2021, is considered &ldquo;routine&rdquo; under applicable rules. A broker or other nominee may generally vote
on routine matters without voting instructions from beneficial owners, and therefore no broker non-votes are expected to exist
in connection with Proposal 2. The remaining proposals are considered &ldquo;non-routine&rdquo; under applicable rules. A broker
or other nominee cannot vote without instructions on non-routine matters, and therefore there may be broker non-votes on those
proposals. Accordingly, if you own shares in street name through a broker, bank or other nominee, please be sure to provide voting
instructions to your nominee to ensure that your vote is counted on each of the proposals.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">With respect to the election of one Class III
Director in Proposal No. 1, such Director is elected by a plurality of the votes cast if a quorum is present. Votes may be cast
for or withheld from the Director. In a plurality election, votes may only be cast in favor of or withheld from each nominee; votes
that are withheld will be excluded entirely from the vote and will have no effect. This means that the person receiving the highest
number of &ldquo;FOR&rdquo; votes will be elected as Director.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Approval of Proposal Nos. 2, 3 and 4 require
the affirmative vote of a majority of the votes cast at the Annual Meeting virtually online or by proxy.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Any shares not voted (whether by abstention,
broker non-vote or otherwise) will have no impact on the election of the Directors, except to the extent that the failure to vote
for an individual results in another individual receiving a larger percentage of votes, and no impact on the voting results of
each other matter expected to be voted on at the Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">You will not receive a printed copy of the proxy
materials unless you request to receive these materials in hard copy by following the instructions provided in the Notice. Instead,
the Notice will instruct you how you may access and review all of the important information contained in the proxy materials. The
Notice also instructs you how you may submit your proxy via the Internet or mail. To the extent you receive a proxy card, such
proxy card will also contain instructions on how you may also vote by telephone (in addition to voting by Internet or mail). If
you received a Notice by mail and would like to receive a printed copy of our proxy materials, you should follow the instructions
for requesting such materials included in the Notice.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We encourage you to vote either online, by telephone
or by completing, signing, dating and returning a proxy card, or if you hold your shares through a broker or nominee, by completing
and returning a voting instruction form. This ensures that your shares will be voted at the Annual Meeting and reduces the likelihood
that we will be forced to incur additional expenses soliciting proxies for the Annual Meeting.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Voting over the Internet, by telephone or mailing
a proxy card will not limit your right to vote virtually online or to attend the Annual Meeting virtually. Any record holder as
of the Record Date may attend the Annual Meeting virtually and may revoke a previously provided proxy at any time by: (i) submitting
a new vote on the Internet or by telephone or submitting a properly completed proxy card with a later date; (ii) sending written
notice that you are revoking your proxy to the corporate secretary at Harvard Bioscience, Inc., 84 October Hill Road, Holliston,
Massachusetts 01746-1371, with such notice received by May 14, 2021; or (iii) attend the Annual Meeting virtually online and vote
through the Annual Meeting website. Attendance at the Annual Meeting will not, by itself, revoke a proxy. If your shares are held
by your broker or nominee, you should follow the instructions provided by such broker or nominee to revoke an earlier vote.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Beneficial holders who wish to attend the Annual
Meeting virtually and vote through the Annual Meeting website should contact their brokerage firm, bank or other financial institution
holding shares of Common Stock on their behalf in order to obtain a &ldquo;legal proxy&rdquo;, which will allow them to vote through
the Annual Meeting website.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">You will be able to participate in the Annual
Meeting online and submit your questions during the meeting by visiting http://www.virtualshareholdermeeting.com/HBIO2021. To be
admitted to the Annual Meeting, you must enter the control number found on your proxy card, voting instruction form or notice you
received. You also will be able to vote your shares electronically prior to or during the Annual Meeting.</P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If you want to submit a question during the
Annual Meeting, log into http://www.virtualshareholdermeeting.com/HBIO2021, type your question into the &ldquo;Ask a Question&rdquo;
field, and click &ldquo;Submit.&rdquo; Questions pertinent to meeting matters will be read and answered during the meeting, subject
to time constraints.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If you encounter any difficulties accessing
the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the Virtual
Shareholder Meeting log in page.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Board of Directors recommends a vote &ldquo;FOR&rdquo;
the nominee of the Board of Directors with respect to Proposal No. 1, and &ldquo;FOR&rdquo; on Proposal Nos. 2, 3 and 4. Proxies
will be voted as specified. If your proxy is properly submitted, it will be voted in the manner you direct. <B>If you submit a
properly executed proxy but do not specify instructions with respect to any particular matter to be acted upon at the meeting,
proxies will be voted in favor of the Board of Directors&rsquo; recommendations</B>.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We will pay the entire expense of soliciting
proxies for the Annual Meeting. In addition to solicitations by mail, certain of our Directors, officers and employees (who will
receive no compensation for their services other than their regular compensation) may solicit proxies by telephone, telegram, personal
interview, facsimile, e-mail or other means of electronic communication. Banks, brokerage houses, custodians, nominees and other
fiduciaries have been requested to forward proxy materials to the beneficial owners of shares of Common Stock held of record by
them as of the Record Date, and such custodians will be reimbursed for their expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Important Notice Regarding the Availability
of Proxy Materials for the Annual Meeting to be Held on Tuesday, May 18, 2021: The proxy statement and Annual Report, are available
at <I><U>www.proxyvote.com</U></I>. The Annual Report, however, is not part of the proxy solicitation material.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Proposal
1<BR>
Election Of Directors</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors of the Company currently
consists of seven members and is divided into three classes of Directors, with two Directors in Class I, two Directors in Class
II and three Directors in Class III.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Once elected, Directors serve for three-year
terms with one class of Directors being elected by our stockholders at each annual meeting to succeed the Directors of the same
class whose terms are then expiring. Each nominee elected as a Director will continue in office until his or her successor has
been duly elected and qualified or until his or her earlier resignation or removal.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">At the Annual Meeting, one Class III Director,
nominated by the Board of Directors, will stand for election to serve until the 2024 annual meeting of stockholders. At the recommendation
of the Governance Committee, the Board of Directors has nominated Mr. Alan Edrick for election as the Class III Director of the
Company. The nominee has agreed to stand for election and, if elected, to serve as Director. However, if any person nominated by
the Board of Directors is unable to serve or will not serve, the proxies will be voted for the election of such other person or
persons as the Governance Committee and the Board of Directors may recommend. Mr. John F. Kennedy and Ms. Susan Steele will not
stand for re-election at the Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Vote Required</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The affirmative vote of a plurality of the votes
cast by holders of shares of Common Stock present or represented by proxy and entitled to vote on the matter at the Annual Meeting
is required for the election of the nominee as Class III Director of the Company.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE &ldquo;FOR&rdquo; THE ELECTION OF THE FOLLOWING NOMINEE OF THE BOARD OF DIRECTORS: ALAN EDRICK.</B></P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Information
Regarding Directors</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Set forth below is certain information regarding
the Directors of the Company, including the Class III Director who has been nominated for election at the Annual Meeting, based
on information furnished to the Company by such Director. The biographical description below for the Director includes his age,
all positions he holds with the Company, his principal occupation and business experience over at least the past five years, and
the names of other publicly-held companies for which he currently serves as a Director or has served as a Director during at least
the past five years. The biographical description below for the Director also includes the specific experience, qualifications,
attributes and skills that led to the conclusion by the Board of Directors that such person should serve as a Director of the Company.
In addition to such specific information, we also believe that all of our Directors have a reputation for integrity, honesty and
adherence to high ethical standards. Further, they have each demonstrated business acumen and an ability to exercise sound judgment
as well as a commitment of service to the Company and our Board.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Independence</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has determined that the
incumbent Directors listed below, other than our Chief Executive Officer, Mr. Green, are &ldquo;independent&rdquo; as such term
is currently defined by applicable Nasdaq rules.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Directors of Harvard Bioscience, Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 35%">
        <P STYLE="font-size: 10pt; margin: 0pt 0; border-bottom: Black 0.5pt solid"><B>Name</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">
        <P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt"><B>Age</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">
        <P STYLE="font-size: 10pt; margin: 0pt 0; border-bottom: Black 0.5pt solid"><B>Principal Occupation</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%">
        <P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt"><B>Director Since</B></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><B>Class I Directors&mdash;Term expires 2022</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I>James W. Green</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">62</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President, Chief Executive Officer and Chairman of the Board of Directors of the Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I>Bertrand Loy</I> (CC)(GC)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">55</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President, CEO and a Director of Entegris Inc., Lead Independent Director of the Board of the Directors of the Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2014</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><B>Class II Directors&mdash;Term expires 2023</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I>Thomas W. Loewald</I> (CC)(GC)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">58</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and CEO of Cambrex</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><I>Katherine A. Eade </I>(AC)(GC)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">General Counsel of Checkmate Pharmaceuticals, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><B>Class III Director&mdash;Term expires 2021; Nominated to Serve a Term Expiring 2024</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><I>Alan Edrick</I> (AC)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">53</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President and Chief Financial Officer of OSI Systems, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2019</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(AC) Member of the Audit Committee</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(CC) Member of the Compensation Committee</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(GC) Member of the Governance Committee</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>James W. Green</I> has served as a Director
of the Company since April 2015 and was appointed Chairman on June 5, 2017. Mr. Green was appointed President and Chief Executive
Officer on July 8, 2019. Immediately prior to becoming our President and Chief Executive Officer, Mr. Green served as President
of Spacelabs Healthcare, a manufacturer of medical equipment, beginning in April 2018. Prior to that position, Mr. Green was General
Partner of Grantchester Group, a private equity investment firm with experience in healthcare and technology. Mr. Green also previously
served as President, Chief Executive Officer and a Director of Analogic Corporation, a leading publicly held advanced medical and
security imaging company from 2007 until October 2016. From 2005 to 2007, Mr. Green worked as Regional Vice President of Unilab
Corp., a California division of Quest Diagnostics Corporation. From 1983 to 2005, Mr. Green worked in various other leadership
positions at Koninklijke Philips Electronics NV, St. Jude Medical Inc., Beckman Instruments, McDonnell Douglas Corporation and
Northrop Advanced Systems. Mr. Green holds a B.S. from the University of Missouri at Columbia, an M.S. from the University of Southern
California and is a graduate of the Stanford University Executive Program. We believe Mr. Green&rsquo;s qualifications to sit on
our Board of Directors include his executive leadership experience and global experience in technology, healthcare and life science
industries in a variety of executive positions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Bertrand Loy</I> has served as a Director
of the Company since November 2014 and currently serves as the Lead Independent Director and is a member of the Governance Committee
and the Compensation Committee. Since November 2012, Mr. Loy has served as President, CEO and a Director of Entegris Inc., a provider
of yield-enhancing materials and solutions used in advanced high-tech manufacturing environments. Prior to that, he served as Chief
Operating Officer of Entegris from 2008 to 2012 and Chief Administrative Officer of Entegris from 2005 to 2008. He previously worked
as Vice President and Chief Financial Officer of Mykrolis Corp. from 2001 until its merger with Entegris in 2005. From 1995 to
2000, Mr. Loy was with Millipore initially as the Director of Finance and Manufacturing for Millipore&rsquo;s Laboratory Water
Division before moving to the position of Chief Information Officer. He began his career with Sandoz Pharmaceuticals (now Novartis)
where he held various positions in strategic planning, finance and audit in Europe, Japan and Latin America from 1989 to 1995.
Since November 2012, Mr. Loy has served as the Chairman of SEMI, a global industry association representing the electronics manufacturing
supply chain. Mr. Loy earned an M.B.A. at ESSEC Business School in France. We believe Mr. Loy&rsquo;s qualifications to sit on
our Board of Directors include his extensive experience as a Chief Executive Officer, as well as his experience in operational
management and his extensive international experience in Europe, Asia-Pacific and the Americas.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-style: italic">Incumbent Class II Directors&mdash;Terms Expiring 2023</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-style: italic">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><I>Thomas W. Loewald</I> has served as a Director
of the Company since October 2017. Mr. Loewald currently serves as Chair of the Compensation Committee and is a member of the Governance
Committee. Since September 2020, Mr. Loewald has served as President and Chief Executive Officer of Cambrex, a leading private
equity-owned Contract Development &amp; Manufacturing Organization. Previously, Mr. Loewald served as President of the Flexible
Packaging Division of ProAmpac, a private-equity owned flexible packaging company from September 2017 to September 2020. Prior
to that, he served as Senior Vice President and Chief Commercial Officer of Thermo Fisher Scientific, a multinational biotechnology
product development company. He previously worked in various roles of Thermo Fisher Scientific from 2002 to 2016. Prior to Thermo
Fisher, Mr. Loewald led sales, marketing, and customer service for the adhesives division of Tyco International from 1998 to 2002.
Prior to Tyco, Tom held a series of roles with General Electric&rsquo;s Plastics and Materials businesses. Mr. Loewald holds a
B.A. in economics from Middlebury College and an M.B.A. in business administration from Dartmouth College. We believe Mr. Loewald&rsquo;s
qualifications to sit on our Board of Directors include his broad global business experience in a wide range of industries from
commodity to high growth, his strong strategic management and leadership skills, and his extensive record of success in leading
business growth and excellence.</P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><I>Katherine A. Eade</I> has served as a Director
of the Company since October 2017. Ms. Eade currently serves as Chair of the Governance Committee and is a member of the Audit
Committee. Ms. Eade is General Counsel of Checkmate Pharmaceuticals, Inc. Previously, Ms. Eade served as Vice President, Strategic
Commercial Affairs at Align Technology, a position she held from July 2019 to July 2020, and prior to that was Deputy General Counsel
of La-Z-Boy Incorporated from 2018 to 2019. Ms. Eade has more than 18 years of experience advising public companies on M&amp;A
and other significant corporate transactions, governance matters and capital markets. Prior to joining La-Z-Boy, Ms. Eade was the
Director, M&amp;A Law and Transactions for Corning Incorporated and Division Counsel for Corning&rsquo;s Life Sciences and Pharmaceutical
Technologies divisions. Her life science acquisitions for Corning included the $730 million purchase of BD&rsquo;s Discovery Labware
business. Previous to her work at Corning, Ms. Eade was an attorney at Cleary Gottlieb Steen &amp; Hamilton LLP, a leading international
law firm, for over seven years. Earlier in her career, she served as a law clerk for Judge Morton I. Greenberg of the U.S. Court
of Appeals for the Third Circuit. Ms. Eade earned a J.D., cum laude, from Harvard Law School and a B.A. in Government, summa cum
laude, from Cornell University. We believe Ms. Eade&rsquo;s qualifications to sit on our Board of Directors include her significant
experience in mergers and acquisitions, including in the life sciences industry, and her extensive experience in capital markets
and corporate governance.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Nominee for Election as Class III Director&mdash;Nominated to Serve
Terms Expiring 2024</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Alan Edrick</I> has served as a Director
of the Company since September 2019. Mr. Edrick currently serves as Chair of the Audit Committee. Mr. Edrick has over 25 years
of financial management and public accounting experience, including mergers and acquisitions, capital markets, financial planning
and analysis, and regulatory compliance. Mr. Edrick has been the Executive Vice President and Chief Financial Officer of OSI Systems,
Inc., a publicly traded multinational company with leading market positions in homeland security, patient monitoring and optoelectronics,
since 2006. Between 2004 and 2006, Mr. Edrick served as Executive Vice President and Chief Financial Officer of BioSource International,
Inc. until its sale to Invitrogen Corporation. Between 1998 and 2004, Mr. Edrick served as Senior Vice President and Chief Financial
Officer of North American Scientific, Inc., a medical device and specialty pharmaceutical company. Between 1989 and 1998, Mr. Edrick
was employed by Price Waterhouse LLP in various positions including Senior Manager, Capital Markets. Mr. Edrick earned a Bachelor
of Arts in economics/business from the University of California, Los Angeles (UCLA) and a Master of Business Administration from
UCLA&rsquo;s Anderson School of Management. We believe Mr. Edrick&rsquo;s qualifications to sit on our Board of Directors include
his executive leadership experience as a Chief Financial Officer, as well as his significant operating, accounting and financial
management expertise, including in the life sciences industry.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Information
Regarding The Board Of Directors And Its Committees</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">During the year ended December 31, 2020, our
Board of Directors held seven meetings. Each of the Directors attended at least 75% of the total number of meetings of the Board
of Directors held while he or she was a Director and of the committees of which he or she was a member. The Board of Directors
generally encourages Directors to attend in person the Annual Meeting of Stockholders of the Company, or Special Meeting in lieu
thereof, or, if unable to attend in person, to participate by other means, if practicable. In light of the unique circumstances
related to COVID-19, the Board of Directors encourages Directors to participate virtually for the 2021 Annual Meeting. All of the
Directors in office at the time attended the 2020 Annual Meeting of Stockholders held on June 11, 2020. The non-employee Directors
meet regularly in executive sessions outside the presence of management.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Board Leadership Structure</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Board leadership structure consists of a
Chairman of the Board who is also our Chief Executive Officer. Prior to Mr. Green being appointed Chief Executive Officer, the
roles of Chairman of the Board of Directors and Chief Executive Officer were separate. Our Board of Directors does not have a current
requirement that the roles of Chief Executive Officer and Chairman of the Board be either combined or separated, because the Board
of Directors currently believes it is in the best interests of our Company to make this determination based on the position and
direction of our Company and the constitution of the Board and management team. From time to time, the Board of Directors will
evaluate whether the roles of Chief Executive Officer and Chairman of the Board should be combined or separated. Both the Chairman
and Chief Executive Officer positions are currently held by Mr. Green and as noted above, Mr. Loy has been appointed and currently
serves as the Lead Independent Director.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Lead Independent Director has broad responsibility
and authority, including to:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Preside at all meetings of the Board at which the Chairman is not present, including executive
sessions of the independent Directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Call meetings of independent Directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Serves as the principal liaison between the Chairman and the independent Directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Approve all information sent to the Board, including the quality, quantity, appropriateness and
timeliness of such information.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Approve meeting agendas for the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Approve the frequency of Board meetings and meeting schedules, assuring there is sufficient time
for discussion of all agenda items.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Recommend to the Governance Committee and to the Chairman, selection for the membership and chairman
position for each Board committee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Interview along with the chair of the Governance Committee, all Director candidates and make recommendations
to the Governance Committee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Be available, when appropriate, for consultation and direct communication with stockholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Retain outside advisors and consultants who report directly to the Board on Board-wide issues.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On an annual basis, in consultation with the independent directors, the Lead Independent Director
will review his responsibility and authority and recommend to the Board for approval any modifications or changes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our Board of Directors has determined that its
current structure, with combined Chairman and Chief Executive Officer roles and a Lead Independent Director is in the best interests
of our Company and its stockholders at this time.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A number of factors support the leadership structure
chosen by the Board, including, among others:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Chief Executive Officer has extensive knowledge of all aspects of our company and its business
and risks, its industry and its customers.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Chief Executive Officer is intimately involved in the day-to-day operations of our company
and is best positioned to elevate the most critical business issues for consideration by the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Board believes having our Chief Executive Officer serve in both capacities allows him to more
effectively execute our company&rsquo;s strategic initiatives and business plans and confront its challenges.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A combined Chairman and Chief Executive Officer structure provides our company with decisive and
effective leadership with clearer accountability to our stockholders and customers, especially within the context of an aggressive
turnaround situation in which rapid decision making is a critical success factor.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">This structure allows one person to speak for and lead the company and the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The combined role is both counterbalanced and enhanced by the effective oversight and independence
of our Board and the independent leadership provided by our Lead Independent Director and independent committee chairs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Board believes that the appointment of a strong Lead Independent Director and the use of regular
executive sessions of the non-management Directors, along with the Board&rsquo;s strong committee system and all Directors being
independent except for Chief Executive Officer, allow it to maintain effective oversight of management.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In our view, splitting the roles would potentially make our management and governance processes
less effective through undesirable duplication of work and possibly lead to a blurring of clear lines of accountability and responsibility.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Board Committees</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has established an Audit
Committee (the &ldquo;Audit Committee&rdquo;), a Compensation Committee (the &ldquo;Compensation Committee&rdquo;) and a Governance
Committee (the &ldquo;Governance Committee&rdquo;). The charters of each our committees are available on the Corporate Governance
page in the Investor Relations section of our website at <I><U>www.harvardbioscience.com</U></I>. Please note that the information
contained on the Company website is not incorporated by reference in, or considered to be a part of, this proxy statement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Audit Committee</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Audit Committee currently consists of Mr.
Edrick, Mr. Kennedy and Ms. Eade. Mr. Edrick serves as the Chair. The Audit Committee is comprised entirely of independent Directors
and it operates under a Board-approved charter that sets forth its duties and responsibilities. The Audit Committee met six times
during 2020. Assuming Mr. Edrick is re-elected at the Annual Meeting, the Audit Committee shall consist of Mr. Edrick (Chair),
Ms. Eade and Mr. Loewald following the Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under its charter, the Audit Committee is responsible
for, among other things:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reviewing our financial statements and related disclosures included in quarterly and annual financial
statements, as well as quarterly earnings releases;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reviewing the adequacy of our internal controls, and financial systems and management practices;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">appointing, retaining and terminating, and determining compensation of, our independent auditors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">overseeing our independent auditors and the evaluation of the independent auditors&rsquo; qualifications,
performance and independence;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">assuring the regular rotation of audit partners, including any lead and concurring partners, in
accordance with applicable laws and regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reporting matters that arise relating to quality or integrity of our financial statements and other
matters to the Board and reviewing such matters with the Board.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Audit Committee is responsible for reviewing
and discussing with management our policies with respect to risk assessment and risk management. The Board and the Audit Committee
discuss matters relating to risks that arise or may arise. The Audit Committee has also established procedures for the receipt,
retention and treatment, on a confidential basis, of complaints received by the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Audit Committee is also responsible for,
and has established policies and procedures with respect to, the pre-approval of all services provided by the independent auditors.
When assessing the independence of our auditors, the Audit Committee considers the independent registered public accounting firm&rsquo;s
provision of non-audit services to the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has determined that Mr.
Edrick, Mr. Kennedy, Ms. Eade and Mr. Loewald are &ldquo;independent&rdquo; as such term is currently defined by Nasdaq rules for
purposes of service on the Audit Committee. The Board of Directors has also determined that each of Messrs. Edrick and Kennedy
qualifies as an &ldquo;audit committee financial expert&rdquo; as this term has been defined under the rules of the SEC.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Compensation Committee</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee currently consists
of Mr. Kennedy, Mr. Loewald, Mr. Loy and Ms. Steele. Mr. Loewald serves as the Chair. The Compensation Committee is comprised entirely
of independent Directors and it operates under a Board approved charter that sets forth its duties and responsibilities. The Compensation
Committee met seven times during 2020.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee determines and oversees
the execution of our compensation philosophy and oversees the administration of our executive compensation programs. Its responsibilities
also include overseeing the Company&rsquo;s compensation and benefit plans and policies, retaining or terminating committee advisors,
independence evaluation of compensation advisors, administering its stock plans (including reviewing and approving equity grants)
and reviewing and approving annually all compensation decisions for the Company&rsquo;s executive officers, including the CEO and
the other executive officers named in the 2020 Summary Compensation Table. See &ldquo;Executive Compensation&mdash;Compensation
Discussion and Analysis&rdquo; later in this proxy statement for information concerning the Compensation Committee&rsquo;s role,
processes and activities in overseeing executive compensation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has determined that Mr.
Kennedy, Mr. Loewald and Ms. Steele are &ldquo;independent&rdquo; as such term is currently defined by Nasdaq rules for purposes
of service on the Compensation Committee.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Governance Committee</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The current members of the Governance Committee
are Mr. Loewald, Mr. Loy and Ms. Eade. Ms. Eade is the Chair. The Governance Committee is comprised entirely of independent Directors
and it operates under a Board approved charter that sets forth its duties and responsibilities. The Governance Committee met six
times during 2020.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under the terms of its charter, the Governance
Committee is responsible for identifying individuals qualified to become Board members, consistent with criteria recommended by
the Governance Committee and approved by the Board of Directors, and recommending that the Board of Directors select the Director
candidates for election at each annual meeting of stockholders. Its responsibilities also include recommending to the Board of
Directors the criteria for membership on Board Committees. The Governance Committee is also responsible for assisting the Board
of Directors with such corporate governance matters as the Board of Directors may request.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In identifying and evaluating nominees for the
Board of Directors, the Governance Committee may solicit recommendations from any or all of the following sources: non-management
Directors, the Chief Executive Officer, other executive officers, third-party search firms or any other source it deems appropriate.
At the Annual Meeting, Mr. Edrick will be standing for election by the stockholders for the first time. Mr. John F. Kennedy and
Ms. Susan Steele will not stand for re-election at the Annual Meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Governance Committee has established procedures
for stockholders to recommend Director candidates. All stockholder recommendations for Director candidates must be submitted in
writing to our Chief Financial Officer at 84 October Hill Road, Holliston, Massachusetts 01746, who will forward all recommendations
to the Governance Committee. All stockholder recommendations for Director candidates must be submitted to the Company not less
than 120 calendar days prior to the anniversary of the date on which our proxy statement was released to stockholders in connection
with the previous year&rsquo;s annual meeting. All stockholder recommendations for Director candidates must include:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the name and address of record of the stockholder,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a representation that the stockholder is a record holder of our securities, or if the stockholder
is not a record holder, evidence of ownership in accordance with Rule 14a-8(b)(2) of the Securities Exchange Act of 1934,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the name, age, business and residential address, educational background, public company directorships,
current principal occupation or employment, and principal occupation or employment for the preceding five full fiscal years of
the proposed Director candidate,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a description of the qualifications and background of the proposed director candidate which addresses
the minimum qualifications and other criteria for Board membership approved by the Board of Directors and set forth in the Governance
Committee Charter,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a description of all arrangements or understandings between the stockholder and the proposed Director
candidate,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the consent of the proposed Director candidate to be named in the proxy statement, to have all
required information regarding such Director candidate included in the proxy statement, and to serve as a Director if elected,
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other information regarding the proposed Director candidate that is required to be included
in a proxy statement filed pursuant to the rules of the Securities and Exchange Commission.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Governance Committee will evaluate all such proposed Director
candidates, including those recommended by stockholders, in compliance with the procedures established by the Governance Committee,
in the same manner, with no regard to the source of the initial recommendation of such proposed Director candidate. When considering
a potential candidate for membership on the Board of Directors, the Governance Committee may consider, in addition to the minimum
qualifications and other criteria for Board membership approved by the Board of Directors, all facts and circumstances that the
Governance Committee deems appropriate or advisable, including, among other things, the skills of the proposed Director candidate,
his or her availability, depth and breadth of business experience or other background characteristics, his or her independence
and the needs of the Board of Directors. At a minimum, each candidate must have high personal and professional integrity, have
demonstrated ability and judgment, and be effective, in conjunction with the other Directors and candidates, in collectively serving
the long-term interests of the stockholders. In addition, the Governance Committee will recommend that the Board select candidates
for nomination to help ensure that a majority of the Board shall be &ldquo;independent&rdquo; in accordance with Nasdaq rules
and that each of its Audit, Compensation and Governance Committees shall be comprised entirely of independent Directors, subject
to certain exceptions under the Nasdaq rules to such requirement. Although there is no specific policy regarding the consideration
of diversity in identifying Director candidates, the Governance Committee may consider whether the candidate, if elected, assists
in achieving a mix of Board members that represents a diversity of background and experience. The Governance Committee also may
consider whether the candidate has direct experience in the biotechnology, pharmaceutical and/or life science research industries
or in the markets in which the Company operates.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">The Board&rsquo;s Role in Risk Oversight</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Risks to the Company are discussed by the Board
of Directors during the year. Management is responsible for the day-to-day management of risks we face, while the Board, as a whole
and through its Committees, oversees risk management. The Audit Committee is responsible for reviewing and discussing with management
our policies with respect to risk assessment and risk management. The Board of Directors and the Audit Committee review and discuss,
including with management, risks that arise or may arise, including in relation to legal, compliance and cyber-security matters,
as well as novel risks that arise such as the impact of the COVID-19 global pandemic. For example, the Audit Committee discusses
financial risk, including with respect to financial reporting and internal controls, with management and our independent registered
public accounting firm and the steps management has taken to minimize those risks. Our Board of Directors also administers its
risk oversight function through the required approval by the Board (or a Committee of the Board) of significant transactions and
other material decisions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Risk Considerations in our Compensation Programs</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee believes that risks
arising from our policies and practices for compensating employees are not reasonably likely to have a material adverse effect
on the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Non-Employee Director Ownership Guidelines</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Board has implemented equity ownership guidelines
with respect to our non-employee Directors. The ownership guidelines require each non-employee member of the Board of Directors,
within five years from their initial election to the Board to own shares of our Common Stock having a value of at least three times
the annual retainer of the non-employee Directors. With respect to satisfying the guidelines, unvested awards of restricted stock
units are included in the calculation while stock options are excluded. All of our Directors are currently in compliance with these
equity ownership guidelines.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Code
Of Business Conduct And Ethics</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board of Directors has adopted a Code of
Business Conduct and Ethics, which applies to all Directors, officers and employees of the Company and its subsidiaries including
the Chief Executive Officer, the Chief Financial Officer, principal accounting officer, controller and any person performing similar
functions. The Code of Business Conduct and Ethics is available on the Corporate Governance page in the Investor Relations section
of our website at <I><U>www.harvardbioscience.com</U></I>. We intend to post any amendments to or waivers from our Code of Business
Conduct and Ethics at this location on our website.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Report
Of The Audit Committee</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Notwithstanding anything to the contrary
set forth in any of the Company&rsquo;s previous or future filings under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended, that might incorporate this proxy statement or any future filing with the Securities and Exchange
Commission, in whole or in part, the following report shall not be deemed incorporated by reference into any such filing.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The undersigned members of the Audit Committee
of the Board of Directors of the Company submit this report in connection with the committee&rsquo;s review of the financial reports
of the Company for the fiscal year ended December 31, 2020 as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Audit Committee has reviewed and discussed with management the audited financial statements
of the Company for the fiscal year ended December 31, 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Audit Committee has discussed with representatives of Grant Thornton LLP the matters required
to be discussed with them by applicable requirements of the Public Company Accounting Oversight Board and the SEC.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">The Audit Committee has received the written disclosures and the letter from the independent accountant
required by the Public Company Accounting Oversight Board regarding the independent accountant&rsquo;s communications with the
Audit Committee concerning independence, and has discussed with the independent accountant the independent accountant&rsquo;s independence.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Based on the review and discussions referred
to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in the Company&rsquo;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2020 for filing with the Securities and Exchange Commission.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Audit Committee:<BR>
<BR>
Alan Edrick, Chairman<BR>
Katherine A. Eade<BR>
John F. Kennedy</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Director
Compensation</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Board of Directors has the authority to
approve all compensation payable to our Directors, although our Compensation Committee is responsible for making recommendations
to our Board regarding Board compensation. Our Board of Directors and Compensation Committee annually review our Board compensation
to evaluate whether it remains competitive such that we are able to recruit and retain qualified Directors. We use a mix of cash
and/or stock-based incentive compensation to attract and retain qualified candidates to serve on our Board. As described below,
our Director Compensation program currently utilizes only stock-based incentive compensation. In setting Board compensation, the
Board of Directors and the Compensation Committee consider the significant amount of time that Directors expend in fulfilling their
duties to the Company as well as the skill-level required by the Company of members of the Board.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Directors who are also employees of the Company
receive no additional compensation for service as a Director. Non-employee Directors receive the compensation described below.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0">Compensation of Non-Employee Directors Upon Initial
Election to the Board</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Each non-employee Director will be entitled
to receive a non-qualified stock option having an aggregate Black-Scholes grant date fair value of $134,400, rounded to the nearest
100 shares, provided that in no case shall such stock option be less than 25,000 shares. Such option shall be for the purchase
of Common Stock of the Corporation and shall vest annually over three years and be granted on the fifth business day following
his or her initial election to the Board.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0">Annual Compensation of Non-Employee Directors</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Annual Retainers</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Each non-employee Director will be entitled
to receive annual retainer amounts for each respective role on the Board. In lieu of cash, such aggregate annual retainer amounts
shall each be satisfied by the issuance of restricted stock unit awards as described herein.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The respective annual retainer value for each
particular role on the Board are as follows:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Role</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Annual Retainer Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font-size: 10pt; text-align: left">Non-employee Director</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">35,280</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Lead Independent Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">35,280</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Chairman of the Board</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">35,280</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Audit Committee chair</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">18,144</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Audit Committee member</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">9,072</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Compensation Committee chair</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">12,096</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Compensation Committee member</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6,048</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Governance Committee chair</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,040</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Governance Committee member</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,040</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The annual retainer awards (each a &ldquo;Retainer
Award&rdquo;) are generally granted on the first trading day of January (the &ldquo;Grant Date&rdquo;) and vest quarterly over
the calendar year on each March 31, June 30, September 30 and December 31, subject to the Director&rsquo;s continued service through
the applicable vesting date. The number of shares of Common Stock to be granted as a Retainer Award is equal to the quotient of
(i) the dollar value of the award as set forth above, divided by (ii) the average daily closing market price of the Common Stock
during the preceding month of November, rounded to the nearest 100 shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Additional Board Member or Board Roles</I>:
In the event that a non-employee Director is added to the Board, or is named Lead Independent Director or chairman (of the board
or any committee), or joins any committee during a fiscal year after the Grant Date, such Director shall be granted a Retainer
Award (the &ldquo;Additional Retainer Award&rdquo;), in relation to such additional roles and respective retainer amounts pro-rated
for the remainder of such year. Such Additional Retainer Award shall be granted on the first trading day of the month after the
individual is appointed to such roles. The Additional Retainer Award shall vest in equal amounts spread over the remaining quarterly
vesting dates of the Retainer Awards for such calendar year subject to continued service as a non-employee Director on the applicable
vesting dates. The number of shares of Common Stock to be granted as an Additional Retainer Award is equal to the quotient of (i)
the dollar value of the award as set forth above (pro-rated for the remainder of the fiscal year following the appointment to the
additional role), divided by (ii) the average daily closing market price of the Common Stock during the calendar month that is
two months prior to the month the Director was appointed to the additional roles, rounded to the nearest 100 shares (for example,
a director appointed to additional roles in August would use the average daily closing market price for the preceding June).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Reduced Board Roles</I>: In the event a Director&rsquo;s
service (including as a Board or committee member, as chairman of the Board or any committee, or as Lead Independent Director)
ends during a particular quarter, the vesting date for such quarter in relation to the portion of the award attributable to such
roles that are ending, shall be the last day of the Director&rsquo;s term in the respective role, and the pro-rated portion of
the quarterly amount attributable to such roles shall vest on that earlier vesting date, with the remaining unvested portion of
the award attributable to such roles being forfeited.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Annual Equity Award</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Each non-employee Director will also be entitled
to receive an equity award in the form of restricted stock units having an aggregate cash value of $80,640, rounded to the nearest
100 shares, vesting fully on the earlier to occur of (i) the date of the Corporation&rsquo;s next Annual Meeting of Stockholders
after the grant date, immediately prior to the commencement of such meeting, and (ii) one year from the date of grant, subject
to the Director&rsquo;s continued service through the applicable vesting date, and granted on the fifth business day following
the Annual Meeting of Stockholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">Expenses</P>

<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In addition, non-employee Directors shall be
reimbursed for expenses incurred in connection with attending Board and Committee meetings.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0">2020 Director Compensation Table</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following table presents the compensation
provided to the non-employee Directors who served during the fiscal year ended December 31, 2020.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name (1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards (1),&nbsp;(2)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Restricted Stock Awards (3)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt; font-style: italic; text-align: left">Katherine Eade</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">135,072</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">135,072</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Alan Edrick</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">135,112</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">135,112</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">John F. Kennedy</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">139,184</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">139,184</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Thomas Loewald</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">139,104</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">139,104</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Bertrand Loy</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">163,683</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">163,683</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Susan Steele</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">135,700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">109,941</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">245,641</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Based on the aggregate grant date fair value computed awards in accordance with the provisions
of FASB ASC 718, &ldquo;Compensation&mdash;Stock Compensation&rdquo;. Assumptions used in the calculation of this amount are included
in Note 10 to the Company&rsquo;s audited financial statements for the fiscal year ended December 31, 2020 included in the Company&rsquo;s
Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The aggregate number of option awards outstanding at December 31, 2020, and held by the non-employee
Directors were as follows: 87,600 options for Ms. Eade; 101,800 options for Mr. Edrick; 37,059 options for Mr. Kennedy; 87,600
options for Mr. Loewald; 55,300 options for Mr. Loy; and 115,900 options for Ms. Steele.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">The aggregate number of restricted stock unit awards outstanding at December 31, 2020, and held
by the non-employee Directors were as follows: 28,100 awards for Ms. Eade; 28,100 awards for Mr. Edrick; 28,100 awards for Mr.
Kennedy; 28,100 awards for Mr. Loewald; 28,100 awards for Mr. Loy; and 28,100 awards for Ms. Steele.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Information
About Our Executive Officers</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following table shows information about
our executive officers:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%">
        <P STYLE="font-size: 10pt; margin: 0pt 0; border-bottom: Black 0.5pt solid"><B>Name</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">
        <P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt"><B>Age</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 58%">
        <P STYLE="font-size: 10pt; margin: 0pt 0; border-bottom: Black 0.5pt solid"><B>Position</B></P></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">James Green</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">62</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Executive Officer, President and Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Michael Rossi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Kenneth Olson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Biographical information for Mr. Green is provided
above under the heading &ldquo;Directors of Harvard Bioscience, Inc.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Michael Rossi</I> was named Chief Financial
Officer in July 2019. Immediately prior to becoming Chief Financial Officer of the Company, Mr. Rossi served as Chief Financial
Officer of Laborie Medical Technologies from August 2018 to May 2019, a manufacturer of urology and gastrointestinal diagnostic
equipment. Prior to that role, he was Chief Financial Officer of Medical Specialties Distributors, a healthcare supply chain management
solutions company, for over three years. Mr. Rossi brings significant experience with turnarounds and driving financial and operational
improvements within complex middle market manufacturing and distribution businesses. He also has over fifteen years of public company
accounting and reporting experience as well as experience managing debt and liquidity during both periods of growth and business
downturns. Earlier in his career, Mr. Rossi held finance roles of increasing responsibility at various public companies, including
Haemonetics Corporation, The Princeton Review, Inc., American Tower Corporation, Sonus Networks and Manufacturers&rsquo; Services
Limited. He began his professional career as an accountant at PricewaterhouseCoopers. Mr. Rossi earned a B.S. in accounting from
Babson College and an MBA from Babson College&rsquo;s Olin School of Management.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Kenneth Olson</I> was named Chief Operating
Officer in April 2020 and is responsible for global manufacturing, supply chain and research and development. Prior to becoming
Chief Operating Officer, Mr. Olson served as Vice President and General Manager, Data Sciences International from October 2019
to April 2020. Prior to joining DSI, Mr. Olson served as the Senior Vice President of Global Engineering and Operations at Spacelabs
Healthcare, a patient monitoring and diagnostic cardiology companies, from May 2017 to October 2019. From July 2013 until October
2019, Mr. Olson ran a successful management consulting firm in the medical device space. Mr. Olson previously served as Vice President
of Research &amp; Development at ABT Molecular Imaging from December 2010 to July 2013. Mr. Olson has significant experience in
Emergency Medical Services (EMS), with over 40 issued patents in cardiology and resuscitation products. He served as Vice President
of Research and Development for Medtronic Physio-Control from May 2006 to December 2010, where he oversaw the development of the
LP15 Monitor/Defibrillator. Prior to Medtronic, Olson was the Chief Technical Officer for Cardiac Science, after a merger with
Survivalink Corporation where he had served as the VP of R&amp;D from its inception. Mr. Olson earned a B.S. in electrical engineering
and an MBA from the University of Minnesota.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Compensation
Discussion &amp; Analysis</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">This Compensation Discussion and Analysis, which
should be read together with the executive compensation tables set forth below, provides information regarding our executive compensation
program for our named executive officers. Our current named executive officers are James Green, our President and Chief Executive
Officer, Michael Rossi, our Chief Financial Officer, and Kenneth Olson, our Chief Operating Officer.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Compensation Committee is responsible for
determining the compensation payable to our executive officers. Our Chief Executive Officer makes recommendations to our Compensation
Committee regarding the compensation of all executive officers, excluding his own, but our Compensation Committee is ultimately
responsible for approving this compensation. Generally, our Chief Executive Officer recommends the terms of an annual corporate
bonus plan to our Compensation Committee. Our Compensation Committee then, after considering the recommendations made by our Chief
Executive Officer, determines the terms and amount of compensation to pay to each of our executive officers, including our Chief
Executive Officer, and the terms of any corporate bonus plans and related targets and objectives. Such determination is made in
reliance on a number of other factors, including analysis and guidance provided by an independent executive compensation consultant
from time to time, as well as compensation for comparable executive positions at peer group companies and our historical practices.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">Objectives of Our Executive Compensation Programs</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our compensation programs for our executive
officers are designed to achieve the following key objectives:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">attract and retain high performing and experienced executives;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">motivate and reward executives whose knowledge, skills and performance are deemed critical to our
success;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">align the interests of our executives and stockholders by motivating executives to increase stockholder
value and rewarding executives when stockholder value increases;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">foster a shared commitment among executives by coordinating their goals; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">motivate our executives to manage our business to meet our short- and long-term objectives, and
reward them for meeting these objectives, including growing our revenues, earnings per share, total market capitalization and share
price.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-style: italic; font-weight: bold">Role of Independent Executive Compensation Consultant</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">From time to time, our Compensation Committee
has engaged an independent executive compensation consultant to provide guidance with respect to the development and implementation
of our compensation programs. The Compensation Committee utilizes the reports, recommendations and insight of the independent executive
compensation consultant, along with a variety of additional factors, including input from the Chief Executive Officer as to the
other executive officers, in determining the appropriate compensation, including salary, bonus and equity grants, with respect
to our named executive officers. Most recently, the Compensation Committee obtained analysis and recommendations from Arthur J.
Gallagher &amp; Co. (&ldquo;Gallagher&rdquo;) pertaining to the compensation, including salary, bonus and equity grants, with respect
to our Chief Executive Officer and Chief Financial Officer. During 2020, the Compensation Committee engaged Frederic W. Cook &amp;
Co., Inc. (&ldquo;FW Cook&rdquo;) as its ongoing independent compensation consultant. FW Cook was not involved in decisions relevant
to setting fiscal 2020 compensation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">After consideration of the independence assessment
factors provided under the listing standards of The Nasdaq Global Market, the Compensation Committee determined that the compensation
consultants are independent and that the work performed in 2020 did not raise any conflicts of interest.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The companies represented in the Gallagher study
from October 2018 (the &ldquo;Peer Group&rdquo;), which are unchanged for fiscal 2020 compensation decisions, represented public
companies from both the life sciences and industrial sectors, with a focus on companies that produce and provide equipment, and
consisted of:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="width: 50%; text-align: center"><I>Life Science Peer Group Companies</I></TD>
    <TD STYLE="width: 50%; text-align: center"><I>Industrial Peer Group Companies</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Teligent, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Gencor Industries Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Jounce Therapeutics, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Northwest Pipe Co.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Recro Pharma, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Eastern Co.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Fluidigm Corp.</I></TD>
    <TD STYLE="text-align: center"><I>Fluent, Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Oxford Immunotec Global Plc</I></TD>
    <TD STYLE="text-align: center"><I>Hurco Companies Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Nanostring Technologies Inc.</I></TD>
    <TD STYLE="text-align: center"><I>BG Staffing, Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Castlight Health, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Willdan Group, Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Concert Pharmaceuticals, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Willis Lease Finance Corp.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Fortress Biotech, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Plug Power Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>RTI Surgical, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Allied Motion Technologies Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Insys Therapeutics, Inc.</I></TD>
    <TD STYLE="text-align: center"><I>NL Industries Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Endologix Inc.</I></TD>
    <TD STYLE="text-align: center"><I>Eagle Bulk Shipping Inc.</I></TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Computer Programs &amp; Systems Inc.</I></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center"><I>Veracyte, Inc.</I></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; font-style: italic; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-style: italic"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; font-style: italic"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">Compensation Elements</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The elements of executive compensation include
base salary, annual cash incentive bonuses, long-term equity incentive compensation, employment agreements, and broad-based benefits
programs. We have not adopted any formal guidelines for allocating total compensation between long-term and short-term compensation,
cash compensation and non-cash compensation, or among different forms of non-cash compensation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Base
Salary</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We pay our executive officers a base salary,
which our Compensation Committee reviews and determines annually. We believe that a competitive base salary is a necessary element
of any compensation program that is designed to attract and retain talented and experienced executives. We also believe that attractive
base salaries can motivate and reward executives for their overall performance. The 2020 annualized base salary of each of Messrs.
Green, Rossi and Olson were:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Current Executive Officers</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020 Base Salary</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase over 2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left">James Green</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">573,710</TD><TD STYLE="width: 3%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Michael Rossi</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">340,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Kenneth Olson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">285,263</TD><TD STYLE="font-size: 10pt; text-align: left">(1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Upon promotion to COO in April 2020, Mr. Olson&rsquo;s base salary was increased from $260,000
to $290,000.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Annual
Cash Incentive Bonuses</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Consistent with our emphasis on performance-based
incentive compensation programs, our executives are eligible to receive annual cash incentive bonuses. The Compensation Committee
has the authority to provide such bonuses for a given fiscal year based on the performance of our executive officers with respect
to key performance areas and targets established by the Compensation Committee for such period. In February 2020, the Compensation
Committee adopted the 2020 Annual Incentive Plan as set forth below:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 25%"><FONT STYLE="font-size: 10pt"><B>Metric</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Weighting</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 63%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Rationale for Metric</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">HBIO Revenue Growth</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">20%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Strategic goal to return the Company to organic growth</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">HBIO Adjusted Operating Income (Non-GAAP Measure)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">80%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Achievement of Adjusted Operating Income targets designed to significantly improve the core profitability of the business, enable HBIO to pay down debt, and invest in products and revenue growth activities.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In response to the economic uncertainty caused
by the COVID-19 pandemic, the Compensation Committee revised the targets under the Annual Incentive Plan to provide for a discretionary
bonus opportunity at a payout level less than originally designed.&nbsp;&nbsp; Following this decision, payouts would be informed
by the Company&rsquo;s year-end leverage ratio (&lt;3.25x) and adjusted operating margin (&gt;17%) for the second half of fiscal
2020, among other factors. The Compensation Committee evaluated our performance against these goals and, based upon that evaluation
and in consideration of our overall performance, the Compensation Committee awarded each named executive officer a 2020 annual
cash incentive bonus that equaled 37% of his target. The Compensation Committee believes these payouts are appropriate due to the
performance of the Company in 2020, particularly in light of the challenges presented by the COVID-19 pandemic, and each participating
named executive officer&rsquo;s contribution to the Company&rsquo;s performance.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">For fiscal year 2020, Mr. Green was eligible
to receive cash incentive compensation equal to 100% of his base salary, with a maximum of 150% of his base salary, and each of
Messrs. Rossi and Olson are eligible to receive cash incentive compensation equal to 50% of their respective base salaries, with
a maximum of 75% of the applicable base salary.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Long-Term
Equity Incentive Compensation</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We place a significant emphasis on performance-based
incentive compensation. We grant long-term equity incentive awards in the form of stock option awards and/or restricted stock units
(&ldquo;RSUs&rdquo;) to executives as part of our total compensation package. These awards generally represent a significant portion
of total executive compensation. We use long-term equity incentive awards in order to align the interests of our executives and
our stockholders by providing our executives with strong incentives to increase stockholder value and a significant reward for
doing so.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Compensation Committee&rsquo;s long-term
incentive strategy allows for use of a portfolio approach when granting awards. Each element of the portfolio is intended to address
a different aspect of long-term incentive compensation, as set forth below:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Time-based RSUs serve as a retentive device and provide an interest in the value of the Company&rsquo;s
shares, because, even though they vest over time, they provide recipients with a certain equity interest, assuming continued employment.
In addition to promoting retention, time-based RSUs further align executives&rsquo; interests with the interests of shareholders
and provide a long-term ownership mentality as well as motivation to succeed in the long-term because the value of RSUs does not
solely depend upon increases in the market price of our shares, which may occur over a short period of time. An RSU is a grant
representing the right to receive a share of Common Stock upon vesting of the RSU and satisfaction of other conditions. A holder
of an RSU does not have any rights of a stockholder until the RSU vests and is converted to Common Stock. The fair value of RSUs
is based on the market price of our stock on the date of grant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Stock options reward recipients based upon the appreciation in value of the Common Stock following
the grant date, and there is no value to these awards if our share price does not increase. Stock options provide our executive
officers with the right to purchase shares of our Common Stock at a fixed exercise price typically for a period of up to ten years.
Stock options are earned based on continued service to us and generally vest over a range of one to four years, subject to continued
employment with our Company. The exercise price of each stock option award granted under our Fourth Amended and Restated 2000 Stock
Option and Incentive Plan (as amended, the &ldquo;Equity Plan&rdquo;) is based on the fair market value of our Common Stock on
the grant date. We do not have any program, plan or practice of setting the exercise price based on a date or price other than
the fair market value of our Common Stock on the grant date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Market condition RSUs provide an additional incentive for executive officers to create shareholder
value, as these awards only vest if the relative total shareholder return, or TSR, of our Common Stock as compared to companies
in the utilized index exceeds the performance goals established by the Committee. The Committee believes that measuring TSR on
a relative, rather than on an absolute, basis provides a more relevant measure of the performance of the Company&rsquo;s stock.
By mitigating the impact of macroeconomic factors (both positive and negative) that are beyond the control of the Company and its
executives, we believe relative TSR provides rewards that are better aligned with relative performance through varying economic
cycles. The maximum number of shares, relative to target, that can be earned under this TSR plan is 150%.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our decisions regarding the amount and type of long-term
equity incentive compensation and relative weighting of these awards among total executive compensation have also been based on
our understanding of market practices of our Peer Companies and take into account additional factors such as level of individual
responsibility, experience and performance. The vesting of our long-term equity incentive compensation is typically subject to
continued employment with our Company, and in some instances, to acceleration in connection with certain termination events and
a change-in-control.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In the second quarter of 2020, the Compensation
Committee granted a mix of stock options, time-based RSU awards and market condition RSUs to Messrs. Green, Rossi, and Olson, each
with vesting subject, among other things, to the executive&rsquo;s continued employment with the Company on the vesting dates.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Time-Based RSUs (1)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options (2)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Market Condition RSUs (3)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt; text-align: left">James W. Green</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">218,141</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">470,254</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">218,141</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Michael A. Rossi</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,093</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">92,896</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,093</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Kenneth Olson</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">36,755</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">79,235</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">36,755</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">297,989</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">642,385</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">297,989</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Each of these time-based RSUs was granted on June 11, 2020 and vests in four equal installments
on each of the first four anniversaries of December 31, 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Each of these options was granted on June 11, 2020 and vests in four equal installments on each
of the first four anniversaries of December 31, 2020. The exercise price is $2.63, being the closing price of the Company&rsquo;s
Common Stock on the grant date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">These market condition restricted stock units were granted on June 11, 2020 with performance based
vesting conditions. The RSUs vest in three equal annual installments on June 11, 2021, June 11, 2022 and June 11, 2023, and are
linked to the achievement of a relative total shareholder return of the Issuer&rsquo;s common stock from June 11, 2020 to the earlier
of June 11, 2021 or upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading
average price before each such date). The target number of these RSUs that may be earned is noted in the table above; the maximum
amount is 150% of the number reported.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">With respect to the market condition RSUs, the
target number of these restricted stock units that may be earned is reported above; the maximum amount that may be earned is 150%
of target, with a cap of 100% in the event of negative TSR. The TSR calculations will be adjusted to reflect stock splits, recapitalizations
and other similar events. The market condition RSUs will vest at target&mdash;the amount reported in the table above&mdash;if the
TSR of the Company&rsquo;s Common Stock is at the 50th percentile of companies in the Nasdaq Biotechnology index. A payout at maximum,
which is 150% of the target award, may be achieved if the relative TSR is at or above the 75th percentile of companies in the Nasdaq
Biotechnology index. In order to receive a payout at equal to 50% of the target award, the relative TSR must be at or above the
33rd percentile of companies in the Nasdaq Biotechnology index. If the relative TSR of the Company&rsquo;s Common Stock is below
the 20th percentile, the market condition RSUs will not vest and the awards will be forfeited. The complete payout matrix for the
market condition RSUs granted in fiscal 2020 is presented in the table below:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%"><FONT STYLE="font-size: 10pt"><B>Relative TSR Percentile Rank</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 69%"><FONT STYLE="font-size: 10pt"><B>Performance Factor</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">20th percentile or lower</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">0%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">21st to 32nd percentile</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">for each 1 percentile in range above 20th percentile, 4%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">33rd percentile</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">50%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">34th to 49th percentile</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">50%, plus for each 1 percentile in range above 33rd percentile, an additional 3%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">50th percentile</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">51st to 74th percentile</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">100%, plus for each 1 percentile in range above 50th percentile, an additional 2%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">75th percentile or higher</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">150%</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">In March 2021, the Compensation Committee approved adjustments to
the named executive officers&rsquo; long-term equity incentive compensation for the 2021 award cycle to better align with the Company&rsquo;s
pay-for-performance philosophy and to support long-term growth. To place greater emphasis on performance-based equity, the mix
of target equity was shifted to 50% time-based RSUs and 50% market condition RSUs. Additionally, the 2021 market condition RSUs
were linked to the achievement of a relative total shareholder return over a three-year period as opposed to one-year. Furthermore,
target payout requires above median relative performance (i.e., 51<SUP>st</SUP> percentile). The Compensation Committee intends
to continue to evaluate the long-term equity incentive design to ensure it appropriately aligns with our strategy and long-term
objectives.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">Broad-Based Benefits Programs</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">All full-time employees in the United States,
including our named executive officers, may participate in our Employee Stock Purchase Plan and in our health and welfare benefit
programs, including medical coverage, dental coverage, disability insurance, life insurance and our 401(k) plan. The 401(k) plan
provides for matching contributions equal to 100% of each dollar contributed up to 1% of eligible compensation plus 50% of each
additional 1% of eligible compensation up to 6% for a maximum matching contribution of 3.5%. We offer similar plans in foreign
countries.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">Executive Stock Ownership Guidelines</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">At the recommendation of our Compensation Committee,
our Board of Directors has implemented updated executive stock ownership guidelines with respect to our named executive officers.
Such ownership guidelines require, within five years from their initial appointment or designation as named executive officers,
our named executive officers to own our Common Stock with a market value equal to at least three times their respective annual
base salary. With respect to satisfying such guidelines, stock options are excluded in the calculation while shares owned outright
or beneficially owned (as defined under Rule 13d-3 of the Securities Exchange Act of 1934, as amended), while restricted shares,
including shares granted but not vested, shares issuable upon the settlement of RSUs and shares acquired pursuant to our Employee
Stock Purchase Plan are all included. The Compensation Committee will monitor compliance with the stock ownership guidelines, including
approving any hardship exceptions or implementing any non-compliance penalties.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">Clawbacks</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Awards under the Company&rsquo;s proposed 2021
Incentive Plan and any shares issued pursuant to such awards will be subject to recovery or &ldquo;clawback&rdquo; by the Company
if and to the extent that the vesting of such awards was determined or calculated based on materially inaccurate financial statements
or any other material inaccurate performance metric criteria; or if the Company or its subsidiaries terminate a grantee&rsquo;s
service relationship due to the grantee&rsquo;s gross negligence or willful misconduct, or determine there are grounds for such
a termination (whether or not such actions also constitute &ldquo;cause&rdquo; under an award agreement), any awards under the
2021 Incentive Plan, whether or not vested, as well as any shares of stock issued pursuant to awards under the 2021 Incentive Plan
shall be subject to forfeiture, recovery and &ldquo;clawback.&rdquo; In addition, the 2021 Incentive Plan provides that if the
Company is required to prepare an accounting restatement due to material noncompliance with the financial reporting requirements
of the securities laws, in certain cases the Compensation Committee may require the repayment of amounts paid under the 2021 Incentive
Plan in excess of what the employee would have received under the accounting restatement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Further, if the Company is required to prepare
an accounting restatement due to the material noncompliance with any financial reporting requirement under the securities laws
as a result of misconduct, the Company&rsquo;s Chief Executive Officer and Chief Financial Officer are required to reimburse the
Company for any bonus or other incentive-based or equity-based compensation received by such officer from the Company during the
twelve-month period following the first public issuance or filing with the Securities and Exchange Commission (whichever first
occurs) of the financial document embodying such financial reporting requirement, and any profits realized from the sale of securities
of Company during such twelve-month period.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">Anti-Short Selling, Anti-Margin and Hedging Policies</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Company&rsquo;s Insider Trading Guidelines
explicitly prohibit directors, officers, employees, contractors and part-time and temporary workers in possession of material non-public
information from (i) buying, selling, or otherwise transacting in Company&rsquo;s securities, including common stock, options and
any other securities that the Company may issue, such as preferred stock, notes, bonds and convertible securities, as well as derivative
securities; (ii) disclosing information to another individual for the purpose of enabling such individual to trade in the Company&rsquo;s
securities on the basis of such information; (iii) engaging in transactions designed to hedge or offset economic risks of owning
the Company&rsquo;s securities, including short sales of the Company&rsquo;s securities and selling security futures related to
the Company&rsquo;s securities; (iv) trading in options or derivatives related to the Company&rsquo;s securities; and (v) and purchasing
the Company&rsquo;s securities on margin (i.e. borrowing money to fund the stock purchase) other than the cashless exercises of
employee stock options.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">2020
Summary Compensation Table</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The table below summarizes the total compensation
paid or earned by each of the named executive officers noted below for services rendered in all capacities, including our President
and Chief Executive Officer, our Chief Financial Officer, and our Chief Operating Officer during 2020, all during the fiscal years
ended December 31, 2020 and 2019. As a smaller reporting company, we are only required to provide two years of compensation information
for our named executive officers.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><b>Name and Principal Position</b></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards ($)(1)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Awards ($)(1)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All Other Compensation ($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total ($)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 21%; font-size: 10pt; font-style: italic; text-align: left">James W. Green</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">2020</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">573,710</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">215,304</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">573,710</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">1,223,771</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">33,958</TD><TD STYLE="width: 3%; font-size: 10pt; text-align: left">(2)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">2,620,453</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9.35pt">President and Chief Executive Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2019</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">264,789</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,972,503</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,431</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,280,723</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Michael A. Rossi</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2020</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">340,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">63,798</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">113,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">241,752</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">19,278</TD><TD STYLE="font-size: 10pt; text-align: left">(3)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">778,161</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9.35pt">Chief Financial Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2019</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">145,157</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">85,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">88,821</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,569</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">320,547</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Kenneth Olson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2020</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">285,263</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">54,416</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">96,667</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">206,196</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">186,540</TD><TD STYLE="font-size: 10pt; text-align: left">(4)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">829,082</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9.35pt">Chief Operating Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2019</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">51,355</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,966</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">156,321</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Based on the aggregate grant date fair value computed in accordance with the provisions of FASB
ASC 718, &ldquo;Compensation&mdash;Stock Compensation&rdquo;. Under FASB ASC 718, the vesting condition related to the market condition
RSUs is considered a market condition and not a performance condition. Accordingly, there is no grant date fair value below or
in excess of the amount reflected in the table above for the named executive officers that could be calculated and disclosed based
on achievement of the underlying market condition. Assumptions used in the calculation of this amount are set forth in Note 10
to the Company&rsquo;s audited financial statements for the fiscal year ended December 31, 2020, included in the Company&rsquo;s
Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Includes $12,000 for personal usage of Company leased automobile (as calculated in accordance with
Internal Revenue Service guidelines and included as compensation on the W-2), $15,230 in Company medical, dental and other insurance
matching, and $6,728 in matching contributions made by the Company to Mr. Green&rsquo;s tax-qualified 401(k) Savings Plan account.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Includes $17,897 in Company medical, dental and other insurance matching, and $1,381 in matching
contributions made by the Company to Mr. Rossi&rsquo;s tax-qualified 401(k) Savings Plan account.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">Includes $7,700 for personal usage of Company leased automobile (as calculated in accordance with
Internal Revenue Service guidelines and included as compensation on the W-2), $7,398 in Company medical, dental and other insurance
matching, $9,396 in matching contributions made by the Company to Mr. Olson&rsquo;s tax-qualified 401(k) Savings Plan account,
and $162,047 for relocation expenses.</TD></TR></TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-style: italic; font-weight: bold">Employment Agreements</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Chief
Executive Officer</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We have entered into an employment agreement
with Mr. Green, dated July 2, 2019, which provides for a term of two years from his commencement date of July 8, 2019, which such
term shall automatically be extended for two additional years on each anniversary of the commencement date unless, not less than
90 days prior to each such date, either party shall have given written notice to the other that it does not wish to extend the
agreement. In addition, the agreement provides for an annual base salary, which is subject to review annually by our Board of Directors
and Compensation Committee. Furthermore, commencing with fiscal year 2020, Mr. Green is eligible to receive cash incentive compensation
on an annual basis of up to one hundred fifty percent (150%) of his base salary upon meeting objectives as determined by the Board
of Directors or the Compensation Committee from time to time. Mr. Green is also eligible to participate in other incentive compensation
plans as the Board of Directors or Committee shall provide for the Company&rsquo;s senior executive officers.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Chief
Financial Officer</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We have entered into an employment agreement
with Mr. Rossi, dated July 18, 2019, which provides for a term of one year, which such term shall automatically be extended for
one additional year on each anniversary of the commencement date unless, not less than 90 days prior to each such date, either
party shall have given written notice to the other that it does not wish to extend the agreement. In addition, the agreement provides
for an annual base salary, which is subject to review annually by our Board of Directors and Compensation Committee. Furthermore,
commencing with fiscal year 2020, Mr. Rossi is eligible to receive cash incentive compensation on an annual basis of up to fifty
percent (50%) of his Base Salary upon meeting objectives as determined by the Board of Directors or the Compensation Committee
from time to time. Mr. Rossi is also eligible to participate in other incentive compensation plans as the Board of Directors or
Committee shall provide for the Company&rsquo;s senior executive officers.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Outstanding
Equity Awards At Fiscal Year-End&mdash;2020</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following table sets forth information concerning
the number and value of exercisable and unexercisable options to purchase Common Stock, and the number of time-based and market
condition RSUs held by the applicable named executive officers noted below as of December 31, 2020.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="13" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Awards</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Number of Securities Underlying Unexercised Options (#) Exercisable</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Number of Securities Underlying Unexercised Options (#) Unexercisable</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Option Exercise Price ($)</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Option Expiration Date</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Number of Shares or Units of Stock That Have Not Vested (#)</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Market Value of Shares or Units of Stock That Have Not Vested ($)(1)</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(1)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; font-size: 10pt; text-align: left">James W. Green</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">60,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">5.27</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">5/5/2025</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: right">243,072 (3)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">1,042,779</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: right">418,360 (6)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">1,794,764</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">117,564</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">352,690 (2)</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.63</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/11/2030</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">313,770 (4)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,346,073</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">218,141 (7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">935,825</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">163,606 (5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">701,870</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Michael A. Rossi</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27,960</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">83,882 (8)</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.78</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">7/18/2029</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">32,320 (5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">138,653</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">47,752 (9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">204,856</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,224</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">69,672 (2)</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.63</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/11/2030</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">43,093 (7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">184,869</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Kenneth Olson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,259</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">27,778 (10)</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.95</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">11/1/2029</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">27,566 (5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">118,258</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">10,057 (11)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,145</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,809</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">59,426 (2)</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.63</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/11/2030</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">36,755 (7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">157,679</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Based on a closing stock price of $4.29 per share on December 31, 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The option was granted on June 11, 2020 and, assuming continued employment with the Company, the
unvested options become exercisable in equal installments on December 31 of each of 2021, 2022 and 2023.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">These RSUs were granted on July 8, 2019 and, assuming continued employment with the Company, the
unvested shares vest in full on July 8, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">These RSUs were granted on July 8, 2019 and, assuming continued employment with the Company, the
unvested shares vest in equal installments on January 1 of each of 2021, 2022 and 2023.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">These RSUs were granted on June 11, 2020 and, assuming continued employment with the Company, the
unvested shares vest in equal installments on December 31 of each of 2021, 2022 and 2023.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: justify">These market condition RSUs were granted on July 8, 2019 with performance-based vesting conditions.
The RSUs vest in three equal installments on July 8, 2020, July 8, 2021 and July 8, 2022, and are linked to the achievement of
a relative total shareholder return of the Company&rsquo;s Common Stock from July 8, 2019 to the earlier of July 8, 2020 or upon
a change of control (measured relative to the Nasdaq Biotechnology index and based on the 20-day trading average price before each
such date, or for a change of control, the per share purchase price in such change of control). The maximum number of RSUs was
earned on July 8, 2020 and an additional 209,179 shares were added to the award.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD STYLE="text-align: justify">These market condition RSUs were granted on June 11, 2020 with performance-based vesting conditions.
The RSUs vest in three equal installments on June 11, 2021, June 11, 2022 and June 11, 2023, and are linked to the achievement
of a relative total shareholder return of the Company&rsquo;s Common Stock from June 11, 2020 to the earlier of June 11, 2021 or
upon a change of control (measured relative to the Nasdaq Biotechnology index and based on the 20-day trading average price before
each such date, or for a change of control, the per share purchase price in such change of control). The target number of these
RSUs that may be earned is noted in the table above; the maximum amount is 150% of the numbers reported.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(8)</TD><TD STYLE="text-align: justify">The option was granted on July 18, 2019 and, assuming continued employment with the Company, the
unvested options become exercisable in equal installments on July 18 of each of 2021, 2022 and 2023.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(9)</TD><TD STYLE="text-align: justify">These market condition RSUs were granted on July 18, 2019 with performance-based vesting conditions.
The RSUs vest in three equal installments on July 18, 2020, July 18, 2021 and July 18, 2022, and are linked to the achievement
of a relative total shareholder return of the Company&rsquo;s Common Stock from July 18, 2019 to the earlier of July 18, 2020 or
upon a change of control (measured relative to the Nasdaq Biotechnology index and based on the 20-day trading average price before
each such date, or for a change of control, the per share purchase price in such change of control). The maximum number of RSUs
was earned on July 18, 2020 and an additional 23,876 shares were added to the award.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(10)</TD><TD STYLE="text-align: justify">The option was granted on November 1, 2019 and, assuming continued employment with the Company,
the unvested options become exercisable in equal installments on November 1 of each of 2021, 2022 and 2023.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(11)</TD><TD STYLE="text-align: justify">These market condition RSUs were granted on November 1, 2019 with performance-based vesting conditions.
The RSUs vest in three equal installments on November 1, 2020, November 1, 2021 and November 1, 2022, and are linked to the achievement
of a relative total shareholder return of the Company&rsquo;s Common Stock from November 1, 2019 to the earlier of November 1,
2020 or upon a change of control (measured relative to the Nasdaq Biotechnology index and based on the 20-day trading average price
before each such date, or for a change of control, the per share purchase price in such change of control). The performance factor
on November 1, 2020 was 89% and 1,863 shares were forfeited from the award.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in">Potential
Payments upon Termination or Change-in-Control</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>Termination Arrangements with Current Named Executive Officers</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The employment agreements with Mr. Green and
Mr. Rossi also require the Company to provide certain payments and benefits in the event of a termination of the executive&rsquo;s
employment by us without cause, by the executive for good reason, upon death or disability or in relation to a change-in-control.
The events constituting cause, good reason and a change-in-control are specified in the respective agreement. Such benefits include,
without limitation, accrued and unpaid base salary to the date of termination, accrued and unused vacation, and if to the extent
required by law, any bonuses or other compensation actually earned for periods ended prior to the termination event. These employment
agreements also provide change-in-control benefits, and have customary best net/modified economic cutback provisions in relation
to Section 280G of the Internal Revenue Code. In some instances, the executive&rsquo;s receipt of such payments and other benefits
in connection with such a termination is subject to the executive signing a general release of claims, as provided in the respective
employment agreement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">With respect to termination due to death or
disability, all equity awards of the named executive officers shall accelerate and fully vest and we shall also pay a cash lump
sum equal to the value of COBRA premiums for a period of twelve (12) months following the termination that may be used by the executive
or his spouse and dependents, as applicable, to pay for health insurance coverage that is substantially similar to the coverage
executive and his eligible dependents received prior to the termination.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In the case of a termination by the executive
for good reason, or by us without cause, and subject to the terms of the agreement, (i) we shall pay the executive an amount equal
to eighteen (18) months for Mr. Green, and twelve (12) months for Mr. Rossi of his respective base salary rate in equal installments
over the period of one year from the date of termination in accordance with our payroll procedures and (ii) any stock options or
other stock based grants which would otherwise vest within 12 months of the date of termination shall become fully vested or non-forfeitable
(provided that with respect to Mr. Green, as to the time-based RSUs granted in connection with his hiring, such period shall be
24 months, and with respect to the market condition RSUs granted in connection with his hiring, the performance period would be
measured as to the period from grant through the termination event). Further, following any such termination, we shall reasonably
determine what annual bonus the executive would have received had he remained employed throughout the fiscal year in which the
termination occurs, and if any such annual bonus would have been earned, we shall pay the executive a pro rata portion of such
determined annual bonus by a lump-sum cash payment. In addition, following the termination we shall also pay a cash lump sum equal
to the value of COBRA premiums for a period of eighteen (18) months for Mr. Green, and twelve (12) months for Mr. Rossi, following
the termination that may be used by the respective executive to pay for health insurance coverage that is substantially similar
to the coverage executive and his eligible dependents received prior to the termination.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In the event that the executive is terminated
within three months prior to, or twelve months after, a change in control (as described in his employment agreement), we shall
pay the executive a single lump sum in cash equal to twenty-four (24) months as to Mr. Green, and eighteen (18) months as to Mr.
Rossi, of his respective base salary, and all stock options and other stock-based awards granted to the executive shall immediately
accelerate and become exercisable or non-forfeitable as of the date of the change in control (and as to Mr. Green, with respect
to the market condition RSUs granted in connection with his hiring, the performance period would be measured as to the period from
grant through the change of control event). In addition, following such termination we shall also pay a cash lump sum equal to
the value of COBRA premiums for a period of twenty four (24) months for Mr. Green, and eighteen (18) months for Mr. Rossi, following
the termination that may be used by the respective executive to pay for health insurance coverage that is substantially similar
to the coverage executive and his eligible dependents received prior to the termination.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We believe that it is fair to provide for accelerated
vesting because equity grants generally provide a high proportion of the total compensation of our executive officers. Very often,
senior management lose their jobs in connection with a change-in-control. By agreeing up front to protect these executive officers
from losing their equity in the event of a change-in-control, we believe we can reinforce and encourage the continued attention
and dedication of our executive officers to their assigned duties without distraction in the face of an actual or threatened change-in-control.
This protection also aligns the interests of such executive officers with that of our stockholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Security
Ownership Of Certain Beneficial Owners And Management</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following table sets forth information regarding
the beneficial ownership of our outstanding Common Stock as of March 24, 2021 by: (i) all persons known by us to own beneficially
more than 5% of our Common Stock; (ii) each of our Directors and nominees for Director; (iii) each of the named executive officers;
and (iv) all of our Directors and executive officers as a group.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The number of shares beneficially owned by each
stockholder is determined under rules issued by the SEC and includes voting or investment power with respect to securities. Under
these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment
power and includes any shares as to which the individual or entity has the right to acquire beneficial ownership within 60 days
after March 24, 2021 through the exercise of any warrant, stock option or other right. The inclusion in this proxy statement of
such shares, however, does not constitute an admission that the named stockholder is a direct or indirect beneficial owner of such
shares. Common stock subject to options currently exercisable, or exercisable within 60 days after March 24, 2021, are deemed outstanding
for the purpose of computing the percentage ownership of the person holding those options, but are not deemed outstanding for computing
the percentage ownership of any other person.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Unless otherwise indicated below, to our knowledge,
all persons named in the table have sole voting and investment power with respect to their shares of Common Stock, except to the
extent spouses share authority under community property laws.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock Beneficially Owned</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner (1)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent (2)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Greater than 5% Holders</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 63%; font-size: 10pt; text-align: left">BlackRock, Inc.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">2,953,905</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">7.4</TD><TD STYLE="width: 5%; font-size: 10pt; text-align: left">%(3)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">55 East 52nd Street</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">New York, NY 10055</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Chane Graziano</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,546,107</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.4</TD><TD STYLE="font-size: 10pt; text-align: left">%(4)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">23610 Peppermill Court</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Bonita Springs, FL 34134</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Dimensional Fund Advisors, LP</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,026,991</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.1</TD><TD STYLE="font-size: 10pt; text-align: left">%(5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">6300 Bee Cave Road, Building One</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Austin, TX 78746</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Non-Employee Directors (1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Bertrand Loy</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">380,217</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*<FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">(6)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">John F. Kennedy</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">350,503</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*<FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">(7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Katherine Eade</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">260,065</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*<FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">(8)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Thomas Loewald</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">243,425</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*<FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">(8)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Alan Edrick</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">137,609</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*<FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">(9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Susan Steele</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79,934</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*<FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">(10)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Named Executive Officers (1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">James Green</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">823,610</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.1</TD><TD STYLE="font-size: 10pt; text-align: left">%(11)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Michael A. Rossi</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,296</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">(12)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Kenneth Olson</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">45,730</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"></FONT>*</TD><TD STYLE="font-size: 10pt; text-align: left">(13)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">All Executive Officers and Directors, as a group (9 persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,396,389</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.9</TD><TD STYLE="font-size: 10pt; text-align: left">%(14)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD STYLE="text-align: justify">Represents beneficial ownership of less than one percent (1%) of our outstanding Common Stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">The address for all non-employee directors and named executive officers is c/o Harvard Bioscience,
Inc., 84&nbsp;October Hill Road, Holliston, Massachusetts 01746.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Based on 39,927,257 shares outstanding on March 24, 2021 together with the applicable options and
restricted stock units for each stockholder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">This information is based solely upon a Schedule 13G filed by BlackRock, Inc. with the Securities
and Exchange Commission on February 2, 2021, reporting sole voting power over 2,918,193 shares and sole dispositive power over
2,953,905 shares.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">This information is based solely upon a Schedule 13G/A filed by Chane Graziano with the SEC on
May 13, 2019, reporting sole voting power over 2,546,107 shares and sole dispositive power over 2,546,107 shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">This information is based solely upon a Schedule 13G/A filed by Dimensional Fund Advisors, LP with
the Securities and Exchange Commission on February 12, 2021, reporting sole voting power over 1,906,529 shares and sole dispositive
power over 2,026,991 shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: justify">Includes options to acquire 55,300 shares that are exercisable within 60 days after March 24, 2021,
as well as 28,100 restricted stock units that will fully vest within 60 days after March 24, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD STYLE="text-align: justify">Includes options to acquire 37,059 shares that are exercisable within 60 days after March 24, 2021,
as well as 28,100 restricted stock units that will fully vest within 60 days after March 24, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(8)</TD><TD STYLE="text-align: justify">Includes options to acquire 87,600 shares that are exercisable within 60 days after March 24, 2021,
as well as 28,100 restricted stock units that will fully vest within 60 days after March 24, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(9)</TD><TD STYLE="text-align: justify">Includes options to acquire 33,934 shares that are exercisable within 60 days after March 24, 2021,
as well as 28,100 restricted stock units that will fully vest within 60 days after March 24, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(10)</TD><TD STYLE="text-align: justify">Includes options to acquire 38,634 shares that are exercisable within 60 days after March 24, 2021,
as well as 28,100 restricted stock units that will fully vest within 60 days after March 24, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(11)</TD><TD STYLE="text-align: justify">Includes options to acquire 177,564 shares that are exercisable within 60 days after March 24,
2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(12)</TD><TD STYLE="text-align: justify">Includes options to acquire 51,184 shares that are exercisable within 60 days after March 24, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(13)</TD><TD STYLE="text-align: justify">Includes options to acquire 29,068 shares that are exercisable within 60 days after March 24, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in">(14) Includes options to acquire
597,943 shares that are exercisable within 60 days after March 24, 2021.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.25in; font-size: 10pt; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 0.25in; font-size: 10pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Equity
Compensation Plan Information</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following table sets forth information as
of December 31, 2020 concerning the number of shares of Common Stock issuable under our existing equity compensation plans.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Plan Category</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Securities to be Issued Upon Exercise of Outstanding Options, Restricted Stock Units, Warrants and Rights</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price of Outstanding Options, Warrants, And Rights</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected In Column&nbsp;(a))</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(a)</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(b)</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(c)</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Equity compensation plans approved by security holders (1)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">5,010,831</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">3.51</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">3,168,058</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Equity compensation plans not approved by security holders</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">0.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,010,831</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,168,058</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Consists of the Harvard Bioscience, Inc. Fourth Amended and Restated 2000 Stock Option and Incentive
Plan (the &ldquo;Prior Plan&rdquo;) and the Harvard Bioscience, Inc. Employee Stock Purchase Plan (as amended, the &ldquo;ESPP&rdquo;).
Number of securities in column (a) for plans approved by security holders consists of 2,637,339 outstanding stock options and 2,373,492
RSUs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Represents 2,975,717 shares available for future issuance under the Prior Plan and 192,341 shares
available for future issuance under the ESPP.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Transactions
With Related Persons</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Audit Committee charter sets forth the standards,
policies and procedures that we follow for the review, approval or ratification of any related person transaction that we are required
to report pursuant to Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission. Pursuant to the Audit
Committee charter, the Audit Committee reviews these related person transactions on an ongoing basis and the approval of the Audit
Committee is required for all such transactions. The Audit Committee relies on management to identify related person transactions
and bring them to the attention of the Audit Committee.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Aside from the indemnification agreements we
have entered into with each of our Directors, each of which provides that we will indemnify our Directors for expenses incurred
because of their status as a Director to the fullest extent permitted by Delaware law, our certificate of incorporation and our
by-laws, during the 2020 fiscal year, we were not a participant in any related person transactions that required disclosure under
this heading.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Delinquent
Section 16(A) Reports</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our executive officers, Directors and beneficial
owners of more than 10% of our Common Stock are required under Section 16(a) of the Securities Exchange Act of 1934 to file reports
of ownership and changes in ownership with the Securities and Exchange Commission. Copies of those reports must also be furnished
to us.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Based solely on a review of the copies of the
reports furnished to us, and written representations from certain reporting persons that no other reports were required, we believe
that during the year ended December 31, 2020, the reporting persons complied on a timely basis with all Section 16(a) filing requirements
applicable to them, other than (i) Mr. Loy, who had one late filing reporting his forfeiture of certain restricted stock units
as a result of a committee change, and (ii) Mr. Kennedy, who had one late filing reporting his forfeiture of certain restricted
stock units as a result of a committee change.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Stockholder
Communications With The Board Of Directors</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Stockholders and other interested parties wishing
to communicate with the Board of Directors may do so by sending a written communication to any Director at the following address:
Harvard Bioscience, Inc., 84 October Hill Road, Holliston, Massachusetts 01746. The mailing envelope should contain a notation
indicating that the enclosed letter is a &ldquo;Board Communication.&rdquo; All such letters should clearly state whether the intended
recipients are all members of the Board of Directors or certain specified individual Directors. Our Secretary or his or her designee
will make a copy of any such communication so received and promptly forward it to the Director or Directors to whom it is addressed.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Independent
Registered Public Accounting Firm</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following table presents fees for professional
services provided by Grant Thornton LLP for the audits of the Company&rsquo;s annual consolidated financial statements for the
last two fiscal years, in each of the following categories is as set forth in the table below.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Audit Fees (1)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">1,026,037</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">1,246,414</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Audit-Related Fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Tax Fees (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,353</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">204,161</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other (3)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total Fees</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,060,390</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,450,574</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Audit Fees included fees billed or expected to be billed for professional services associated with
the annual audit of our consolidated financial statements and internal controls over financial reporting and the reviews of our
quarterly reports on Form 10-Q, and fees related to the registration statement on Form S-8.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Tax Fees included domestic and international tax compliance, tax advice and tax planning.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Grant Thornton LLP did not provide any &ldquo;other services&rdquo; during the period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">All of the services performed in the year ended
December 31, 2020 were pre-approved by the Audit Committee. It is the Audit Committee&rsquo;s policy to pre-approve all audit and
permitted non-audit services to be provided to us by the independent registered public accounting firm. The Audit Committee&rsquo;s
authority to pre-approve non-audit services may be delegated to one or more members of the Audit Committee, who shall present all
decisions to pre-approve an activity to the full Audit Committee at its first meeting following such decision. The Audit Committee
has delegated this pre-approval authority to its Chairman for non-audit services. In addition, the Audit Committee has considered
whether the provision of the non-audit services above is compatible with maintaining the independent registered public accounting
firm&rsquo;s independence.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Proposal
2<BR>
Ratification Of Appointment Of Independent Registered Public<BR>
Accounting Firm</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Audit Committee of the Board of Directors
has appointed Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
Grant Thornton LLP has served as our independent registered public accounting firm since 2017. The Audit Committee is responsible
for the appointment, retention, termination, compensation and oversight of the work of our independent registered public accounting
firm. To execute this responsibility, the Audit Committee annually evaluates the independent auditor&rsquo;s qualifications, performance
and independence and whether the independent registered public accounting firm should be rotated, and considers the advisability
and potential impact of selecting a different independent registered public accounting firm.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Although ratification of the appointment of
our independent registered public accounting firm is not required by our Bylaws or otherwise, the Board is submitting the appointment
of Grant Thornton LLP to our stockholders for ratification because we value the views of our stockholders. In the event that our
stockholders fail to ratify the appointment of Grant Thornton LLP, the Audit Committee will reconsider the appointment of Grant
Thornton LLP. Even if the appointment is ratified, the ratification is not binding and the Audit Committee may in its discretion
select a different independent registered public accounting firm at any time during the year if it determines that such a change
would be in the best interests of the Company and our stockholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A representative of Grant Thornton LLP is expected
to be present virtually at the Annual Meeting. He or she will have an opportunity to make a statement, if he or she desires to
do so, and will be available to respond to appropriate questions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Vote Required</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The affirmative vote of a majority of the votes
cast by holders of shares of Common Stock present or represented by proxy and entitled to vote on the matter at the Annual Meeting
is required for the ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm
for the fiscal year ending December 31, 2021.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE &ldquo;FOR&rdquo; THE RATIFICATION OF THE APPOINTMENT OF GRANT THORNTON LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2021.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Proposal
3<BR>
Adoption and approval Of The Harvard Bioscience, Inc. 2021 Incentive Plan</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Board of Directors has adopted and is seeking
stockholder approval of the Harvard Bioscience, Inc. 2021 Incentive Plan (the &ldquo;2021 Incentive Plan&rdquo;), including the
authority to issue approximately 4.2 million shares of common stock (subject to adjustment for stock splits, stock dividends, and
similar events) under the 2021 Incentive Plan. The Board is proposing a new plan rather than simply amending its existing Fourth
Amended and Restated 2000 Stock Option and Incentive Plan (the &ldquo;Prior Plan&rdquo;) because recent changes in tax laws make
certain of the provisions in the Prior Plan (including those related to Section 162(m) of the Code) unnecessary with respect to
prospective awards. The Board adopted the 2021 Incentive Plan on April 6, 2021, subject to stockholder approval of the 2021 Incentive
Plan at the Annual Meeting. Awards will not be made under the 2021 Incentive Plan until stockholder approval is obtained for the
2021 Incentive Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Board believes that an adequate reserve
of shares available for issuance is necessary to enable the Company to attract, motivate, and retain key employees, directors,
advisors to and consultants of the Company, its affiliates and/or its subsidiaries through the use of competitive incentives that
are tied to stockholder value and other factors. For this purpose, subject to the approval of stockholders, the Board adopted the
2021 Incentive Plan based in part on a belief that the number of shares currently available under the Company&rsquo;s existing
equity incentive plan does not allow for sufficient authority and flexibility to adequately provide for future incentives. If our
stockholders do not approve the 2021 Incentive Plan, there are insufficient shares available under the Company&rsquo;s existing
equity incentive plans to make grants to new and continuing employees and non-employee directors. In that event, the Compensation
Committee would be required to revise its compensation philosophy and create other non-equity related compensation programs to
attract, retain and compensate executives, non-employee directors and other key employees. The 2021 Incentive Plan will become
effective on the date it is approved by the Company&rsquo;s stockholders (the &ldquo;Effective Date&rdquo;). Upon stockholder approval,
this 2021 Incentive Plan will be the only long-term incentive plan under which equity compensation may then be awarded to our employees,
consultants, and members of the Board. Awards currently outstanding under the Prior Plan will remain outstanding under such plans
in accordance with their terms.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Vote Required</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The proposal to approve the 2021 Incentive Plan
will be approved upon the affirmative vote of a majority of the votes properly cast for and against such matter. Abstentions and
broker non-votes are not included in the number of votes cast for and against a matter and therefore have no effect on the vote
on such matter.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>THE BOARD OF DIRECTORS OF THE COMPANY UNANIMOUSLY
RECOMMENDS A VOTE &ldquo;FOR&rdquo; THE ADOPTION AND APPROVAL OF THE HARVARD BIOSCIENCE, INC. 2021 INCENTIVE PLAN.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Summary of the proposed 2021 Incentive Plan</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following is a summary of the material terms
of the 2021 Incentive Plan. This summary is not complete and is qualified in its entirety by reference to the full text of the
Form of 2021 Incentive Plan attached to this Proxy Statement as&nbsp;<B>Annex A</B>, which assumes that this Proposal 3 is approved.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Purpose</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The 2021 Incentive Plan allows the Company to
provide employees, consultants and all members of the Board who are selected to receive awards under the 2021 Incentive Plan the
opportunity to acquire an equity interest in the Company. The Board believes that equity incentives are a significant factor in
attracting and motivating eligible persons whose present and potential contributions are important to the Company and aligning
their interests with those of our shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Proposed Share Reserve</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">On the Effective Date, a total of (i) 2,200,000
shares of common stock <I>plus</I> (ii) the number of shares available for grant under the Prior Plan as of the Effective Date,
will be available for issuance pursuant to awards granted under the 2021 Incentive Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Impact on Dilution and Fully-Diluted Overhang</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">Our Board recognizes the impact of dilution on our shareholders and
has evaluated this share request carefully in the context of the need to motivate, retain and ensure that our leadership team is
focused on our strategic and long-term growth priorities.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">The following table sets forth certain information as of March 24,
2021, unless otherwise noted, with respect to the Company&rsquo;s equity compensation plans:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 79%; padding-left: 4.1pt">Stock Options/SARs Outstanding</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-left: 4.1pt; text-align: center">1,852,861</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 4.1pt">Weighted-Average Exercise Price of Outstanding Stock Options/SARs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 4.1pt; text-align: center">$3.14</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 4.1pt">Weighted-Average Remaining Term of Outstanding Stock Options/SARs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 4.1pt; text-align: center">6.2 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 4.1pt">Total Stock-Settled Full-Value Awards Outstanding</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 4.1pt; text-align: center">3,053,174</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 4.1pt">Remaining shares available for grant under the Prior Plan* </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 4.1pt; text-align: center">1,964,046</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 4.1pt">Additional shares being requested under the 2021 Incentive Plan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 4.1pt; text-align: center">2,200,000</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 4.1pt">Basic common shares outstanding as of the record date (March 24, 2021)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 4.1pt; text-align: center">39,927,257</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><BR>
* The actual number of shares to be rolled-over into the 2021 Incentive Plan will be equal to the actual number of shares which
remain available for grant under the Prior Plan as of the Effective Date of the 2021 Incentive Plan. Upon stockholder approval
of the 2021 Incentive Plan, no further awards will be made under the Prior Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Board believes that the number of shares
of common stock that would be available for issuance under the 2021 Incentive Plan represents a reasonable amount of potential
equity dilution given our strategic and long-term growth priorities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Expected Duration of the Share Reserve</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If this proposal is approved by our shareholders,
we expect that the share reserve under the 2021 Incentive Plan will be sufficient for awards for at least two to four years. Expectations
regarding future share usage could be impacted by a number of factors, such as award type mix; hiring and promotion activity at
the executive level; the rate at which shares are returned to the 2021 Incentive Plan&rsquo;s reserve upon the awards&rsquo; expiration,
forfeiture or cash settlement; the future performance of our stock price; the consequences of acquiring other companies; and other
factors. While we believe that the assumptions we used are reasonable, future share usage may differ from current expectations.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Burn Rate</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information regarding our equity awards
granted and performance-based equity awards earned over each of the last three fiscal years:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-size: 10pt; text-align: left">Stock options granted</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">894,154</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">943,424</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">104,585</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Restricted stock units granted and stock-settled performance units earned</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,267,691</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,656,498</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">708,793</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Total awards granted (1)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">2,161,845</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">2,599,922</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">813,378</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Weighted-average basic common shares outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">38,640,284</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37,813,580</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">36,453,126</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Annual burn rate</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">5.59</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">%</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">6.88</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">%</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">2.23</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">With respect to performance-based RSUs in the table above, we calculate the share usage rate based
on the applicable number of shares earned each year. For reference, the performance-based RSUs granted during the foregoing 3-year
period were as follows: 332,622 shares in 2020, 605,005 shares in 2019 and 156,944 shares in 2018.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.25in; font-size: 10pt; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 0.25in; font-size: 10pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Key Provisions</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following is a summary of the key provisions
of the 2021 Incentive Plan:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: left; text-indent: 0in">Plan Termination Date:</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 73%; text-align: left; text-indent: 0in">Ten years from the Effective Date</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Eligible Participants:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Employees, officers, directors, consultants and advisors (except that only employees are eligible for Incentive Stock Options)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Shares Authorized:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">The sum of (i) 2,200,000 shares plus (ii) the number of shares available for grant under the Prior Plan as of the Effective Date, subject to certain adjustments as set forth in the 2021 Incentive Plan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Award Types:</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(1) Incentive Stock Options</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(2) Non-qualified Stock Options</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(3) Restricted Stock</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(4) Stock Appreciation Rights</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(5) Performance Bonus Awards</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(6) Deferred Stock</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(7) Restricted Stock Units</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(8) Dividend Equivalents</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(9) Performance Stock Units</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(10) Performance Share Awards</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">(11) Other Stock-Based Awards</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Vesting:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Determined by the Compensation Committee. Subject to the acceleration of vesting in certain circumstances as permitted under the terms of the 2021 Incentive Plan, each award under the 2021 Incentive Plan will have a minimum vesting period of one year, except under certain limited circumstances and with permitted exceptions up to 5% of the share reserve.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Not Permitted:</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">No discount stock options or stock appreciation rights</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">No &ldquo;liberal share recycling&rdquo; of options
        or stock appreciation rights</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">No payment of dividends or dividend equivalents on
        unvested awards</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">No repricing of stock options and amendments that
        under the Internal Revenue Code (the &ldquo;Code&rdquo;) or Nasdaq rules require stockholder approval</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font-size: 10pt; text-align: left; text-indent: 0in; margin: 0pt 0">No &ldquo;evergreen&rdquo; share increases or automatic
        &ldquo;reload&rdquo; awards</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Incentive Stock Option Limit:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">No more than 2,000,000 shares may be issued pursuant to incentive stock options</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">Limitation on Number of Shares Granted to Non-Employee Directors:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">The sum of the grant date fair market value of equity-based awards and the amount of
any cash-based awards granted to a non-employee director during any calendar year, under the 2021 Incentive Plan, may not exceed
$500,000</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0"><B>Awards under the 2021 Incentive Plan</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Stock Options.</I>&nbsp;The 2021 Incentive
Plan permits the Compensation Committee to issue incentive stock options and non-qualified stock options to participants, which
directly link their financial success to that of the Company&rsquo;s stockholders. The Compensation Committee shall determine the
number of shares subject to options and all other terms and conditions of the options, including vesting requirements. In no event,
however, may the exercise price of a stock option be less than 100% of the fair market value of the Company&rsquo;s common stock
on the date of the stock option&rsquo;s grant, nor may any option have a term of more than ten years. Except for adjustments based
on changes in the corporate structure or as otherwise provided in the 2021 Incentive Plan, the terms of an option may not be amended
to reduce the exercise price nor may options be canceled or exchanged for cash, other awards or options with an exercise price
that is less than the exercise price of the original options.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Additionally, in the case of an incentive stock
option granted to any individual who, at the date of grant, owns stock possessing more than ten percent (10%) of the total combined
voting power all classes of stock of the Company, such incentive stock option shall be granted at a price that is not less than
one hundred and ten percent (110%) of fair market value on the date of grant and such incentive stock option shall be exercisable
for no more than five (5) years from the date of grant.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">As of March 24, 2021, the fair market value
of a share of our common stock was $5.50.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Stock Appreciation Rights.</I>&nbsp;The 2021
Incentive Plan permits the Compensation Committee to issue stock appreciation rights (&ldquo;SARs&rdquo;), either free-standing
or in tandem with stock options. The Compensation Committee shall determine the number of SARs to be granted and other terms and
conditions of the SARs. In no event, however, may the exercise of a SAR be less than 100% of the fair market value of the Company&rsquo;s
common stock on the date of grant, and the terms shall not exceed ten years. SARs may be settled in cash, stock, or a combination
of both.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Restricted Stock and Restricted Stock Units.</I>&nbsp;The
2021 Incentive Plan permits the Compensation Committee to grant restricted stock awards. Each share of restricted stock shall be
subject to such terms, conditions, restrictions, and/or limitations, if any, as the Compensation Committee deems appropriate, including,
but not by way of limitation, restrictions on transferability and continued employment. Holders of shares of restricted stock may
vote the shares and receive dividends on such shares. Notwithstanding the foregoing, with respect to a share of restricted stock,
dividends shall only be paid out to the extent that the share of restricted stock vests. The vesting period for restricted stock
shall be determined by the Compensation Committee, which may accelerate the vesting of any such award. The Compensation Committee
may also grant restricted stock units, which have substantially the same terms as restricted stock, except that units have no voting
rights, and unless otherwise determined by the Compensation Committee, will not receive dividends or dividend equivalents (which
in an event shall only be paid out to the extent that the restricted stock units vest). The Compensation Committee may also grant
unrestricted stock under this provision.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Performance Shares and Performance Stock
Units.</I>&nbsp;The 2021 Incentive Plan permits the Compensation Committee to issue &ldquo;performance shares&rdquo; and &ldquo;performance
stock units.&rdquo; These are contingent incentive awards that are converted into stock and/or cash and paid out to the participant
only if specific performance goals are achieved over performance periods, as set by the Compensation Committee. If the performance
goals are not achieved, the awards are canceled or reduced. Performance shares are each equivalent in value to a share of common
stock (payable in cash and/or stock), while performance stock units are equal to a specific amount of cash.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Stock Payments and Other Stock-Based Awards.</I>&nbsp;The
2021 Incentive Plan also permits the Compensation Committee to grant awards of deferred stock, dividend equivalents, other stock-based
awards, and performance bonus awards as provided in the 2021 Incentive Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Eligible for Participation.</I>&nbsp;Persons
eligible to participate in the 2021 Incentive Plan include employees, directors, consultants and advisors, as determined by the
Compensation Committee. Approximately 459 employees and 4 nonemployee directors currently are eligible to participate in the 2021
Incentive Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Available Shares.</I>&nbsp;The 2021 Incentive
Plan authorizes the issuance of an aggregate number of shares of common stock equal to the sum of (i) 2,200,000 shares plus (ii)
the number of shares available for grant under the Prior Plan as of the Effective Date, subject to certain adjustments as set forth
in the 2021 Incentive Plan. Upon the effectiveness of the 2021 Incentive Plan, no further awards shall be granted under the Prior
Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If an outstanding award under the 2021 Incentive
Plan or the Prior Plan expires or is terminated or canceled for any reason without having been exercised or settled in full, or
if shares acquired pursuant to an award subject to forfeiture are forfeited under the 2021 Incentive Plan or the Prior Plan, the
shares allocable to the terminated portion of such award or such forfeited shares shall again be available for issuance under the
2021 Incentive Plan. Shares shall not be deemed to have been issued pursuant to the 2021 Incentive Plan with respect to any portion
of an award that is settled in cash. In the event that withholding tax liabilities arising from a full-value award (i.e., an award
other than an option or stock appreciation right) or, after the Effective Date, arising from a full-value award under the Prior
Plan, are satisfied by the delivery or withholding of shares, the shares so tendered or withheld shall be added to the 2021 Incentive
Plan&rsquo;s reserve.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding anything to the contrary, the
following shares shall not again be made available for issuance or delivery under the 2021 Incentive Plan: (i) shares tendered
in payment of an option; (ii) shares delivered or withheld by the Company to satisfy any tax withholding obligation with respect
to an option or stock appreciation right; (iii) shares covered by a stock-settled stock appreciation right that were not issued
upon the settlement of the stock appreciation right; or (iv) shares purchased on the open market with option proceeds.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In the event of merger, reorganization, consolidation,
recapitalization, separation, split-up, liquidation, share combination, stock split, stock dividend, an extraordinary cash distribution
on stock, a corporate separation or other reorganization or liquidation or other change in the corporate or capital structure of
the Company, as described in the 2021 Incentive Plan, affecting the shares that may be issued under the 2021 Incentive Plan, an
adjustment shall be made in the number and class of shares which may be delivered under the 2021 Incentive Plan (including but
not limited to individual grant limits). Upon termination of the 2021 Incentive Plan, no further awards may be issued under the
2021 Incentive Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Minimum Vesting</I>. Subject to the acceleration
of vesting in certain circumstances as permitted under the terms of the 2021 Incentive Plan, each award under the 2021 Incentive
Plan will have a minimum vesting period of one year, except that awards to non-employee Directors that vest on the earlier of the
one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately
preceding year&rsquo;s annual meeting shall not be subject to such minimum vesting requirements, and the Compensation Committee
may determine in its discretion that up to 5% of the shares of common stock which may be issued under the 2021 Incentive Plan may
be granted free of such minimum vesting provisions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Dividends and Dividend Equivalents</I>. With
respect to any award that provides for or includes a right to dividends or dividend equivalents, if dividends are declared during
the period that an equity award is outstanding, such dividends (or dividend equivalents) shall either (a) not be paid or credited
with respect to such award or (b) be accumulated but remain subject to vesting requirement(s) to the same extent as the applicable
award and shall only be paid at the time or times such vesting requirement(s) are satisfied. A participant holding an option or
stock appreciation right is not eligible to receive dividends or dividend equivalents.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Clawback</I>. Awards under the 2021 Incentive
Plan and any shares issued pursuant to awards under the 2021 Incentive Plan shall be subject to recovery or &ldquo;clawback&rdquo;
by the Company if and to the extent that the vesting of such awards was determined or calculated based on materially inaccurate
financial statements or any other material inaccurate performance metric criteria; or if the Company or its subsidiaries terminate
a grantee&rsquo;s service relationship due to the grantee&rsquo;s gross negligence or willful misconduct, or determine there are
grounds for such a termination (whether or not such actions also constitute &ldquo;cause&rdquo; under an award agreement), any
awards under the 2021 Incentive Plan, whether or not vested, as well as any shares of stock issued pursuant to awards under the
2021 Incentive Plan shall be subject to forfeiture, recovery and &ldquo;clawback.&rdquo; In addition, the 2021 Incentive Plan provides
that if the Company is required to prepare an accounting restatement due to material noncompliance with the financial reporting
requirements of the securities laws, in certain cases the Compensation Committee may require the repayment of amounts paid under
the 2021 Incentive Plan in excess of what the employee would have received under the accounting restatement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Performance Awards</I>. Subject to the general
purposes, terms and conditions of the 2021 Incentive Plan and applicable law, and under the direction of the Board, the Compensation
Committee shall have complete control over the administration of the 2021 Incentive Plan and shall have full authority to grant
awards and determine who shall receive awards, when such awards shall be granted and the terms and conditions of such awards, including,
but not limited to, conditioning the exercise, vesting, payout or other term of condition of an award on the achievement of performance
goals. Such performance goals shall be based on the attainment of specified levels of one or more of the following: (i) earnings
per share; (ii) sales; (iii) operating income; (iv) gross income; (v) basic or adjusted net income (before or after taxes); (vi)
cash flow; (vii) gross profit; (viii) gross or operating margin; (ix) working capital; (x) earnings before interest and taxes;
(xi) earnings before interest, tax, depreciation and amortization; (xii) return measures, including return on invested capital,
sales, assets, or equity; (xiii) revenues; (xiv) market share; (xv) the price or increase in price of common stock; (xvi) total
shareholder return; (xvii) economic value created or added; (xviii) expense reduction; (xix) implementation or completion of critical
projects, including acquisitions, divestitures, and other strategic objectives, including market penetration and product development;
or (xx) specified objectives with regard to limiting the level of increase in all or a portion of the Company&rsquo;s bank debt
or other long-term or short-term public or private debt or other similar financial obligations of the Company; and any other metric
that may be determined by the Committee. Such performance goals also may be based solely by reference to the Company&rsquo;s performance
or the performance of a subsidiary, division, business segment or business unit of the Company or a subsidiary, or based upon performance
relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance
of other companies.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Other Information.&nbsp;</I>The 2021 Incentive
Plan may be amended in whole or in part by the Board or the Compensation Committee with the approval of the Board and in certain
circumstances with stockholder approval. Unless the Compensation Committee provides otherwise in advance of the grant, in the event
of a Change in Control (as defined in the 2021 Incentive Plan), if the employee is terminated other than for &ldquo;cause&rdquo;
within one year of a Change in Control, options and restricted stock (including restricted stock units) shall vest.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Tax Aspects Under the Code</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following summary is intended only as a
general guide to the U.S. federal income tax consequences under current law of equity-based awards that may be granted under the
2021 Incentive Plan. It does not attempt to describe all possible federal or other tax consequences of participation in the 2021
Incentive Plan or tax consequences based on particular circumstances. The exact federal income tax treatment of transactions under
the 2021 Incentive Plan will vary depending upon the specific facts and circumstances involved and participants are advised to
consult their personal tax advisors with regard to all consequences arising from the grant or exercise of awards and the disposition
of any acquired shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Incentive Stock Options.</I>&nbsp;Incentive
stock options under the 2021 Incentive Plan are intended to be eligible for the favorable tax treatment accorded &ldquo;incentive
stock options&rdquo; under the Code. There generally are no federal income tax consequences to the participant or the Company by
reason of the grant or exercise of an incentive stock option. However, the exercise of an incentive stock option may increase the
participant&rsquo;s alternative minimum tax liability, if any.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If a participant holds stock acquired through
exercise of an incentive stock option for at least two (2) years from the date on which the option is granted and at least one
(1) year from the date on which the shares are transferred to the participant upon exercise of the option, any gain or loss on
a disposition of such stock will be treated for tax purposes as long-term capital gain or loss.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Generally, if the participant disposes of the
stock before the expiration of either of these holding periods (a &ldquo;disqualifying disposition&rdquo;), then at the time of
disposition the participant will recognize taxable ordinary income equal to the lesser of (a) the excess of the stock&rsquo;s fair
market value on the date of exercise over the exercise price, or (b) the participant&rsquo;s actual gain, if any, on the purchase
and sale. The participant&rsquo;s additional gain (or any loss) upon the disqualifying disposition will be a capital gain (or loss),
which will be long-term or short-term depending on whether the stock was held for more than one (1) year.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">To the extent the participant recognizes ordinary
income by reason of a disqualifying disposition, the Company will generally be entitled to a corresponding business expense deduction
in the tax year in which the disqualifying disposition occurs, subject to Section 162(m) of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Non-qualified Stock Options, Restricted Stock
Awards, Restricted Stock Units, and Deferred Stock.</I>&nbsp;Non-qualified stock options, restricted stock awards, restricted stock
units and deferred stock granted under the 2021 Incentive Plan generally have the following federal income tax consequences:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">There are no tax consequences to the participant
or the Company by reason of the grant of a non-qualified stock option. Upon exercise of the option, the participant ordinarily
will recognize taxable ordinary income equal to the excess, if any, of the stock&rsquo;s fair market value on the exercise date
over the exercise price. If the stock received pursuant to the exercise is subject to further vesting requirements, the taxable
event will be delayed until the vesting restrictions lapse unless the participant elects under Section 83(b) of the Code to be
taxed on receipt of the stock.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">There are no tax consequences to the participant
or the Company by reason of the grant of restricted stock, restricted stock units or deferred stock awards. The participant ordinarily
will recognize taxable ordinary income equal to the excess, if any, of the stock&rsquo;s fair market value over the purchase price,
if any, when such award vests. Under certain circumstances, the participant may be permitted to elect under Section 83(b) of the
Code to be taxed on the grant date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">With respect to employees, the Company is generally
required to withhold from regular wages or supplemental wage payments an amount based on the ordinary income recognized. The Company
will generally be entitled to a business expense deduction equal to the taxable ordinary income realized by the participant, subject
to Section 162(m) of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Upon disposition of the stock, the participant
will generally recognize a capital gain or loss equal to the difference between the selling price and the sum of the amount paid
for such stock (if any) plus any amount recognized as ordinary income upon acquisition (or vesting) of the stock. Such gain or
loss will be long-term or short-term depending on whether the stock was held for more than one (1) year.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Stock Appreciation Rights.</I>&nbsp;No taxable
income is generally recognized upon the receipt of a SAR, but upon exercise of the SAR, the fair market value of the shares (or
cash in lieu of shares) received generally will be taxable as ordinary income to the recipient in the year of such exercise. The
Company generally will be entitled to a compensation deduction for the same amount which the recipient recognizes as ordinary income,
subject to Section 162(m) of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Performance Awards.</I>&nbsp;A participant
who has been granted a performance award generally will not recognize taxable income at the time of grant, and the Company will
not be entitled to a deduction at that time. When an award is paid, whether in cash or common shares, the participant generally
will recognize ordinary income, and the Company will be entitled to a corresponding deduction, subject to Section 162(m) of the
Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Stock Payments and Other Stock-Based Awards.</I>&nbsp;A
participant who receives a stock payment in lieu of a cash payment that would otherwise have been made will generally be taxed
as if the cash payment has been received, and the Company generally will be entitled to a deduction for the same amount, subject
to Section 162(m) of the Code.&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Section 409A of the Code.</I>&nbsp;Most of
the awards under the 2021 Incentive Plan are exempt from Section 409A of the Code. To the extent that any award hereunder could
be subject to Section 409A of the Code, it will be structured to comply with Section 409A of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Section 162(m) of the Code.</I>&nbsp;The
Tax Reform and Jobs Act of 2017 (the &ldquo;Tax Act&rdquo;) generally eliminated the ability to deduct compensation qualifying
for the &ldquo;performance-based compensation&rdquo; exception under Section 162(m) of the Code for tax years commencing after
December 31, 2017. Section 162(m) of the Code imposes a $1 million limit on the amount that a public company may deduct for compensation
paid to anyone who has ever been the Company&rsquo;s chief executive officer, chief financial officer or one of the three highest
compensated officers in any fiscal year beginning after December 31, 2016 (i.e., a &ldquo;covered employee&rdquo;). For 2017 and
prior taxable years, an exception to this deduction limit applied to &ldquo;performance-based compensation,&rdquo; such as stock
options and other equity awards that satisfied certain criteria. Under the Tax Act, the performance-based pay exception to Section
162(m) was eliminated, but a transition rule may allow the exception to continue to apply to certain performance-based compensation
payable under written binding contracts that were in effect on November 2, 2017. The Board of Directors and the committee intend
to consider the potential impact of Section 162(m) on grants made under the 2021 Incentive Plan, but reserve the right to approve
grants of options and other awards for an executive officer that exceeds the deduction limit of Section 162(m). The adoption of
the 2021 Incentive Plan is not intended to affect the grandfathered status of awards previously granted under the Company&rsquo;s
existing equity incentive plans that were intended to qualify as &ldquo;performance-based compensation&rdquo; under Section 162(m).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">New Plan Benefits</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">No awards have been granted under the 2021 Incentive
Plan, and it is not possible to determine specific amounts that may be awarded in the future under the 2021 Incentive Plan because
grants of awards under the 2021 Incentive Plan are at the discretion of the Compensation Committee.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Please see the Summary Compensation Table and
Outstanding Equity awards at Fiscal Year-End Table for information with respect to prior awards granted to our individual named
executive officers under the Prior Plan. Please see the 2020 Director Compensation Table for awards granted to our non-employee
directors under the Prior Plan.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Proposal
4<BR>
Advisory Vote On The Compensation Of<BR>
Our Named Executive Officers</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Background</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The SEC adopted final rules on January 26, 2011
to implement Section 951 of the Dodd-Frank Wall Street Reform and Consumer Protection Act requiring public companies to provide
stockholders with periodic advisory votes on executive compensation (&ldquo;Say-on-Pay Proposal&rdquo;). Accordingly, we are seeking
an advisory vote from our stockholders to approve our named executive officer compensation, as set forth below. The Board of Directors
welcomes our stockholders&rsquo; views on this subject, and will carefully consider the outcome of this vote consistent with the
best interests of all stockholders. As an advisory vote, however, the outcome is not binding on us or the Board of Directors. Consistent
with the preference of our stockholders as determined by the last vote to approve the frequency of our Say-on-Pay Proposal, we
intend to conduct a Say-on-Pay Proposal annually.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">As described in detail under the heading &ldquo;Compensation
Discussion and Analysis,&rdquo; our executive compensation program is designed to attract and retain high performing and experienced
executives; motivate and reward executives whose knowledge, skills and performance are critical to our success; align the interests
of our executives and stockholders by motivating executives to increase stockholder value and rewarding executives when stockholder
value increases; foster a shared commitment among executives by coordinating their goals; and motivate our executives to manage
our business to meet our short and long-term objectives, and reward them for meeting these objectives. The elements of executive
compensation include base salary, annual cash incentive bonuses, employment agreements, long-term equity incentive compensation
and broad-based benefits programs. Please read the &ldquo;Compensation Discussion and Analysis&rdquo; for additional details about
our executive compensation programs, including information about the fiscal year 2019 compensation of our named executive officers.
Specifically, we are seeking a vote on the following resolution:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">RESOLVED, that the stockholders approve, on
a non-binding advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to
the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis,
the compensation tables and related narrative discussion.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Recommendation</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0">OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE &ldquo;FOR&rdquo; THE RESOLUTION TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Submission
Of Stockholder Proposals For The 2022 Annual Meeting</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In order to be considered for inclusion in our
proxy statement and form of proxy for our 2022 annual meeting, stockholder proposals intended to be presented at our 2022 annual
meeting of stockholders must be received by us on or before December 9, 2021 and otherwise comply with the requirements set forth
in Rule 14a-8 under the Exchange Act. These proposals must also comply with the rules of the Securities and Exchange Commission
governing the form and content of proposals in order to be included in our proxy statement and form of proxy and should be mailed
to: Secretary, Harvard Bioscience, Inc., 84 October Hill Road, Holliston, Massachusetts 01746.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">To the extent a stockholder of record wishes
to have a stockholder proposal or Director nomination considered at an annual meeting even though such proposal is not included
in our proxy statement, our Bylaws provide that such stockholder of record must provide written notice of such proposal or nomination
and appropriate supporting documentation, as set forth in the Bylaws, to our Secretary at our principal executive office not less
than 90 days or not more than 120 days prior to the first anniversary of the date of the preceding year&rsquo;s annual meeting.
For the 2022 annual meeting of stockholders, such proposal or nomination must be received no earlier than January 18, 2022 and
no later than February 17, 2022.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Multiple
Stockholders Sharing The Same Address</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Owners of Common Stock in street name may receive
a notice from their broker or bank stating that only one notice of internet availability of proxy materials, annual report or proxy
statement will be delivered to multiple stockholders sharing an address. This practice, known as &ldquo;householding,&rdquo; is
designed to reduce printing and postage costs. However, if any stockholder residing at such an address wishes to receive a separate
notice of internet availability of proxy materials, annual report or proxy statement, we will promptly deliver a separate copy
to any stockholder upon written or oral request to our investor relations department at Harvard Bioscience, Inc., 84 October Hill
Road, Holliston, Massachusetts 01746-1371 or by telephone at 508-893-8066 or by e-mail at info@harvardbioscience.com. In addition,
any stockholder who receives multiple copies at the same address can request delivery of a single copy by notifying our investor
relations department pursuant to the contact information provided above.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Other
Matters</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The Board of Directors does not know of any
matters, other than those described in this proxy statement that will be presented for action at the Annual Meeting. If other matters
are duly presented, proxies will be voted in accordance with the best judgment of the proxy holders.</P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0">YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU PLAN
TO ATTEND THE ANNUAL MEETING VIRTUALLY, PLEASE CAST YOUR VOTE ONLINE, BY TELEPHONE OR BY COMPLETING, DATING, SIGNING AND PROMPTLY
RETURNING YOUR PROXY CARD OR VOTING INSTRUCTIONS CARD IN THE POSTAGE-PAID ENVELOPE (WHICH WILL BE PROVIDED TO THOSE STOCKHOLDERS
WHO REQUEST PAPER COPIES OF THESE MATERIALS BY MAIL) BEFORE THE ANNUAL MEETING SO THAT YOUR SHARES ARE REPRESENTED AT THE ANNUAL
MEETING.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0">THIS PROXY STATEMENT IS ACCOMPANIED BY THE COMPANY&rsquo;S
ANNUAL REPORT. THE COMPANY WILL FURNISH, WITHOUT CHARGE, A COPY OF ITS ANNUAL REPORT AND ANY EXHIBITS THERETO TO ANY STOCKHOLDER,
UPON WRITTEN REQUEST TO HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON, MASSACHUSETTS 01746-1371. A LIST OF STOCKHOLDERS
ENTITLED TO VOTE AT THE ANNUAL MEETING WILL BE AVAILABLE FOR INSPECTION BY STOCKHOLDERS DURING REGULAR BUSINESS HOURS AT OUR OFFICES
AND THE OFFICES OF OUR TRANSFER AGENT DURING THE TEN DAYS PRIOR TO THE ANNUAL MEETING AS WELL AS AT THE ANNUAL MEETING.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; text-align: center">Annex A</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; text-align: center"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">Harvard Bioscience, Inc.</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">2021 Incentive Plan</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 1<BR>
<BR>
<U>Establishment and Purpose</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Establishment of the Plan</U>. Harvard Bioscience, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), hereby
establishes an incentive compensation plan (as amended from time to time, the &ldquo;<U>Plan</U>&rdquo;), as set forth in this
document.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purpose of the Plan</U>. The purposes of the Plan are to (a) enable the Company and any Affiliate to attract and retain
the types of Employees, Consultants and Directors who will contribute to the Company&rsquo;s long-range success; (b) provide incentives
that align the interests of Employees, Consultants and Directors with those of shareholders of the Company; and (c) promote the
success of the Company&rsquo;s business.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effective Date of the Plan</U>. The Plan is effective as of the date the Plan is approved by the Company&rsquo;s stockholders
(the &ldquo;<U>Effective Date</U>&rdquo;). The Plan will be deemed to be approved by the stockholders if it receives the affirmative
vote of the holders of a majority of the shares of stock of the Company present or represented and entitled to vote at a meeting
duly held in accordance with the applicable provisions of the Company&rsquo;s Bylaws.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duration of the Plan</U>. Unless sooner terminated as provided herein, the Plan shall terminate ten (10) years from the
Effective Date. After the Plan is terminated, no Awards may be granted but Awards previously granted shall remain outstanding in
accordance with their applicable terms and conditions and the Plan&rsquo;s terms and conditions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 2<BR>
<BR>
<U>Definitions</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Whenever used in the Plan, the following terms
shall have the meanings set forth below and, when the meaning is intended, the initial letter of the word is capitalized:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Affiliate</U>&rdquo; means, with respect to any Person, any other Person that directly or indirectly through one
or more intermediaries controls, is controlled by or is under common control with, the Person in question, including any subsidiary.
As used herein, the term &ldquo;control&rdquo; means the possession, direct or indirect, of the power to direct or cause the direction
of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise. As used herein,
the term &ldquo;subsidiary&rdquo; means any corporation, partnership, venture or other entity in which the Company holds, directly
or indirectly, a fifty percent (50%) or greater ownership interest.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Applicable Law</U>&rdquo; means any applicable law, including without limitation: (a) provisions of the Code,
the Securities Act, the Exchange Act and any rules or regulations thereunder; (b) corporate, securities, tax or other laws, statutes,
rules, requirements or regulations, whether federal, state, local or foreign; and (c) rules of any securities exchange or automated
quotation system on which the Shares are listed, quoted or traded.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Award</U>&rdquo; means, individually or collectively, a grant or award under this Plan of Options, Stock Appreciation
Rights, Restricted Stock (including unrestricted Stock), Restricted Stock Units, Performance Stock Units, Performance Shares, Deferred
Stock Awards, Other Stock-Based Awards, Dividend Equivalent Awards and Performance Bonus Awards, in each case subject to the terms
of the Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Award Agreement</U>&rdquo; means an agreement, certificate, resolution or other type or form of writing or other
evidence approved by the Committee which sets forth the terms and conditions of an Award. An Award Agreement may be in any electronic
medium, may be limited to a notation on the books and records of the Company and, with the approval of the Committee, need not
be signed by a representative of the Company or a Participant. In the event of any inconsistency between the Plan and an Award
Agreement, the terms of the Plan shall govern.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Beneficial Owner</U>&rdquo; or &ldquo;<U>Beneficial Ownership</U>&rdquo; has the meaning ascribed to such term
in Rule 13d-3 and Rule 13d-5 under the Exchange Act.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Board</U>&rdquo; or &ldquo;<U>Board of Directors</U>&rdquo; means the Company&rsquo;s Board of Directors.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Cause</U>&rdquo; means, except as otherwise defined in an Award Agreement, a Participant&rsquo;s: (a) conviction
of, or the entry of a plea of guilty or no contest to, a felony or any other crime that causes the Company or its Affiliates public
disgrace or disrepute, or materially and adversely affects the Company&rsquo;s or its Affiliates&rsquo; operations or financial
performance or the relationship the Company has with its customers; (b) gross negligence or willful misconduct with respect to
the Company or any of its Affiliates, including, without limitation fraud, embezzlement, theft or proven dishonesty in the course
of his or her employment or other service; (c) refusal to perform any lawful, material obligation or fulfill any duty (other than
any duty or obligation of the type described in clause (e) below) to the Company or its Affiliates (other than due to a Disability),
which refusal, if curable, is not cured within fifteen (15) days after delivery of written notice thereof; (d) material breach
of any agreement with or duty owed to the Company or any of its Affiliates, which breach, if curable, is not cured within fifteen
(15) days after the delivery of written notice thereof; or (e) any breach of any obligation or duty to the Company or any of its
Affiliates (whether arising by statute, common law or agreement) relating to confidentiality, noncompetition, nonsolicitation or
proprietary rights. Notwithstanding the foregoing, if a Participant and the Company (or any of its Affiliates) have entered into
an employment agreement, consulting agreement or other similar agreement that specifically defines &ldquo;cause,&rdquo; then with
respect to such Participant, &ldquo;Cause&rdquo; shall have the meaning defined in that employment agreement, consulting agreement
or other agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Change in Control</U>&rdquo; shall be deemed to have occurred if:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Person, other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or
a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership
of stock of the Company, becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifty
percent (50%) or more of the total voting power represented by the Company&rsquo;s then outstanding voting securities;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>during any period of two (2) consecutive years, individuals who at the beginning of such period constitute the Board of
Directors of the Company and any new Director whose election by the Board of Directors or nomination for election by the Company&rsquo;s
stockholders was approved by a vote of a majority of the Directors then still in office who either were Directors at the beginning
of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority
thereof, provided that this does not apply to a Director whose initial assumption of office during the lookback period is in connection
with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of
Directors of the Company;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the consummation of a merger or consolidation of the Company with any other business entity, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either
by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of
the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after
such merger or consolidation;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the stockholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition
by the Company of all or substantially all the Company&rsquo;s assets; or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>consummation of the sale or disposition by the Company of all or substantially all of the Company&rsquo;s assets.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">Notwithstanding the foregoing, if a Change in
Control constitutes a payment event with respect to any Award (or any portion of an Award) that provides for the deferral of compensation
that is subject to Section 409A of the Code, to the extent required to avoid the imposition of additional taxes under Section 409A
of the Code, the transaction or event described in subsection (a), (b), (c) or (d) with respect to such Award (or portion thereof)
shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes
a &ldquo;change in control event,&rdquo; as defined in Treasury Regulation Section 1.409A-3(i)(5).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">The Committee shall have full and final authority,
which shall be exercised in its sole discretion, to determine conclusively whether a Change in Control has occurred pursuant to
the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided
that any exercise of authority in conjunction with a determination of whether a Change in Control is a &ldquo;change in control
event&rdquo; as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Code</U>&rdquo; means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations
issued thereunder.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Committee</U>&rdquo; has the meaning set forth in <U>Section 3.1</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Company</U>&rdquo; has the meaning set forth in <U>Section 1.1</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Consultant</U>&rdquo; means any individual or entity who renders bona fide services to the Company or an Affiliate,
other than as an Employee or Director, <I>provided that</I> such services are not in connection with the offer or sale of securities
in a capital-raising transaction and do not, directly or indirectly, promote or maintain a market for the Company&rsquo;s or its
Affiliates&rsquo; securities.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Deferred Stock</U>&rdquo; means a right to receive a specified number of shares of Stock during specified time
periods pursuant to <U>Article 9</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.14<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Director</U>&rdquo; means a member of the Board.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.15<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Disability</U>&rdquo; means, unless otherwise determined by the Committee or determined in the applicable Award
Agreement, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable
physical or mental impairment; provided, however, that to entitle a Participant to an extended exercise period for an Incentive
Stock Option, the Participant must be described in Section 22(e)(3) of the Code. Notwithstanding the foregoing, for Awards subject
to Section 409A of the Code, Disability shall mean that a Participant is disabled under Section 409A(a)(2)(C)(i) or (ii) of the
Code. Notwithstanding the above, the Committee may rely on any determination that a Participant is disabled for purposes of benefits
under any long-term disability plan maintained by the Company or any Affiliate in which a Participant participates.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.16<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Dividend Equivalent</U>&rdquo; means a right granted to a Participant pursuant to <U>Article 9</U> to receive
the equivalent value (in cash or Stock) of dividends paid on Stock.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.17<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Effective Date</U>&rdquo; has the meaning set forth in <U>Section 1.3</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.18<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Eligible Person</U>&rdquo; means any person who is an employee, officer, director, consultant, advisor or other
individual service provider of the Company or any Affiliate, or any person who is determined by the Committee to be a prospective
employee, officer, director, consultant, advisor or other individual service provider of the Company or any Affiliate.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.19<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<U>Employee</U>&rdquo; means any person employed by the Company, its Affiliates and/or Subsidiaries; <I>provided</I>,
<I>that</I>, for purposes of determining eligibility to receive Incentive Stock Options, an Employee shall mean an employee of
the Company or a parent or subsidiary corporation within the meaning of Section 424 of the Code. Mere service as a Director or
payment of a director&rsquo;s fee by the Company or an Affiliate shall not be sufficient to constitute &ldquo;employment&rdquo;
by the Company or an Affiliate.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.20<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Exchange Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended from time to time, or any successor
act thereto.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.21<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Exercise Price</U>&rdquo; means the price at which a Share may be purchased by a Participant pursuant to an Option,
as determined by the Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.22<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Fair Market Value</U>&rdquo; or &ldquo;<U>FMV</U>&rdquo; means, as of any date, unless otherwise determined by
the Committee or determined in an applicable Award Agreement, the value of Stock determined as follows:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Stock is listed on one or more established stock exchanges or national market systems, including without limitation,
The NASDAQ Global Select Market, The NASDAQ Global Market or The NASDAQ Capital Market of The NASDAQ Stock Market LLC, its Fair
Market Value shall be the closing sales price for such Stock (or the closing bid, if no sales were reported) as quoted on the principal
exchange or system on which the Stock is listed (as determined by the Committee) on the date of determination (or, if no closing
sales price or closing bid was reported on that date, as applicable, on the last immediately preceding trading date such closing
sales price or closing bid was reported), as reported in <I>The Wall Street Journal </I>or such other source as the Committee deems
reliable;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Stock is regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized
securities dealer, its Fair Market Value shall be the closing sales price for such Stock as quoted on such system or by such securities
dealer on the date of determination, but if selling prices are not reported, the Fair Market Value of a share of Stock shall be
the mean between the high bid and low asked prices for the Stock on the date of determination (or, if no such prices were reported
on that date, on the last date such prices were reported), as reported in <I>The Wall Street Journal</I> or such other source as
the Committee deems reliable; or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the absence of an established market for the Stock of the type described in (a) and (b), above, the Fair Market Value
thereof shall be determined by the Committee in good faith using any reasonable method of valuation, which method may be set forth
with greater specificity in the Award Agreement, (and, to the extent necessary or advisable, in a manner consistent with Section
409A of the Code and Section 422 of the Code for Incentive Stock Options), which determination shall be conclusive and binding
on all interested parties. Such reasonable method may be determined by reference to (i) the placing price of the latest private
placement of the Shares and the development of the Company&rsquo;s business operations and the general economic and market conditions
since such latest private placement; (ii) other third party transactions involving the Shares and the development of the Company&rsquo;s
business operation and the general economic and market conditions since such sale; (iii) an independent valuation of the Shares
(by a qualified valuation expert); or (iv) such other methodologies or information as the Committee determines to be indicative
of Fair Market Value.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.23<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Incentive Stock Option</U>&rdquo; means an Option that is intended to qualify as an &ldquo;incentive stock option&rdquo;
within the meaning of Section 422 of the Code and that meets the requirements set out in the Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.24<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Insider</U>&rdquo; means an individual who is, on the relevant date, an officer, director, or ten percent (10%)
beneficial owner of the Company, as those terms are defined under Section 16 of the Exchange Act, who is required to file reports
pursuant to Rule 16a-3 under the Exchange Act.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.25<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Non-Employee Director</U>&rdquo; means a member of the Board who is not an Employee of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.26<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Non-Qualified Stock Option</U>&rdquo; means an Option that, by its terms, does not qualify or is not intended
to qualify as an Incentive Stock Option.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.27<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Option</U>&rdquo; means the right to purchase Stock granted to a Participant in accordance with <U>Article 6</U>.
Options granted under the Plan may be Non-Qualified Stock Options, Incentive Stock Options or a combination thereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.28<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Other Stock-Based Award</U>&rdquo; means an equity-based or equity-related Award not otherwise described by the
terms of the Plan, granted pursuant to <U>Article 9</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.29<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Participant</U>&rdquo; means an Eligible Person to whom an Award is granted under the Plan or, if applicable,
such other person who holds an outstanding Award.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.30<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Performance Goal</U>&rdquo; means any goals established by the Committee pursuant to an Award, which may be based
on the attainment of specified levels of one or more of the following: (i) earnings per share; (ii) sales; (iii) operating income;
(iv) gross income; (v) basic or adjusted net income (before or after taxes); (vi) cash flow; (vii) gross profit; (viii) gross or
operating margin; (ix) working capital; (x) earnings before interest and taxes; (xi) earnings before interest, tax, depreciation
and amortization; (xii) return measures, including return on invested capital, sales, assets, or equity; (xiii) revenues; (xiv)
market share; (xv) the price or increase in price of Stock; (xvi) total shareholder return; (xvii) economic value created or added;
(xviii) expense reduction; (xix) implementation or completion of critical projects, including acquisitions, divestitures, and other
strategic objectives, including market penetration and product development; (xx) specified objectives with regard to limiting the
level of increase in all or a portion of the Company's bank debt or other long-term or short-term public or private debt or other
similar financial obligations of the Company; or (xxi) any other metric that may be determined by the Committee. Such performance
goals also may be based solely by reference to the Company&rsquo;s performance or the performance of a Subsidiary, division, business
segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or
upon comparisons of any of the indicators of performance relative to performance of other companies. The Committee may provide
for exclusion of the impact of an event or occurrence which the Committee determines should appropriately be excluded, including
(a) restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges
or events, (b) asset write-downs, (c) litigation or claim judgments or settlements, (d) acquisitions or divestitures, (e) reorganization
or change in the corporate structure or capital structure of the Company, (f) an event either not directly related to the operations
of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g)
foreign exchange gains and losses, (h) a change in the fiscal year of the Company, (i) the refinancing or repurchase of bank loans
or debt securities, (j), unbudgeted capital expenditures, (k) the issuance or repurchase of equity securities and other changes
in the number of outstanding shares, (l) conversion of some or all of convertible securities to common stock, (m) any business
interruption event (n) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting
principles, or (o) the effect of changes in other laws or regulatory rules affecting reported results. The Committee may adjust
upwards or downwards the amount payable pursuant to such performance-based Award, and the Committee shall certify the amount of
any such Award for the applicable performance period before payment is made.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.31<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Performance Period</U>&rdquo; means one or more periods of time, which may be of varying and overlapping durations,
as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining
a Participant&rsquo;s right to, and the payment of, Performance Stock Units and Performance Shares.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.32<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Performance Stock Unit</U>&rdquo; and &ldquo;<U>Performance Share</U>&rdquo; each mean an Award granted to an
Employee pursuant to <U>Article 9</U> herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.33<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Permitted Transferee</U>&rdquo; shall mean, with respect to a Participant, any &ldquo;family member&rdquo; of
the Participant, as defined in the General Instructions to Form S-8 Registration Statement under the Securities Act (or any successor
form thereto), or to any other transferee specifically approved by the Committee after taking into account Applicable Law, but
excluding any third-party financial institutions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.34<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Person</U>&rdquo; has the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections
13(d) and 14(d) thereof, including a &ldquo;group&rdquo; as defined in Section 13(d) thereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.35<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Plan</U>&rdquo; means this Harvard Bioscience, Inc. 2021 Incentive Plan, as it may be amended from time to time.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.36<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Prior Plan</U>&rdquo; means the 2000 Stock Option and Incentive Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.37<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Restricted Stock</U>&rdquo; means Stock awarded to a Participant pursuant to <U>Article 8</U> as to which the
Restriction Period has not lapsed.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.38<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Restricted Stock Unit</U>&rdquo; means an Award granted pursuant to <U>Section 8.9</U> as to which the Restriction
Period has not lapsed.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.39<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Restriction Period</U>&rdquo; means the period when Restricted Stock or Restricted Stock Units are subject to
a &ldquo;substantial risk of forfeiture&rdquo; within the meaning of Section 83 of the Code (based on the passage of time, the
achievement of performance goals, or upon the occurrence of other events as determined by the Committee, in its discretion), as
provided in <U>Article 8</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.40<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Securities Act</U>&rdquo; means the Securities Act of 1933, as amended.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.41<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Share</U>&rdquo; means a share of Stock of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.42<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.43<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Stock Appreciation Right</U>&rdquo; or &ldquo;<U>SAR</U>&rdquo; means a right granted pursuant to <U>Article 7</U>
to receive an amount payable in cash or Shares equal to the excess of (a) the Fair Market Value of a specified number of Shares
on the date the SAR is exercised over (b) the Fair Market Value of such Shares on the date the SAR was granted as set forth in
the applicable Award Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.44<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Subsidiary</U>&rdquo; means any corporation, partnership, venture, unincorporated association or other entity
in which the Company holds, directly or indirectly, a fifty percent (50%) or greater ownership interest, provided, however, that
with respect to an Incentive Stock Option, a Subsidiary must be a corporation. The Committee may, at its sole discretion, designate,
on such terms and conditions as the Committee shall determine, any other corporation, partnership, limited liability company, venture,
or other entity a Subsidiary for purposes of this Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.45<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Ten Percent Owner</U>&rdquo; means a person who owns, or is deemed within the meaning of Section&nbsp;424(d) of
the Code to own, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (or any
parent or subsidiary corporations of the Company, as defined in Sections&nbsp;424(e) and (f), respectively, of the Code). Whether
a person is a Ten Percent Owner shall be determined with respect to an Option based on the facts existing immediately prior to
the grant date of the Option.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.46<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Termination of Employment</U>&rdquo; or a similar reference means the event where the Employee is no longer an
Employee of the Company or of any Subsidiary, including but not limited to where the employing company ceases to be a Subsidiary.
With respect to any Participant who is not an Employee, &ldquo;Termination of Employment&rdquo; shall mean cessation of the performance
of services. With respect to any Award that provides &ldquo;non-qualified deferred compensation&rdquo; within the meaning of Section
409A of the Code, &ldquo;Termination of Employment&rdquo; shall mean a &ldquo;separation from service&rdquo; as defined under Section
409A of the Code. Military or sick leave or other bona fide leave shall not be deemed a termination of employment, provided that
it does not exceed the longer of three (3) months or the period during which the absent Participant&rsquo;s reemployment rights,
if any, are guaranteed by statute or by contract.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">2.47<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Treasury Regulation</U>&rdquo; or &ldquo;<U>Treas. Reg.</U>&rdquo; means any regulation promulgated under the
Code, as such regulation may be amended from to time.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 3<BR>
<BR>
<U>Administration</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>The Committee</U>. Except as otherwise provided herein, the Plan shall be administered by the Compensation Committee
of the Board (the &ldquo;<U>Committee</U>&rdquo;). Unless otherwise determined by the Board, the Committee shall consist solely
of two or more members of the Board each of whom is (a) a &ldquo;non-employee director&rdquo; within the meaning of Rule 16b-3
of the Exchange Act, and (b) an &ldquo;independent director&rdquo; under the rules of the Nasdaq Capital Market (or any similar
rule or listing requirement that may be applicable to the Company from time to time); provided, that any action taken by the Committee
shall be valid and effective, whether or not members of the Committee at the time of such action are later determined not to have
satisfied the requirements for membership set forth in this <U>Section 3.1</U> or otherwise provided in any charter of the Committee.
Notwithstanding the foregoing: (a) the full Board, acting by a majority of its members in office or by designation to a Committee,
shall conduct the general administration of the Plan with respect to all Awards granted to Non-Employee Directors and for purposes
of such Awards the term &ldquo;Committee&rdquo; as used in this Plan shall be deemed to refer to the Board and (b) the Committee
may delegate its authority hereunder to the extent permitted by <U>Section 3.4</U>. In its sole discretion, the Board may at any
time and from time to time exercise any and all rights and duties of the Committee under the Plan except with respect to matters
which under Rule 16b-3 under the Exchange Act, or any regulations or rules issued thereunder, are required to be determined in
the sole discretion of the Committee. Except as may otherwise be provided in any charter of the Committee, appointment of Committee
members shall be effective upon acceptance of appointment; Committee members may resign at any time by delivering written notice
to the Board; and vacancies in the Committee may only be filled by the Board.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority of the Committee</U>. Subject to the general purposes, terms and conditions of this Plan and Applicable Law,
and to the direction of the Board, the Committee shall have complete control over the administration of the Plan and shall have
full authority to (a) exercise all of the powers granted to it under the Plan, (b) construe, interpret and implement the Plan,
grant terms and grant notices, and all Award Agreements, (c) prescribe, amend and rescind rules and regulations relating to the
Plan, including rules governing its own operations, (d) make all determinations necessary or advisable in administering the Plan,
(e) correct any defect, supply any omission and reconcile any inconsistency in the Plan, (f) amend the Plan to reflect changes
in applicable law (whether or not the rights of the holder of any Award are adversely affected, unless otherwise provided by the
Committee), (g) grant Awards and determine who shall receive Awards, when such Awards shall be granted and the terms and conditions
of such Awards, including, but not limited to, conditioning the exercise, vesting, payout or other term of condition of an Award
on the achievement of Performance Goals, (h) unless otherwise provided by the Committee, amend any outstanding Award in any respect,
not materially adverse to the Participant, including, without limitation, to (i) accelerate the time or times at which the Award
becomes vested, unrestricted or may be exercised (and, in connection with such acceleration, the Committee may provide that any
Shares acquired pursuant to such Award shall be restricted Shares, which are subject to vesting, transfer, forfeiture or repayment
provisions similar to those in the Participant&rsquo;s underlying Award), provided, however, that any accelerated vesting is subject
to stockholder approval, (ii) accelerate the time or times at which Shares are delivered under the Award (and, without limitation
on the Committee&rsquo;s rights, in connection with such acceleration, the Committee may provide that any shares of Stock delivered
pursuant to such Award shall be Restricted Shares, which are subject to vesting, transfer, forfeiture or repayment provisions similar
to those in the Participant&rsquo;s underlying Award), or (iii) waive or amend any goals, restrictions or conditions applicable
to such Award, or impose new goals, restrictions and (i) determine at any time whether, to what extent and under what circumstances
and method or methods (i) Awards may be (A) settled in cash, Shares, other securities, other Awards or other property (in which
event, the Committee may specify what other effects such settlement will have on the Participant&rsquo;s Award), (B) exercised
or (C) canceled, forfeited or suspended, (ii) Shares, other securities, cash, other Awards or other property and other amounts
payable with respect to an Award may be deferred either automatically or at the election of the Participant or of the Committee,
or (iii) Awards may be settled by the Company or any of its Subsidiaries or any of its or their designees.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">No Award may be made under the Plan after the
tenth (10<SUP>th</SUP>) anniversary of the Effective Date.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Committee Decisions Final</U>. The act or determination of a majority of the Committee shall be the act or determination
of the Committee and any decision reduced to writing and signed by all of the members of the Committee shall be fully effective
as if it had been made by a majority at a meeting duly held. The Committee may employ attorneys, consultants, accountants, agents,
and other persons, any of whom may be an Employee, and the Committee, the Company, and its officers and Directors shall be entitled
to rely upon the advice, opinions, or valuations of any such persons. All actions taken and all interpretations and determinations
made by the Committee pursuant to the provisions of the Plan and all related orders or resolutions shall be final and binding upon
the Participants, the Company, and all other interested persons, including but not limited to the Company, its stockholders, Employees,
Participants, and their estates and beneficiaries.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delegation of Authority</U>. The Board or Committee may from time to time delegate to a committee of one or more members
of the Board or one or more officers of the Company the authority to grant or amend Awards or to take other administrative actions
pursuant to this <U>Article 3</U>; provided, however, that in no event shall an officer of the Company be delegated the authority
to grant Awards to, or amend Awards held by, the following individuals: (a) individuals who are subject to Section 16 of the Exchange
Act, or (b) officers of the Company (or Directors) to whom authority to grant or amend Awards has been delegated hereunder; provided,
further, that any delegation of administrative authority shall only be permitted to the extent it is permissible under the Company&rsquo;s
Certificate of Incorporation, Bylaws and Applicable Law. Any delegation hereunder shall be subject to the restrictions and limits
that the Board or Committee specifies at the time of such delegation or that are otherwise included in the applicable Organizational
Documents, and the Board or Committee, as applicable, may at any time rescind the authority so delegated or appoint a new delegatee.
At all times, the delegatee appointed under this <U>Section 3.4</U> shall serve in such capacity at the pleasure of the Board or
the Committee, as applicable, and the Board or the Committee may abolish any committee at any time and re-vest in itself any previously
delegated authority.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>. To the extent allowable pursuant to applicable law, each member of the Committee or of the Board
shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably
incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a
party or in which he or she may be involved by reason of any action or failure to act pursuant to the Plan and against and from
any and all amounts paid by him or her in satisfaction of judgment in such action, suit, or proceeding against him or her; provided
he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle
and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification
to which such persons may be entitled pursuant to the Company&rsquo;s Certificate of Incorporation or Bylaws, as a matter of law,
or otherwise, or any power that the Company may have to indemnify them or hold them harmless.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 4<BR>
<BR>
<U>Shares Subject to the Plan</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Number of Shares</U>. Subject to adjustment as provided in <U>Sections 4.2</U> and <U>4.3</U>, the aggregate number of
Shares of Stock which may be issued or transferred pursuant to Awards under the Plan shall be the sum of 2,200,000 shares plus
the number of shares available for grant under the Prior Plan as of the Effective Date. Notwithstanding the foregoing, in order
that the applicable regulations under the Code relating to Incentive Stock Options be satisfied, the maximum number of shares of
Stock that may be delivered upon exercise of Incentive Stock Options shall be 2,000,000, as adjusted under <U>Sections 4.2</U>
and <U>4.3</U>. Shares of Stock issued pursuant to the Plan may be either authorized but unissued Shares or Shares held by the
Company in its treasury. Upon effectiveness of the Plan, no further awards shall be granted under a Prior Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Share Accounting</U>. Without limiting the discretion of the Committee under this section, the following rules will apply
for purposes of the determination of the number of Shares available for grant under the Plan or compliance with the foregoing limits:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If an outstanding Award for any reason expires or is terminated or canceled without having been exercised or settled in
full, or if Shares acquired pursuant to an Award subject to forfeiture are forfeited under the terms of the Plan or the relevant
Award, the Shares allocable to the terminated portion of such Award or such forfeited Shares shall again be available for issuance
under the Plan. This <U>subsection 4.2(a)</U> shall also apply to awards granted under the Prior Plan, which are outstanding as
of the Effective Date.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Shares shall not be deemed to have been issued pursuant to the Plan (or the Prior Plan) with respect to any portion of an
Award that is settled in cash, other than an Option.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that withholding tax liabilities arising from a full-value Award (i.e., an award other than an Option or SAR)
or, after the Effective Date, arising from a full-value award under the Prior Plan, are satisfied by the delivery or withholding
of shares, the shares so tendered or withheld shall be added to the 2021 Incentive Plan&rsquo;s reserve. Notwithstanding anything
to the contrary contained herein, shares subject to an Award shall not again be made available for issuance or delivery under the
Plan if such shares are (i) shares tendered in payment of an Option; (ii) shares delivered or withheld by the Company to satisfy
any tax withholding obligation with respect to an Option or SAR; (iii) shares covered by a stock-settled Stock Appreciation Right
that were not issued upon the settlement of the SAR; or (iv) shares purchased on the open market with Option proceeds.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustments in Authorized Plan Shares and Outstanding Awards</U>. In the event of any merger, reorganization, consolidation,
recapitalization, separation, split-up, spin-off, liquidation, Share combination, Stock split, Stock dividend, an extraordinary
cash distribution on Stock, a corporate separation or other reorganization or liquidation or other change in the corporate or capital
structure of the Company affecting the Shares, an adjustment shall be made in a manner consistent with Sections 422 and 424(h)(3)
of the Code for Incentive Stock Options and in a manner consistent with Section 409A of the Code for Non-Qualified Stock Options
and Stock Appreciation Rights and in the number and class of and/or price of Shares subject to outstanding Awards granted under
the Plan, and/or the number of outstanding Options, Stock Appreciation Rights, Shares of Restricted Stock, and Performance Shares
(and Restricted Stock Units, Performance Stock Units and other Awards whose value is based on a number of Shares) constituting
outstanding Awards, as may be determined to be appropriate and equitable by the Committee, in its sole discretion, to prevent dilution
or enlargement of rights. The Committee shall also adjust any available share reserve accordingly. The Committee may make adjustments
in the terms and conditions of, and the criteria included in Awards in recognition of unusual or nonrecurring events (including,
without limitation, the events described in this Section) affecting the Company or the financial statements of the Company or of
changes in applicable laws, regulations, or accounting principles, whenever the Committee determines that such adjustments are
appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under
the Plan. Adjustments under this <U>Section 4.3</U> shall be consistent with Section 409A of the Code and adjustments pursuant
to determination of the Committee shall be conclusive and binding on all Participants under the Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation on Number of Shares Granted to Non-Employee Directors</U>. The maximum number of Shares subject to Awards
granted during a single fiscal year to any Non-Employee Director, taken together with any cash fees paid during the fiscal year
to the Non-Employee Director, in respect of such Director&rsquo;s service as a member of the Board during such year (including
service as a member or chair of any committees of the Board), shall not exceed $500,000 in total value (calculating the value of
any such Awards based on the grant date Fair Market Value of such Awards for financial reporting purposes). The independent members
of the Board may make exceptions to this limit for a non-executive chair of the Board, provided that the Non-Employee Director
receiving such additional compensation may not participate in the decision to award such compensation.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 5<BR>
<BR>
<U>Eligibility and Participation</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Eligibility and Participation</U>. Subject to the provisions of the Plan, the Committee may, from time to time, select
from all Eligible Persons, those to whom Awards shall be granted and shall determine, in its sole discretion, the nature of, any
and all terms permissible by law, and the amount of each Award. In making this determination, the Committee may consider any factors
it deems relevant, including without limitation, the office or position held by a Participant or the Participant&rsquo;s relationship
to the Company, the Participant&rsquo;s degree of responsibility for and contribution to the growth and success of the Company
or any Subsidiary or Affiliate, the Participant&rsquo;s length of service, promotions and potential. No individual shall have the
right to be selected to receive an Award under this Plan, or, having been so selected, to be selected to receive a future Award.
In addition, there is no obligation for uniformity of treatment of Participants or holders or beneficiaries of Awards. The terms
and conditions of Awards and the Committee&rsquo;s determinations and interpretations with respect thereto need not be the same
with respect to each Participant and may be made selectively among Participants, whether or not such Participants are similarly
situated.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Participants</U>. In order to assure the viability of Awards granted to Participants employed in foreign countries,
the Committee may provide for such special terms as it may consider necessary or appropriate to accommodate differences in local
law, tax policy, or custom. Moreover, the Committee may approve such supplements to, or amendments, restatements, or alternative
versions of, the Plan as it may consider necessary or appropriate for such purposes without thereby affecting the terms of the
Plan as in effect for any other purpose; provided, however, that no such supplements, amendments, restatements, or alternative
versions shall increase the share limitations contained in <U>Section 4.1</U> of the Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 6<BR>
<BR>
<U>Options</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Grant of Options</U>. Subject to the terms and provisions of the Plan, Options may be granted to Participants in such
number, and upon such terms and conditions, and at any time and from time to time as shall be determined by the Committee, in its
sole discretion, subject to the limitations set forth in <U>Article 4</U> and the following terms and conditions:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Award Agreement</U>. Each Option grant shall be evidenced by an Award Agreement that shall specify the terms and conditions
of the Option, including the Exercise Price, the maximum duration of the Option, the number of Shares to which the Option pertains,
the conditions upon which an Option shall become vested and exercisable, and such other provisions as the Committee shall determine
which are not inconsistent with the terms of the Plan. The Award Agreement also shall specify whether the Option is intended to
be an Incentive Stock Option or a Non-Qualified Stock Option.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Period</U>. Unless a shorter period is otherwise provided by the Committee at the time of grant, each Option
will expire on the tenth (10<SUP>th</SUP>) anniversary date of its grant or on the fifth (5<SUP>th</SUP>) anniversary of its grant
date if the Participant is a Ten Percent Owner. Notwithstanding the foregoing, in the event that on the last business day of the
term of an Option (x) the exercise of which is prohibited by applicable law or (y) Shares may not be purchased or sold by certain
Employees or Directors of the Company due to a &ldquo;black-out period&rdquo; of a Company policy or a &ldquo;lock-up&rdquo; agreement
undertaken in connection with an issuance of securities by the Company, the Committee may provide that the term of the Option shall
be extended but not beyond a period of thirty (30) days following the end of the legal prohibition, black-out period or lock-up
agreement and provided further that no extension will be made if the grant price of such Option at the date the initial term would
otherwise expire is above the Fair Market Value.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. Unless a greater Exercise Price is determined by the Committee, the Exercise Price for each Option
awarded under this Plan shall be equal to one hundred percent (100%) of the Fair Market Value of a Share on the date the Option
is granted. Notwithstanding the foregoing, the Committee may determine the Exercise Price for a substitute Award, provided such
Exercise Price does not violate applicable law (including, but not limited to, Section 409A of the Code).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Vesting of Options</U>. A grant of Options shall vest at such times and under such terms and conditions as determined
by the Committee including, without limitation, suspension of a Participant&rsquo;s vesting during all or a portion of a Participant&rsquo;s
leave of absence.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitations on Incentive Stock Options</U>. In addition to the general requirements of <U>Article 6</U>, the terms of
any Incentive Stock Option (&ldquo;<U>ISO</U>&rdquo;) granted pursuant to the Plan must comply with the provisions of this <U>Section
6.2</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>ISO Eligibility</U>. ISOs may be granted only to Employees of the Company or of any parent or subsidiary corporation
(as permitted under Sections 422 and 424 of the Code). No ISO Award may be made pursuant to this Plan after the tenth (10th) anniversary
of the Effective Date.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>ISO Individual Dollar Limitation</U>. The aggregate Fair Market Value (determined as of the date the Option is granted)
of all Shares with respect to which Incentive Stock Options are first exercisable by a Participant in any calendar year may not
exceed one hundred thousand dollars ($100,000.00) or such other limitation as imposed by Section 422(d) of the Code. To the extent
that Incentive Stock Options are first exercisable by a Participant in excess of such limitation, the excess shall be considered
Non-Qualified Stock Options.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>ISO Expiration</U>. An ISO will expire and may not be exercised to any extent by anyone after the first to occur of the
following events:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Ten (10) years from the date of grant, unless an earlier time is set in the Award Agreement;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Three (3) months after the date of the Participant&rsquo;s Termination of Employment other than on account of Disability
or death. Whether a Participant continues to be an employee shall be determined in accordance with Treas. Reg. Section 1.421-1(h)(2);
and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>One (1) year after the date of the Participant&rsquo;s Termination of Employment on account of Disability or death. Upon
the Participant&rsquo;s Disability or death, any ISOs exercisable at the Participant&rsquo;s Disability or death may be exercised
by the Participant&rsquo;s legal representative or representatives, by the person or persons entitled to do so pursuant to the
Participant&rsquo;s last will and testament, or, if the Participant fails to make testamentary disposition of such ISO or dies
intestate, by the person or persons entitled to receive the ISO pursuant to the applicable laws of descent and distribution.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Any ISO that remains exercisable pursuant to
a Participant&rsquo;s agreement with the Company following Termination of Employment and is unexercised more than one (1) year
following Termination of Employment by reason of death or Disability or more than three (3) months following Termination of Employment
for any reason other than death or Disability will thereafter be deemed to be a Non-Qualified Stock Option.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ten Percent Owners.</U> In the case of an ISO granted to a Ten Percent Owner, such ISO shall be granted at an exercise
price that is not less than one hundred and ten percent (110%) of Fair Market Value on the date of grant and, unless a shorter
period is otherwise provided by the Committee at the time of grant, each ISO will expire on the fifth (5<SUP>th</SUP>) anniversary
of its grant date.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification of Disposition</U>. If a Participant disposes of Shares acquired upon exercise of an ISO within two (2)
years from the date the Option is granted or within one (1) year after the issuance of such Shares to the Participant, the Participant
shall notify the Company of such disposition and provide information regarding the date of disposition, sale price, number of Shares
disposed of, and any other information relating thereto that the Company may reasonably request.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Exercise</U>. During a Participant&rsquo;s lifetime, an Incentive Stock Option may be exercised only by the
Participant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Failure to Meet ISO Requirements</U>. If an Option is intended to be an Incentive Stock Option, and if, for any reason,
such Option (or any portion thereof) shall not qualify as an Incentive Stock Option, then, to the extent of such nonqualification,
such Option (or portion thereof) shall be regarded as a Non-Qualified Stock Option appropriately granted under the Plan; <I>provided
that</I> such Option (or portion thereof) otherwise complies with the Plan&rsquo;s requirements relating to Non-Qualified Stock
Options.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Options</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Options granted under the Plan shall be exercisable at such times and be subject to such restrictions and conditions as
the Committee shall in each instance approve, which need not be the same for each grant or for each Participant. Exercises of Options
may be effected only on days and during the hours NASDAQ is open for regular trading. The Company may change or limit the times
or days Options may be exercised. If an Option expires on a day or at a time when exercises are not permitted, then the Options
may be exercised no later than the immediately preceding date and time that the Options were exercisable.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>An Option shall be exercised by providing notice to the designated agent selected by the Company (if no such agent has been
designated, then to the Company), in the manner and form determined by the Company, which notice shall be irrevocable, setting
forth the exact number of Shares with respect to which the Option is being exercised and including with such notice payment of
the Exercise Price, as applicable. When an Option has been transferred, the Company or its designated agent may require appropriate
documentation that the person or persons exercising the Option, if other than the Participant, has the right to exercise the Option.
No Option may be exercised with respect to a fraction of a Share.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Employment</U>. Unless otherwise provided by the Committee in the applicable Award Agreement, the following
limitations on the exercise of Options shall apply upon Termination of Employment:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by Death or Disability</U>. In the event of the Participant&rsquo;s Termination of Employment by reason of
death or Disability, all outstanding Options granted to such Participant which are vested and exercisable as of the effective date
of Termination of Employment by reason of death or Disability may be exercised, if at all, no more than one (1) year from such
date of Termination of Employment, unless the Options, by their terms, expire earlier. All unvested Options granted to such Participant
shall immediately become forfeited.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Involuntary Termination Without Cause</U>. If a Participant&rsquo;s Termination of Employment is by involuntary termination
without Cause, all Options held by such Participant that are vested and exercisable at the time of the Participant&rsquo;s Termination
of Employment may be exercised by the Participant at any time within a period of ninety (90) days from the date of such Termination
of Employment, but in no event beyond the expiration of the stated term of such Options. All Options held by the Participant which
are not vested on or before the effective date of Termination of Employment shall immediately be forfeited to the Company (and
the Shares subject to such forfeited Options shall once again become available for issuance under the Plan).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voluntary Termination</U>. If a Participant&rsquo;s Termination of Employment is voluntary (other than a voluntary termination
described in <U>Section 6.4(d)</U>), all Options held by such Participant that are vested and exercisable at the time of the Participant&rsquo;s
Termination of Employment may be exercised by the Participant at any time within a period of ninety (90) days from the date of
such Termination of Employment, but in no event beyond the expiration of the stated terms of such Options. All Options held by
the Participant which are not vested on or before the effective date of Termination of Employment shall immediately be forfeited
to the Company (and the Shares subject to such forfeited Options shall once again become available for issuance under the Plan).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination for Cause</U>. If the Participant&rsquo;s Termination of Employment (i) is by the Company for Cause or (ii)
is a voluntary Termination (as provided in <U>Subsection (c)</U> above) after the occurrence of an event that would be grounds
for Termination of Employment for Cause, all outstanding Options held by the Participant shall immediately be forfeited to the
Company and no additional exercise period shall be allowed, regardless of the vested status of the Options (and the Shares subject
to such forfeited Options shall once again become available for issuance under the Plan).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Terms and Conditions</U>. A Participant holding an Option is not eligible to receive dividends or Dividend Equivalents.
Notwithstanding the foregoing, the Committee may, in its sole discretion, establish different, or waive, terms and conditions pertaining
to the effect of Termination of Employment on Options, whether or not the Options are outstanding, but no such modification shall
be materially adverse to the Participant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment</U>. The Committee shall determine the methods by which payments by any Participant with respect to any Awards
granted under the Plan may be paid and the form of payment. Unless otherwise determined by the Committee, the Exercise Price shall
be paid in full at the time of exercise. No Shares shall be issued or transferred until full payment has been received or the next
business day thereafter, as determined by the Company. The Committee may, from time to time, determine or modify the method or
methods of exercising Options or the manner in which the Exercise Price is to be paid. Unless otherwise provided by the Committee
in full or in part, to the extent permitted by Applicable Law, payment may be made by any of the following:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>cash or certified or bank check;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>delivery of Shares owned by the Participant duly endorsed for transfer to the Company, with a Fair Market Value of such
Shares delivered on the date of delivery equal to the Exercise Price (or portion thereof) due for the number of Shares being acquired;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the Company has designated a stockbroker to act as the Company&rsquo;s agent to process Option exercises, an Option may
be exercised by issuing an exercise notice together with instructions to such stockbroker irrevocably instructing the stockbroker:
(i) to immediately sell (which shall include an exercise notice that becomes effective upon execution of a sale order) a sufficient
portion of the Shares to be received from the Option exercise to pay the Exercise Price of the Options being exercised and the
required tax withholding, and (ii) to deliver on the settlement date the portion of the proceeds of the sale equal to the Exercise
Price and tax withholding to the Company. In the event the stockbroker sells any Shares on behalf of a Participant, the stockbroker
shall be acting solely as the agent of the Participant, and the Company disclaims any responsibility for the actions of the stockbroker
in making any such sales. However, if the Participant is an Insider, then the instruction to the stock broker to sell in the preceding
sentence is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) of the Exchange Act to the extent permitted by
law. No Shares shall be issued until the settlement date and until the proceeds (equal to the Exercise Price and tax withholding)
are paid to the Company;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at any time, the Committee may, in addition to or in lieu of the foregoing, provide that an Option may be &ldquo;stock settled,&rdquo;
which shall mean upon exercise of an Option, the Company may fully satisfy its obligation under the Option by delivering that number
of shares of Stock found by taking the difference between (i) the Fair Market Value of the Stock on the exercise date, multiplied
by the number of Options being exercised and (ii) the total Exercise Price of the Options being exercised, and dividing such difference
by the Fair Market Value of the Stock on the exercise date; or</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any combination of the foregoing methods.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding any other provision of the Plan
to the contrary, no Participant who is a Director or an &ldquo;executive officer&rdquo; of the Company shall be permitted to pay
the Exercise Price of an Option in any method which would violate Section 13(h) of the Exchange Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 7</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Stock Appreciation Rights</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Grant of SARs</U>. Any Participant selected by the Committee may be granted one or more SARs. SARs may be granted alone
or in tandem with Options. Each SAR shall be evidenced by an Award Agreement that shall specify the exercise price, the term of
the SAR, and such other provisions as the Committee shall determine. With respect to SARs granted in tandem with Options, the exercise
of either such Options or such SARs shall result in the simultaneous cancellation of the same number of tandem SARs or Options,
as the case may be.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per Share covered by a SAR granted pursuant to the Plan shall be equal to or greater
than Fair Market Value on the date the SAR was granted.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. The term of each SAR shall be determined by the Committee in its sole discretion, but in no event shall the
term exceed ten (10) years from the date of grant. Notwithstanding the foregoing, in the event that on the last business day of
the term of a SAR (x) the exercise of which is prohibited by applicable law or (y) Shares may not be purchased or sold by certain
Employees or Directors of the Company due to a &ldquo;black-out period&rdquo; of a Company policy or a &ldquo;lock-up&rdquo; agreement
undertaken in connection with an issuance of securities by the Company, the Committee may provide that the term of the SAR shall
be extended but not beyond a period of thirty (30) days following the end of the legal prohibition, black-out period or lock-up
agreement and provided further that no extension will be made if the grant price of such SAR at the date the initial term would
otherwise expire is above the Fair Market Value.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment</U>. SARs may be settled in the form of cash, shares of Stock or a combination of cash and shares of Stock, as
determined by the Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Provisions</U>. Except as the Committee may deem inappropriate or inapplicable in the circumstances, SARs shall
be subject to terms and conditions substantially similar to those applicable to Non-Qualified Options as set forth in <U>Article
6</U>, including, but not limited to, the ineligibility to receive dividends or Dividend Equivalents.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 8<BR>
<BR>
<U>Restricted Stock Awards</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Grant of Restricted Stock</U>. Subject to the terms and provisions of the Plan, the Committee, at any time and from time
to time, may grant shares of Restricted Stock to Eligible Persons in such amounts and upon such terms and conditions as the Committee
shall determine. In addition to any other terms and conditions imposed by the Committee, vesting of Restricted Stock may be conditioned
upon the achievement of Performance Goals.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restricted Stock Agreement</U>. The Committee may require, as a condition to receiving a Restricted Stock Award, that
the Participant enter into a Restricted Stock Award Agreement, setting forth the terms and conditions of the Award. In lieu of
a Restricted Stock Award Agreement, the Committee may provide the terms and conditions of an Award in a notice to the Participant
of the Award, on the Stock certificate representing the Restricted Stock, in the resolution approving the Award, or in such other
manner as it deems appropriate. If certificates representing the Restricted Stock are registered in the name of the Participant,
any certificates so issued shall be printed with an appropriate legend referring to the terms, conditions, and restrictions applicable
to such Award as determined or authorized in the sole discretion of the Committee. Shares recorded in book-entry form shall be
recorded with a notation referring to the terms, conditions, and restrictions applicable to such Award as determined or authorized
in the sole discretion of the Committee. The Committee may require that the stock certificates or book-entry registrations evidencing
shares of Restricted Stock be held in custody by a designated escrow agent (which may but need not be the Company) until the restrictions
thereon shall have lapsed, and that the Participant deliver a stock power, endorsed in blank, relating to the Stock covered by
such Award.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Restricted Stock shall be subject to such vesting terms, including the achievement of Performance
Goals, as may be determined by the Committee. Unless otherwise provided by the Committee, to the extent Restricted Stock is subject
to any condition to vesting, if such condition or conditions are not satisfied by the time the period for achieving such condition
has expired, such Restricted Stock shall be forfeited. The Committee may impose such other conditions and/or restrictions on any
shares of Restricted Stock granted pursuant to the Plan as it may deem advisable including but not limited to a requirement that
Participants pay a stipulated purchase price for each share of Restricted Stock and/or restrictions under Applicable Law. The Committee
may also grant Restricted Stock without any terms or conditions in the form of vested Stock Awards.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Removal of Restrictions</U>. Except as otherwise provided in this <U>Article 8</U> or otherwise provided in the grant
thereof, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan shall become freely transferable
by the Participant after completion of all conditions to vesting, if any. However, the Committee, in its sole discretion, shall
have the right to waive all or part of the restrictions and conditions with regard to all or part of the shares held by any Participant
at any time.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voting Rights, Dividends and Other Distributions</U>. Participants holding shares of Restricted Stock granted hereunder
may exercise full voting rights and, subject to the provisions of this <U>Section 8.5</U>, may receive all dividends and distributions
paid with respect to such Shares. If any such dividends or distributions are paid in Shares, the Shares shall automatically be
subject to the same restrictions and conditions as the Restricted Stock with respect to which they were paid. In addition, with
respect to a share of Restricted Stock, dividends shall only be paid out to the extent that the Share of Restricted Stock vests.
Any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld by the Company for the Participant&rsquo;s
account, and interest may be credited on the amount of the cash dividends withheld at a rate and subject to such terms as determined
by the Committee. The cash dividends or stock dividends so withheld by the Committee and attributable to any particular share of
Restricted Stock (and earnings thereon, if applicable) shall be distributed to the Participant in cash or, at the discretion of
the Committee, in shares of Stock having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release
of restrictions on such share and, if such share is forfeited, the Participant shall have no right to such dividends.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Employment Due to Death or Disability</U>. In the event of the Participant&rsquo;s Termination of Employment
by reason of death or Disability, unless otherwise determined by the Committee, all restrictions imposed on outstanding Shares
of Restricted Stock held by the Participant shall immediately lapse and the Restricted Stock shall immediately become fully vested
as of the date of Termination of Employment.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Employment for Other Reasons</U>. Unless otherwise provided by the Committee, in the event of the Participant&rsquo;s
Termination of Employment for any reason other than those specifically set forth in <U>Section 8.6</U> herein, subject to <U>Section
10.2</U>, all shares of Restricted Stock held by the Participant which are not vested as of the effective date of Termination of
Employment shall immediately be forfeited and returned to the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 83(b) Election</U>. The Committee may provide in an Award Agreement that the Award of Restricted Stock is conditioned
upon the Participant making or refraining from making an election with respect to the Award under Section 83(b) of the Code. If
a Participant makes an election pursuant to Section 83(b) of the Code concerning a Restricted Stock Award, the Participant shall
be required to file a copy of such election with the Company within thirty (30) days following the date of grant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restricted Stock Units</U>. In lieu of or in addition to Restricted Stock, the Committee may grant Restricted Stock Units
under such terms and conditions as shall be determined by the Committee in accordance with <U>Section 3.2</U>. Restricted Stock
Units shall be subject to the same terms and conditions under this Plan as Restricted Stock except as otherwise provided in this
Plan or as otherwise provided by the Committee. Except as otherwise provided by the Committee, the award shall be settled and paid
out promptly upon vesting (to the extent permitted by Section 409A of the Code), and the Participant holding such Restricted Stock
Units shall receive, as determined by the Committee, Shares (or cash equal to the Fair Market Value of the number of Shares as
of the date the Award becomes payable) equal to the number of such Restricted Stock Units. Restricted Stock Units shall not be
transferable, shall have no voting rights, and, unless otherwise determined by the Committee, shall not receive dividends or Dividend
Equivalents (which in any event shall only be paid out to the extent that the Restricted Stock Units vest). Upon a Participant&rsquo;s
Termination of Employment due to death or Disability, the Committee will determine whether there should be any acceleration of
vesting.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 9<BR>
<BR>
<U>Other Types of Awards</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance Share Awards</U>. Any Participant selected by the Committee may be granted one or more Performance Share
awards which shall be denominated in a number of shares of Stock and which may be linked to any one or more of the Performance
Goals or other specific performance criteria determined appropriate by the Committee, in each case on a specified date or dates
or over any period or periods determined by the Committee. In making such determinations, the Committee shall consider (among such
other factors as it deems relevant in light of the specific type of award) the contributions, responsibilities and other compensation
of the particular Participant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance Stock Units</U>. Any Participant selected by the Committee may be granted one or more Performance Stock Unit
awards which shall be denominated in units of value including dollar value of shares of Stock and which may be linked to any one
or more of the Performance Goals or other specific performance criteria determined appropriate by the Committee, in each case on
a specified date or dates or over any period or periods determined by the Committee. In making such determinations, the Committee
shall consider (among such other factors as it deems relevant in light of the specific type of award) the contributions, responsibilities
and other compensation of the particular Participant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dividend Equivalents</U>. Any Participant selected by the Committee may be granted Dividend Equivalents based on the
dividends declared on the Shares that are subject to any Award, to be credited as of dividend payment dates, during the period
between the date the Award is granted and the date the Award is exercised, vests or expires, as determined by the Committee. Such
Dividend Equivalents shall be converted to cash or additional shares of Stock by such formula and at such time and subject to such
limitations as may be determined by the Committee, in a matter consistent with the rules of Section 409A of the Code; provided
that, to the extent Shares subject to an Award are subject to vesting conditions, any Dividend Equivalents relating to such Shares
shall be subject to the same vesting conditions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deferred Stock</U>. Any Participant selected by the Committee may be granted an award of Deferred Stock in the manner
determined from time to time by the Committee. The number of shares of Deferred Stock shall be determined by the Committee and
may be linked to the Performance Goals or other specific performance criteria determined to be appropriate by the Committee, in
each case on a specified date or dates or over any period or periods determined by the Committee. Stock underlying a Deferred Stock
Award will not be issued until the Deferred Stock Award has vested, pursuant to a vesting schedule or performance criteria set
by the Committee. Unless otherwise provided by the Committee, a Participant awarded Deferred Stock shall have no rights as a Company
stockholder with respect to such Deferred Stock until such time as the Deferred Stock Award has vested and the Stock underlying
the Deferred Stock Award has been issued.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Stock-Based Awards</U>. Any Participant selected by the Committee may be granted one or more Awards that provide
Participants with shares of Stock or the right to purchase shares of Stock or that have a value derived from the value of, or an
exercise or conversion privilege at a price related to, or that are otherwise payable in shares of Stock and which may be linked
to any one or more of the Performance Goals or other specific performance criteria determined appropriate by the Committee, in
each case on a specified date or dates or over any period or periods determined by the Committee. In making such determinations,
the Committee shall consider (among such other factors as it deems relevant in light of the specific type of Award) the contributions,
responsibilities and other compensation of the particular Participant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance Bonus Awards</U>. Any Participant selected by the Committee may be granted one or more Awards in the form
of a cash bonus (a &ldquo;<U>Performance Bonus Award</U>&rdquo;) payable upon the attainment of Performance Goals that are established
by the Committee, in each case on a specified date or dates or over any period or periods determined by the Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. Except as otherwise provided herein, the term of any Award of Performance Shares, Performance Stock Units,
Dividend Equivalents, Deferred Stock, Other Stock-Based Award and Performance Bonus Award shall be set by the Committee in its
discretion.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise or Purchase Price</U>. The Committee may establish the exercise or purchase price, if any, of any Award of Performance
Shares, Performance Stock Units, Deferred Stock, Other Stock-Based Award and Performance Bonus Award; provided, however, that such
price shall not be less than the Fair Market Value of a share of Stock on the date of grant, unless otherwise permitted by Applicable
Law.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Upon Termination of Employment or Service</U>. An Award of Performance Shares, Performance Stock Units, Deferred
Stock, Other Stock-Based Awards and Performance Bonus Awards shall only be exercisable or payable while the Participant is an Employee,
Consultant or Non-Employee Director, as applicable; provided, however, that the Committee in its sole and absolute discretion may
provide that an Award of Performance Shares, Performance Stock Units, Deferred Stock, Stock Appreciation Rights, Other Stock-Based
Award and Performance Bonus Award may be exercised or paid subsequent to a Termination of Employment without Cause. In the event
of the Termination of Employment of a Participant by the Company for Cause, all Awards under this <U>Article 9</U> shall be forfeited
by the Participant to the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Form of Payment</U>. Payments with respect to any Awards granted under this <U>Article 9</U> shall be made in cash, in
Stock or a combination of both, as determined by the Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Award Agreement</U>. All Awards under this <U>Article 9</U> shall be subject to such additional terms and conditions
as determined by the Committee and shall be evidenced by a written Award Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 10<BR>
<BR>
<U>Change in Control</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Vesting Upon Change in Control</U>. For the avoidance of doubt, the Committee may not accelerate the vesting and exercisability
(as applicable) of any outstanding Awards, in whole or in part, solely upon the occurrence of a Change in Control except as provided
in this <U>Section 10.1</U>. In the event of a Change in Control after the date of the adoption of the Plan, then:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the extent an outstanding Award subject solely to time-based vesting is not assumed or replaced by a comparable Award
referencing shares of the capital stock of the successor corporation or its &ldquo;parent corporation&rdquo; (as defined in Section
424(e) of the Code) or &ldquo;subsidiary corporation&rdquo; (as defined in Section 424(f) of the Code) which is publicly traded
on a national stock exchange or quotation system, as determined by the Committee in its sole discretion, with appropriate adjustments
as to the number and kinds of shares and the exercise prices, if applicable, then any outstanding Award subject solely to time-based
vesting then held by Participants that is unexercisable, unvested or still subject to restrictions or forfeiture shall, in each
case as specified by the Committee in the applicable Award Agreement or otherwise, be deemed exercisable or otherwise vested, as
the case may be, as of immediately prior to such Change in Control;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any stock-denominated performance-based Awards outstanding as of the date such Change in Control is determined to have occurred
shall be converted into, as applicable, time-based restricted stock of the successor corporation or its &ldquo;parent corporation&rdquo;
(as defined in Section 424(e) of the Code) or &ldquo;subsidiary corporation&rdquo; (as defined in Section 424(f) of the Code) or
time-based restricted stock units based on the capital stock of the successor corporation or its &ldquo;parent corporation&rdquo;
(as defined in Section 424(e) of the Code) or &ldquo;subsidiary corporation&rdquo; (as defined in Section 424(f) of the Code) and,
if, during the 12-month period following the date of such Change in Control, the Participant&rsquo;s employment is terminated by
such successor (or an affiliate thereof) without Cause or by the Participant for Good Reason, such Awards, to the extent then outstanding,
shall fully vest. With respect to performance-based Awards that are outstanding as of the date of such Change in Control and are
not converted to a time-based Award, any deferral or other restriction shall lapse and such Awards shall be settled in cash as
promptly as is practicable (unless otherwise required by Section 409A of the Code and the applicable terms of the Awards). In either
case, unless otherwise determined by the Committee in an Award Agreement or otherwise, the value of the performance-based Awards
as of the date of the Change in Control shall be determined assuming target performance has been achieved, except that the value
shall be determined based on actual performance as of such date if (i) more than half of the performance period has elapsed as
of such date and (ii) actual performance is determinable as of such date; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each outstanding Award that is assumed in connection with a Change in Control, or is otherwise to continue in effect subsequent
to the Change in Control, will be appropriately adjusted, immediately after the Change in Control, as to the number and class of
securities and other relevant terms in accordance with <U>Section 4.3</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Employment Upon Change in Control</U>. Notwithstanding any other provision of the Plan to the contrary,
and except as may otherwise be provided in any applicable Award Agreement or other written agreement entered into between the Company
or Affiliate and a Participant, upon (i) a Participant&rsquo;s involuntary Termination of Employment without Cause on or within
one (1) year following a Change in Control, or (ii) a Participant&rsquo;s Termination of Employment for Good Reason (including
the Termination of Employment of the Participant if he or she is employed by an Affiliate at the time the Company sells or otherwise
divests itself of such Affiliate), all outstanding Awards shall immediately become fully vested and exercisable; <I>provided that</I>
Restricted Stock Units shall be settled in accordance with the terms of the grant without regard to the Change in Control unless
the Change in Control constitutes a &ldquo;change in control event&rdquo; within the meaning of Section 409A of the Code and such
Termination of Employment occurs within one (1) year following such Change in Control, in which case the Restricted Stock Units
shall be settled and paid out with such Termination of Employment.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cancellation and Termination of Awards</U>. The Committee may, in connection with any merger, consolidation, share exchange
or other transaction entered into by the Company in good faith, determine that any outstanding Awards granted under the Plan, whether
or not vested, will be canceled and terminated and that in connection with such cancellation and termination the holder of such
Award may receive for each Share subject to such Award a cash payment (or the delivery of shares of stock, other securities or
a combination of cash, stock and securities equivalent to such cash payment) equal to the difference, if any, between the amount
determined by the Committee to be the Fair Market Value of the Stock and the purchase price per Share (if any) under the Award
multiplied by the number of Shares subject to such Award; provided that if such product is zero or less or to the extent that the
Award is not then exercisable, the Award will be canceled and terminated without payment therefor.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 11<BR>
<BR>
<U>Amendment, Modification, and Termination</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment, Modification, and Termination of Plan</U>. At any time and from time to time, the Board may amend, modify,
alter, suspend, discontinue or terminate the Plan, in whole or in part, without stockholder approval; provided, however, that (a)
to the extent necessary and desirable to comply with any Applicable Law, regulation, or stock exchange rule, the Company shall
obtain stockholder approval of any Plan amendment in such a manner and to such a degree as required, and (b) stockholder approval
is required for any amendment to the Plan that (i) increases the number of shares available under the Plan (other than any adjustment
as provided by <U>Section 4.3</U>) or the number of shares available for issuance as ISOs, or (ii) permits the Committee to grant
Options with an Exercise Price that is below Fair Market Value on the date of grant (except as otherwise provided in <U>Section
6.1</U>), or (iii) permits the Committee to extend the exercise period for an Option beyond ten (10) years from the date of grant
(except as otherwise provided in <U>Section 6.1</U>), or (iv) results in a material increase in benefits or a change in eligibility
requirements, or (v) changes the granting corporation or (vi) changes the type of stock.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment of Awards</U>. Subject to <U>Section 4.3</U>, at any time and from time to time, the Committee may amend the
terms of any one or more outstanding Awards, provided that the Award as amended is consistent with the terms of the Plan or if
necessary or advisable for the purpose of conforming the Plan or an Award Agreement to any present or future law relating to plans
of this or similar nature (including, without limitation, Section 409A), and to the administrative regulations and rulings promulgated
thereunder.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Awards Previously Granted</U>. No termination, amendment, or modification of the Plan or any Award shall adversely affect
in any material way any Award previously granted under the Plan, without the written consent of the Participant holding such Award;
provided, however, that any such modification made for the purpose of complying with Section 409A of the Code may be made by the
Company without the consent of any Participant.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Repricing and Backdating Prohibited</U>. Notwithstanding anything in this Plan to the contrary, except as provided under
<U>Section 4.3</U> and <U>Section 11.2</U>, neither the Committee nor any other person may (i) amend the terms of outstanding Options
or SARs to reduce the exercise or grant price of such outstanding Options or SARs; (ii) cancel outstanding Options or SARs in exchange
for Options or SARs with an exercise or grant price that is less than the exercise price of the original Options or SARs; or (iii)
cancel outstanding Options or SARs with an exercise or grant price above the current Share price in exchange for cash or other
securities. In addition, the Committee may not make a grant of an Option or SAR with a grant date that is effective prior to the
date the Committee takes action to approve such Award.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 12<BR>
<BR>
<U>Withholding</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Withholding</U>. Unless otherwise provided by the Committee, the Company shall deduct or withhold any amount needed
to satisfy any foreign, federal, state, or local tax (including but not limited to the Participant&rsquo;s employment tax obligations)
required by law to be withheld with respect to any taxable event arising or as a result of this Plan (&ldquo;<U>Withholding Taxes</U>&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Share Withholding</U>. Unless otherwise provided by the Committee, upon the exercise of Options, the lapse of restrictions
on Restricted Stock, the vesting of Restricted Stock Units the distribution of Performance Shares in the form of Stock, or any
other taxable event hereunder involving the transfer of Stock to a Participant, the Company shall withhold Stock equal in value,
using the Fair Market Value on the date determined by the Company to be used to value the Stock for tax purposes, to the Withholding
Taxes applicable to such transaction.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Unless otherwise determined by the Committee,
when the method of payment for the Exercise Price is from the sale by a stockbroker pursuant to <U>Section 6.5(c)</U>, herein,
of the Stock acquired through the Option exercise, then the tax withholding shall be satisfied out of the proceeds. For administrative
purposes in determining the amount of taxes due, the sale price of such Stock shall be deemed to be the Fair Market Value of the
Stock.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If permitted by the Committee, prior to the
end of any Performance Period a Participant may elect to have a greater amount of Stock withheld from the distribution of Performance
Shares to pay withholding taxes; provided, however, the Committee may prohibit or limit any individual election or all such elections
at any time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Alternatively, or in combination with the foregoing,
the Committee may require Withholding Taxes to be paid in cash by the Participant or by the sale of a portion of the Stock being
distributed in connection with an Award, or by a combination thereof.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The withholding of taxes is intended to comply
with the requirements of Rule 10b5-1(c)(1)(i)(B) of the Exchange Act to the extent permitted by law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 13<BR>
<BR>
<U>General Provisions Applicable to Awards</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="background-color: white"><U>Minimum Vesting Requirement</U>. Notwithstanding any other provision of the Plan
to the contrary, Awards granted under the Plan (other than cash-based awards) shall vest no earlier than the first anniversary
of the date on which the Award is granted;&nbsp;<U>provided</U>, that the following Awards shall not be subject to the foregoing
minimum vesting requirement: any (i) <FONT STYLE="color: #212121">substitute Awards granted </FONT>in connection with awards that
are assumed, converted or substituted pursuant to a merger, acquisition or similar transaction entered into by the Company or any
of its Subsidiaries, (ii) Shares delivered in lieu of fully vested cash obligations, (iii) Awards to Non-Employee Directors that
vest on&nbsp; the earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is
at least 50 weeks after the immediately preceding year&rsquo;s annual meeting, and (iv) any additional Awards the Committee may
grant, up to a maximum of five percent (5%) of the available share reserve authorized for issuance under the Plan pursuant to <U>Section
4.1</U> (subject to adjustment under <U>Section 4.3</U>); and,&nbsp;<U>provided</U>,&nbsp;<U>further</U>, that the foregoing restriction
does not apply to the Committee&rsquo;s discretion to provide for accelerated exercisability or vesting of any Award, including
in cases of retirement, death, Disability or a Change in Control, in the terms of the Award Agreement or otherwise.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Form of Payment</U>. Subject to the provisions of this Plan, the Award Agreement and any Applicable Law, payments or
transfers to be made by the Company or any Affiliate on the grant, exercise, or settlement of any Award may be made in such form
as determined by the Committee including, without limitation, cash, Stock, other Awards, other property, or any combination thereof,
and may be made in a single payment or transfer, in installments, or any combination thereof, in each case determined by rules
adopted by the Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Treatment of Dividends and Dividend Equivalents on Unvested Awards</U>. Notwithstanding any other provision of the Plan
to the contrary, with respect to any Award that provides for or includes a right to dividends or Dividend Equivalents, if dividends
are declared during the period that an equity Award is outstanding, such dividends (or Dividend Equivalents) shall either (a) not
be paid or credited with respect to such Award or (b) be accumulated but remain subject to vesting requirement(s) to the same extent
as the applicable Award and shall only be paid at the time or times such vesting requirement(s) are satisfied.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limits on Transfer</U>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as otherwise provided in <U>Section 13.4(b)</U>,</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>no Award may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or the
laws of descent and distribution or pursuant to a domestic relations order, unless and until such Award has been exercised, or
the Shares underlying such Award have been issues, and all restrictions applicable to such Shares have lapsed;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>no Award or interest or right therein shall be liable for or otherwise subject to the debts, contracts or engagements of
the Participant or the Participant&rsquo;s successors in interest or shall be subject to disposition by transfer, alienation, anticipation,
pledge, hypothecation, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation
of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy) unless and
until such Award has been exercised, or the Shares underlying such Award have been issued, and all restrictions applicable to such
Shares have lapsed, and any attempted disposition of an Award prior to satisfaction of these conditions shall be null and void
and of no effect, except to the extent that such disposition is permitted by <U>Section 13.4(a)(i)</U>; and</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>during a Participant&rsquo;s lifetime, only the Participant or the Participant&rsquo;s guardian or legal representative
may exercise an Award (or any portion thereof) granted to him or her under the Plan, unless it has been disposed of pursuant to
a domestic relations order. After a Participant&rsquo;s death, any exercisable portion of an Award may, prior to the time when
such portion becomes unexercisable under the Plan or the applicable Award Agreement, be exercised by such Participant&rsquo;s personal
representative or by any person empowered to do so under the deceased Participant&rsquo;s will or under the then applicable laws
of descent and distribution.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding <U>Section 13.4(a)</U>, the Committee, in its sole discretion, may determine to permit a Participant or
a Permitted Transferee of such Participant to transfer an Award other than an Incentive Stock Option (unless such Incentive Stock
Option is intended to become a Non-Qualified Stock Option) to any one or more Permitted Transferees of such Participant without
consideration, subject to the following terms and conditions: (i) an Award transferred to a Permitted Transferee shall not be assignable
or transferable by the Permitted Transferee other than (A) to another Permitted Transferee of the applicable Participant or (B)
by will or the laws of descent and distribution or, subject to the consent of the Committee, pursuant to a domestic relations order;
(ii) an Award transferred to a Permitted Transferee shall continue to be subject to all the terms and conditions of the Award as
applicable to the original Participant (other than the ability to further transfer the Award to any person other than another Permitted
Transferee of the applicable Participant); and (iii) the Participant (or transferring Permitted Transferee) and the receiving Permitted
Transferee shall execute any and all documents requested by the Committee, including, without limitation documents to (A) confirm
the status of the transferee as a Permitted Transferee, (B) satisfy any requirements for an exemption for the transfer under Applicable
Law and (C) evidence the transfer. In addition, and further notwithstanding <U>Section 13.4(a)</U>, hereof, the Committee, in its
sole discretion, may determine to permit a Participant to transfer Incentive Stock Options to a trust that constitutes a Permitted
Transferee if, under Section 671 of the Code and other Applicable Law, the Participant is considered the sole beneficial owner
of the Incentive Stock Option while it is held in the trust.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Beneficiaries</U>. Notwithstanding <U>Section 13.4</U>, if provided in the applicable Award Agreement, a Participant
may, in the manner determined by the Committee, designate a beneficiary to exercise the rights of the Participant and to receive
any distribution with respect to any Award upon the Participant&rsquo;s death. A beneficiary, legal guardian, legal representative,
or other person claiming any rights pursuant to the Plan is subject to all terms and conditions of the Plan and any Award Agreement
applicable to the Participant, except to the extent the Plan and Award Agreement otherwise provide, and to any additional restrictions
deemed necessary or appropriate by the Committee. If the Participant is married and resides in a community property state, a designation
of a person other than the Participant&rsquo;s spouse as his or her beneficiary with respect to more than fifty percent (50%) of
the Participant&rsquo;s interest in the Award shall not be effective without the prior written consent of the Participant&rsquo;s
spouse. If no beneficiary has been designated or survives the Participant, payment shall be made to the person entitled thereto
pursuant to the Participant&rsquo;s will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation
may be changed or revoked by a Participant at any time provided the change or revocation is filed with the Committee.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Forfeiture Events/Representations</U>. The Committee may specify in an Award Agreement at the time of the Award that
the Participant&rsquo;s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture
or recoupment upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions
of an Award. Such events shall include, but shall not be limited to, termination of service for Cause, violation of material Company
policies, breach of noncompetition, confidentiality or other restrictive covenants that may apply to the Participant, or other
conduct by the Participant that is detrimental to the business or reputation of the Company. The Committee may also specify in
an Award Agreement that the Participant&rsquo;s rights, payments and benefits with respect to an Award shall be conditioned upon
the Participant making a representation regarding compliance with noncompetition, confidentiality or other restrictive covenants
that may apply to the Participant and providing that the Participant&rsquo;s rights, payments and benefits with respect to an Award
shall be subject to reduction, cancellation, forfeiture or recoupment on account of a breach of such representation. In addition
and without limitation of the foregoing, any amounts paid hereunder shall be subject to recoupment in accordance with The Dodd&ndash;Frank
Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any &ldquo;clawback&rdquo; policy adopted
by the Company or as is otherwise required by applicable law or stock exchange listing condition.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Awards under the Plan shall be subject to the
Company&rsquo;s clawback policy, as in effect from time to time. If there shall be no such clawback policy in effect, (1) awards
under the Plan and any Shares issued pursuant to Awards under the Plan (and any gains thereon) shall be subject to recovery or
&ldquo;clawback&rdquo; by the Company if and to the extent that the vesting of such Awards was determined or calculated based on
materially inaccurate financial statements or any other material inaccurate performance metric criteria; or (2) if the Company
or its Subsidiaries terminate a Participant&rsquo;s service relationship due to the Participant&rsquo;s gross negligence or willful
misconduct, or determine there are grounds for such a termination (whether or not such actions also constitute &ldquo;cause&rdquo;
under an Award Agreement), any Awards under the Plan, whether or not vested, as well as any shares of Stock issued pursuant to
Awards under this Plan (and any gains thereon) shall be subject to forfeiture, recovery and &ldquo;clawback.&rdquo; Notwithstanding
anything to the contrary contained herein, if a Participant has engaged in any detrimental activity (including noncompliance with
restrictive covenants), as determined by the Committee, the Committee may, in its sole discretion, provide for cancellation of
any or all of such Participant&rsquo;s outstanding Awards and/or forfeiture by the Participant of any gain realized in respect
of Awards, and repayment of any such gain promptly to the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares</U>. No fractional Shares shall be issued or delivered pursuant to the Plan or any Award. The Committee
shall determine whether cash, Awards, or other property shall be issued or paid in lieu of fractional Shares or whether such fractional
Shares or any rights thereto shall be forfeited or otherwise eliminated.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reservation of Stock</U>. The Company shall at all times during the term of the Plan and any outstanding Awards granted
hereunder reserve or otherwise keep available such number of Shares of Stock as will be sufficient to satisfy the requirements
of the Plan (if then in effect) and the Awards and shall pay all fees and expenses necessarily incurred by the Company in connection
therewith.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reimbursement of Company for Unearned or Ill-gotten Gains</U>. Unless otherwise specifically provided in an Award Agreement,
and to the extent permitted by Applicable Law, if the Company is required to prepare an accounting restatement due to the material
noncompliance of the Company with any financial reporting requirement under the securities laws, the Committee may, without obtaining
the approval or consent of the Company&rsquo;s shareholders or of any Participant, require that any Participant who personally
engaged in one of more acts of fraud or misconduct that have caused or partially caused the need for such restatement or any current
or former chief executive officer, chief financial officer, or executive officer, regardless of their conduct, to reimburse the
Company in a manner consistent with Section 409A of the Code, if the Award constitutes &ldquo;Non-Qualified Deferred Compensation,&rdquo;
for all or any portion of any Awards granted or settled under this Plan (with each such case being a &ldquo;<U>Reimbursement</U>&rdquo;),
or the Committee may require the termination or rescission of, or the recapture associated with, any Award, in excess of the amount
the Participant would have received under the accounting restatement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delay in Payment</U>. To the extent required in order to avoid the imposition of any interest and/or additional tax under
Section 409A(a)(1)(B) of the Code, any amount that is considered deferred compensation under the Plan or Award Agreement and that
is required to be postponed pursuant to Section 409A of the Code, following the a Participant&rsquo;s Termination of Employment
shall be delayed for six (6) months if a Participant is deemed to be a &ldquo;specified employee&rdquo; as defined in Section 409A(a)(2)(i)(B)
of the Code; provided that, if the Participant dies during the postponement period prior to the payment of the postponed amount,
the amounts withheld on account of Section 409A of the Code shall be paid to the executor or administrator of the decedent&rsquo;s
estate within 60 days following the date of his death. A &ldquo;<U>Specified Employee</U>&rdquo; means any Participant who is a
&ldquo;key employee&rdquo; (as defined in Section 416(i) of the Code without regard to paragraph (5) thereof), as determined by
the Company in accordance with its uniform policy with respect to all arrangements subject to Section 409A of the Code, based upon
the twelve (12) month period ending on each December 31st (the &ldquo;<U>Identification Period</U>&rdquo;). All Participants who
are determined to be key employees under Section 416(i) of the Code (without regard to paragraph (5) thereof) during the identification
period shall be treated as Specified Employees for purposes of the Plan during the twelve (12) month period that begins on the
first day of the 4th month following the close of such identification period.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 14<BR>
<BR>
<U>Successors</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">All obligations of the Company under the Plan,
with respect to Awards granted hereunder, shall be binding on any successor to the Company, whether the existence of such successor
is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business
and/or assets of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">Article 15</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in"><U>Miscellaneous Provisions</U></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Substitute Awards in Corporate Transactions</U>. Nothing contained in the Plan shall be construed to limit the right
of the Committee to grant Awards under the Plan in connection with the acquisition, whether by purchase, merger, consolidation
or other corporate transaction, of the business or assets of any corporation or other entity. Without limiting the foregoing, the
Committee may grant Awards under the Plan to an employee or director of another corporation who becomes an Eligible Person by reason
of any such corporate transaction in substitution for awards previously granted by such corporation or entity to such person. The
terms and conditions of the substitute Awards may vary from the terms and conditions that would otherwise be required by the Plan
solely to the extent the Committee deems necessary for such purpose. Any shares of Stock subject to these substitute Awards shall
not be counted against the share reserve set forth in <U>Article 4</U> of the Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>409A Compliance</U>. It is intended that all Awards issued under the Plan be in a form and administered in a manner that
will comply with the requirements of Section 409A of the Code, or the requirements of an exception to Section 409A of the Code,
and the Award Agreement and this Plan will be construed and administered in a manner that is consistent with and gives effect to
such intent. The Committee is authorized to adopt rules or regulations deemed necessary or appropriate to qualify for an exception
from or to comply with the requirements of Section 409A of the Code. With respect to an Award that constitutes a deferral of compensation
subject to Section 409A of the Code: (a) if any amount is payable under such Award upon a termination of service, a termination
of service will be treated as having occurred only at such time the Participant has experienced a &ldquo;separation from service&rdquo;
as such term is defined for purposes of Section 409A of the Code; (b) if any amount is payable under such Award upon a disability,
a disability will be treated as having occurred only at such time the Participant has experienced a &ldquo;disability&rdquo; as
such term is defined for purposes of Section 409A of the Code; (c) if any amount is payable under such Award on account of the
occurrence of a Change in Control, a Change in Control will be treated as having occurred only at such time a &ldquo;change in
the ownership or effective control of the corporation or in the ownership of a substantial portion of the assets of the corporation&rdquo;
has occurred as such terms are defined for purposes of Section 409A of the Code, (d) if any amount becomes payable under such Award
on account of a Participant&rsquo;s separation from service at such time as the Participant is a &ldquo;specified employee&rdquo;
within the meaning of Section 409A of the Code, then no payment shall be made, except as permitted under Section 409A of the Code,
prior to the first business day after the earlier of (i) the date that is six months after the date of the Participant&rsquo;s
separation from service or (ii) the Participant&rsquo;s death, (e) any right to receive any installment payments under this Plan
shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall
at all times be considered a separate and distinct payment, and (f) no amendment to or payment under such Award will be made except
and only to the extent permitted under Section 409A of the Code.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding the foregoing, the tax treatment
of the benefits provided under the Plan or any Award Agreement is not warranted or guaranteed, and in no event shall the Company
be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Participant on
account of non-compliance with Section 409A of the Code.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 16(b) of the Exchange Act</U>. All elections and transactions under the Plan by persons subject to Section 16
of the Exchange Act involving shares of Stock are intended to comply with any applicable exemptive condition under Rule 16b-3.
The Committee may, in its sole discretion, establish and adopt written administrative guidelines, designed to facilitate compliance
with Section 16(b) of the Exchange Act, as it may deem necessary or proper for the administration and operation of the Plan and
the transaction of business thereunder.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Unfunded Status of the Plan</U>. The Plan is intended to constitute an &ldquo;unfunded&rdquo; plan for incentive compensation,
and the Plan is not intended to constitute a plan subject to the provisions of ERISA. With respect to any payments not yet made
to a Participant by the Company, nothing contained herein shall give any such Participant any rights that are greater than those
of a general creditor of the Company. In its sole discretion, the Committee may authorize the creation of trusts or other arrangements
to meet the obligations created under the Plan to deliver Stock or payments with respect to Options, Stock Appreciation Rights
and other Awards hereunder, provided, however, that the existence of such trusts or other arrangements is consistent with the unfunded
status of the Plan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonexclusivity of the Plan</U>. Neither the adoption of the Plan by the Board nor the submission of the Plan to the stockholders
of the Company shall be construed as creating any limitations on the power of the Board to adopt such other incentive arrangements
as it may deem desirable, including without limitation, the granting of stock options and restricted stock other than under the
Plan, and such arrangements may be either applicable generally or only in specific cases.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investment Representations</U>. The Company shall be under no obligation to issue any shares covered by any Award unless
the shares to be issued pursuant to Awards granted under the Plan have been effectively registered under the Securities Act of
1933, as amended, or the Participant shall have made such written representations to the Company (upon which the Company believes
it may reasonably rely) as the Company may deem necessary or appropriate for purposes of confirming that the issuance of such shares
will be exempt from the registration requirements of that Act and any applicable state securities laws and otherwise in compliance
with all applicable laws, rules and regulations, including but not limited to that the Participant is acquiring the shares for
his or her own account for the purpose of investment and not with a view to, or for sale in connection with, the distribution of
any such shares.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration</U>. If the Company shall deem it necessary or desirable to register under the Securities Act of 1933, as
amended or other applicable statutes any Shares of Stock issued or to be issued pursuant to Awards granted under the Plan, or to
qualify any such Shares of Stock for exemption from the Securities Act of 1933, as amended or other applicable statutes, then the
Company shall take such action at its own expense. The Company may require from each recipient of an Award, or each holder of Shares
of Stock acquired pursuant to the Plan, such information in writing for use in any registration statement, prospectus, preliminary
prospectus or offering circular as is reasonably necessary for that purpose and may require reasonable indemnity to the Company
and its officers and directors from that holder against all losses, claims, damage and liabilities arising from use of the information
so furnished and caused by any untrue statement of any material fact therein or caused by the omission to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under
which they were made. In addition, the Company may require of any such person that he or she agree that, without the prior written
consent of the Company or the managing underwriter in any public offering of Shares of Stock, he or she will not sell, make any
short sale of, loan, grant any option for the purchase of, pledge or otherwise encumber, or otherwise dispose of, any shares of
Stock during the 180 day period commencing on the effective date of the registration statement relating to the underwritten public
offering of securities. Without limiting the generality of the foregoing provisions of this <U>Section 15.7</U>, if in connection
with any underwritten public offering of securities of the Company the managing underwriter of such offering requires that the
Company&rsquo;s directors and officers enter into a lock-up agreement containing provisions that are more restrictive than the
provisions set forth in the preceding sentence, then (a)&nbsp;each holder of shares of Stock acquired pursuant to the Plan (regardless
of whether such person has complied or complies with the provisions of clause (b)&nbsp;below) shall be bound by, and shall be deemed
to have agreed to, the same lock-up terms as those to which the Company&rsquo;s directors and officers are required to adhere;
and (b)&nbsp;at the request of the Company or such managing underwriter, each such person shall execute and deliver a lock-up agreement
in form and substance equivalent to that which is required to be executed by the Company&rsquo;s directors and officers.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Placement of Legends; Stop Orders; etc</U>. Each share of Stock to be issued pursuant to Awards granted under the Plan
may bear a reference to the investment representation made in accordance with <U>Section 15.6</U> in addition to any other applicable
restriction under the Plan, the terms of the Award and to the fact that no registration statement has been filed with the Securities
and Exchange Commission in respect to such shares of Stock. All shares of Stock or other securities delivered under the Plan shall
be subject to such stock transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations,
and other requirements of any stock exchange upon which the Stock is then listed, and any applicable federal or state securities
law, and the Committee may cause a legend or legends to be put on any certificates or recorded in connection with book-entry accounts
representing the shares to make appropriate reference to such restrictions.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Uncertificated Shares</U>. To the extent that the Plan provides for issuance of certificates to reflect the transfer
of Shares, the transfer of such Shares may be effected on a noncertificated basis, to the extent not prohibited by Applicable Law.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Rights in Stock</U>. A Participant shall not be deemed for any purpose to be a stockholder of the Company
with respect to any of the Shares of Stock subject to an Award, unless and until Shares shall have been issued therefor and delivered
to the Participant or his agent. Any Stock to be issued pursuant to Awards granted under the Plan shall be subject to all restrictions
upon the transfer thereof which may be now or hereafter imposed by the Certificate of Incorporation and the Bylaws of the Company.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employment Not Guaranteed</U>. Nothing in the Plan shall interfere with or limit in any way the right of the Company
(or any Affiliate) to terminate any Participant&rsquo;s Employment at any time, nor confer upon any Participant any right to continue
in the employ of the Company (or any Affiliate), subject to the terms of any separate employment or consulting agreement or provision
of law or corporate articles or by-laws to the contrary, at any time to terminate such employment or consulting agreement or to
increase or decrease, or otherwise adjust, the other terms and conditions of the recipient&rsquo;s employment or other association
with the Company and its Affiliates.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Compensation Arrangements</U>. Nothing contained in this Plan shall prevent the Board from adopting other or additional
compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may be either generally
applicable or applicable only in specific cases.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Gender and Number</U>. Except where otherwise indicated by the context, any masculine term used herein also shall include
the feminine; the plural shall include the singular and the singular shall include the plural.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.14<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Plan Headings</U>. The headings in the Plan are for purposes of convenience only and are not intended to define or limit
the construction of the provisions thereof.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.15<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In the event any provision of the Plan shall be held illegal or invalid for any reason, the illegality
or invalidity shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as if the illegal
or invalid provision had not been included.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.16<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Requirements of Law</U>. The granting of Awards and the issuance of Shares under the Plan shall be subject to Applicable
Law and to such approvals by any governmental agencies or national securities exchanges as may be required.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.17<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Errors</U>. At any time the Company may correct any error made under the Plan without prejudice to the Company. Such
corrections may include, among other things, changing or revoking an issuance of an Award.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.18<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Elections and Notices</U>. Notwithstanding anything to the contrary contained in this Plan, all elections and notices
of every kind shall be made on forms prepared by the Company or the general counsel, secretary or assistant secretary, or their
respective delegates or shall be made in such other manner as permitted or required by the Company or the general counsel, secretary
or assistant secretary, or their respective delegates, including but not limited to elections or notices through electronic means,
over the Internet or otherwise. An election shall be deemed made when received by the Company (or its designated agent, but only
in cases where the designated agent has been appointed for the purpose of receiving such election), which may waive any defects
in form. The Company may limit the time an election may be made in advance of any deadline.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Where any notice or filing required or permitted
to be given to the Company under the Plan, it shall be delivered to the principal office of the Company, directed to the attention
of the general counsel of the Company or his or her successor. Such notice shall be deemed given on the date of delivery.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notice to the Participant shall be deemed given
when mailed (or sent by telecopy) to the Participant&rsquo;s work or home address as shown on the records of the Company or, at
the option of the Company, to the Participant&rsquo;s e-mail address as shown on the records of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">It is the Participant&rsquo;s responsibility
to ensure that the Participant&rsquo;s addresses are kept up to date on the records of the Company. In the case of notices affecting
multiple Participants, the notices may be given by general distribution at the Participants&rsquo; work locations.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.19<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. To the extent not preempted by Federal law, the Plan, and all awards and agreements hereunder, and
any and all disputes in connection therewith, shall be governed by and construed in accordance with the substantive laws of the
State of Delaware, without regard to conflict or choice of law principles which might otherwise refer the construction, interpretation
or enforceability of this Plan to the substantive law of another jurisdiction.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.20<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Venue</U>. The Company and the Participant to whom an Award under this Plan is granted, for themselves and their successors
and assigns, irrevocably submit to the exclusive and sole jurisdiction and venue of the state or federal courts of Delaware with
respect to any and all disputes arising out of or relating to this Plan, the subject matter of this Plan or any awards under this
Plan, including but not limited to any disputes arising out of or relating to the interpretation and enforceability of any awards
or the terms and conditions of this Plan. To achieve certainty regarding the appropriate forum in which to prosecute and defend
actions arising out of or relating to this Plan, and to ensure consistency in application and interpretation of the Governing Law
to the Plan, the parties agree that (a) sole and exclusive appropriate venue for any such action shall be an appropriate federal
or state court in Delaware, and no other, (b) all claims with respect to any such action shall be heard and determined exclusively
in such Delaware court, and no other, (c) such Delaware court shall have sole and exclusive jurisdiction over the person of such
parties and over the subject matter of any dispute relating hereto and (d) that the parties waive any and all objections and defenses
to bringing any such action before such Delaware court, including but not limited to those relating to lack of personal jurisdiction,
improper venue or <I>forum non conveniens</I>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.21<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Obligation to Notify</U>. The Company shall have no duty or obligation to any holder of an Option to advise such holder
as to the time or manner of exercising such Option. Furthermore, the Company shall have no duty or obligation to warn or otherwise
advise such holder of a pending transaction or expiration of an Option or a possible period in which the Option may not be exercised.
The Company has no duty or obligation to minimize the tax consequences of an Option to the holder of such Option.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; font-weight: bold; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="proxy_01.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK  BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP  THIS  POR TION  FOR  YOUR  RECORDS DE T ACH AND RETURN THIS POR TION ON L Y THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. D44438 - P52334 Fo r W i t hh o l d F o r All   A ll Al l Except ! ! ! For Against Abstain ! ! ! ! ! ! ! ! ! To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below . 01) Alan Edrick 1. Election of Director Nominee: 2. Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending  December 31, 2021. 3. Adoption and approval of the Harvard Bioscience, Inc. 2021 Incentive Plan. 4. Approval, by a non - binding advisory vote, of the compensation of the Company's named executive  officers. NOTE: Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof. The Board of Directors recommends you vote FOR proposals 2, 3 and 4: HARVARD BIOSCIENCE, INC. The Board of Directors recommends you vote FOR  the following: Please sign exactly as your name(s) appear(s) hereon. When signing as attorney,  executor, administrator,  or other fiduciary,  please give full title as such. Joint  owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. VOTE BY INTERNET Before The Meeting - Go to  www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11 : 59 p . m . Eastern Time the day before the cut - off date or meeting date . Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form . During The Meeting - Go to www.virtualshareholdermeeting.com/HBIO2021 You may attend the meeting via the Internet and vote during the meeting . Have the information that is printed in the box marked by the arrow available and follow the instructions . VOTE BY PHONE - 1 - 800 - 690 - 6903 Use any touch - tone telephone to transmit your voting instructions up until 11 : 59 p . m . Eastern Time the day before the cut - off date or meeting date . Have your proxy card in hand when you call and then follow the instructions . VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage - paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 . SCAN TO VIE W M A TERIAL S &amp; VO TE HARVARD  BIOSCIENCE, INC.  84 OCTOBER  HILL  ROAD  HOLLISTON, MA 01746 - 1371</P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="proxy_02.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">D44439 - P52334 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice &amp; Proxy Statement and Annual Report are available at www.proxyvote.com. HARVARD BIOSCIENCE, INC. Annual Meeting of Stockholders  May 18, 2021 at 11:00 AM, EDT This proxy is solicited by the Board of Directors The stockholder(s) hereby appoint(s) James Green and Michael A . Rossi, or any of them, as proxies, each with the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of Harvard Bioscience, Inc . that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 11 : 00 AM, EDT on May 18 , 2021 . Due to the public health impact of the coronavirus outbreak (COVID - 19 ) and to support the health and well - being of our partners and stockholders, the Annual Meeting will be held by virtual meeting only . You will not be able to attend the Annual Meeting in person . To be admitted to the Annual Meeting at www . virtualshareholdermeeting . com/HBIO 2021 , you must enter the control number found on your proxy card, voting instruction form or notice you previously received . You may vote during the Annual Meeting by following the instructions available on the meeting website during the meeting . This proxy, when properly executed, will be voted in the manner directed herein . If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations . Continued and to be signed on reverse side</P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ballot_01.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Your Vote Counts! HARVARD BIOSCIENCE, INC.  84 OCTOBER HILL ROAD   HOLLISTON, MA 01746 - 1371 HARVARD BIOSCIENCE, INC. 2021 Annual Meeting Vote by May 17, 2021 11:59 PM ET You invested in HARVARD BIOSCIENCE, INC. and it&#8217;s time to vote! You have the right to vote  on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 18, 2021. Get informed before you vote View the Notice &amp; Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s)  by requesting prior to May 4, 2021. If you would like to request a copy of  the material(s) for this and/or future stockholder meetings,  you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send  an email  to sendmaterial@proxyvote.com. If sending  an email,  please  include your control number (indicated below) in the subject line. Unless requested, you will not otherwise  receive a paper  or email copy. Vote Virtually at the Meeting* May 18, 2021 11:00 AM EDT Virtually  at:  www.virtualshareholdermeeting.com/HBIO2021 *Please check the meeting materials for any special requirements  for meeting attendance. Smartphone users Point your camera here and  vote  without entering  a  control  number V1 For complete information and to  vote, visit www.ProxyVote.com Control # D44458 - P52334</P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ballot_02.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This  is  an  overview  of  the  proposals  being  presented  at  the  upcoming stockholder  meeting. Please follow the instructions on  the reverse side to  vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click  &#8220;Sign up for E - delivery&#8221;. V oting Items Board  Recommends D44459 - P52334 1. Election of Director Nominee: 1) Alan Edrick For 2. Ratification of the appointment of Grant Thornton LLP as the Company&#8217;s independent registered public accounting  firm for the fiscal year ending December 31, 2021. For 3. Adoption and approval of the Harvard Bioscience, Inc. 2021 Incentive Plan. For 4. Approval, by a non - binding advisory  vote, of the compensation of the Company&#8217;s named executive  officers. For NOTE: Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.</P>



<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ballot_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ballot_01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" ./ L # 2(  A$! Q$!_\0
M'0 !  (" P$!              4&! @" P<!"?_$ &,0  $# P("! 8," L%
M! @$!P$  @,$!1$2(08Q$R)!40<456%QT146%Q@R5H&1DI.4T@@C-D)R=*&R
M)#,U-U)35&*QL\%S=8+AXS2$HL,E)F-D@\+P\3A#1+0G186&E:3$_\0 &P$!
M  ,! 0$!              $" P0%!@?_Q  W$0 " 0(#! <'! ,! 0$
M 0(#$1(A4003%#$505)QD:'P!2(R,V&QT4*!P>$T4_$6(W+_V@ , P$  A$#
M$0 _ -J41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M.&2R-K]6!W EY)QSV[E(<#<+WFU\7WR\WR:">:YP0E[H2=+9&EV6-!WTM;I
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MKN_)]C[ _P 9][^R"(B\H]P(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B+'N-
M=36ZCEJZZ>.GIHAJDED=I:T=Y*#D9"+%=<*1M=!1NJ(A53L,L41=UGM&,D#N
M&1\ZX4UVH*JXU5!35D$M;2Z>GA8\%\>1D:AV94V9%T9J*"@XNX?GK)*2&\T#
MZJ,N#H1.W7EN=0QG)Q@Y64;]:Q;8+AX_3^)5#FMBGUC1(7'#0#VDG9,+740I
MQ?62:+"@NU!/=*BVPUD#Z^G:'RT[7@OC!P02.8YCYUA4G%5AK+B:"EO%!+6A
M[F= V=NO4.8 SDD8.4PO08EJ32*%I>*[!55QHJ>\V^2L#S'T J&Z]0." W.2
M1CL6;=[M06>D\:NE7#24^H,Z29X:W4>0R4PN]K#$K7N9J*)IN([-504T]-<Z
M.:&IF\7A?'*'!\F"= Q^=@';FNFKXML%)<C05-WHHJP.##$Z4 M<>33W$]@.
MY3"]!CCJ3B*(KN)+/0W**WU=PIXJV4M#82[K=8X;D=F3L,KA=N*;):*H4USN
M=+3U!;KZ)[^L&_TB.8'G.R86^H8XKK)I%"U?%5BHX72U5VHX8FSNIBY\H $K
M?A,_2':%V0\1V>>:BAAN5(^6M:7TS!(,S-&<EH[<8/S)A>@QQU)9%&27ZU14
MM94RW"E93T<AAJ)'2 -B>,$M<>P[C;SA8)XTX<%(*I]YHF4YDZ(/?)I&O&<;
M]N-_0BBWR0<XKFRPHL>WUM-<:2.JH9XYZ:099)&<M</,5AU_$%IMYK/';A30
M>)M8^HZ20#H@\X87=V3R2SY$XE:Y*(L$76A=/2P-JX3-5QF6!@>,RL !+F]X
MW&_G6)1<462NN?L?1W.EGK,N;T<;]76:,EN1MD '(YI9C$M291$4$A$1 $1$
M 0HA1@TYXB_*"Y_K4O[Y4>I#B+\H+G^M2_OE1Z^WA\*/S:K\;[PB(K&9=_ O
M_./:O1-_E/6SX6L'@7_G'M7HF_RGK9\+YOVO\]=WY/L?8'^,^]_9!$1>4>X$
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5.\,$;Y?!IQ!'$QSWNIB UHR3N.Q7
M%%:+PM,K..*+CJ>4UPKK%QU:+C=JZ:XP4]HJY"13M9H Z,Z1I&Y.-LJN\*TU
M[X<O/#_$EUMO1>R\\L=QF9+K+O&#KCU,QE@80T')/R+WC [DP.X+55LK6,7L
M^=[^LOP>"V>AKHJJPU-R#I;*.)*K\0V#2^&5SY!'(7\RPNY\ARYKMME+44/$
ML/#-9#.++PW6U-XZ0L):Z$-#X&M/:0Z1^W]U>ZX'<F!W!2Z[?40MFMUG@=AB
MOEFN=FXRN%L,3;E6R.KI6RZG&"ITAC7,QD"/2P\^]<[/0U\-78JJX!TME;Q-
M5'H&P:9(92]_12%_,LU<^0Y<U[S@=P3 [D>T7ZB%LUNOUE^#P29T-=P%=[!!
M05-7?YKO4NI&1P/S \U!+93)C# !DYRKUX8&RMX9M#A*Z-\5UHWOG:S7T8#\
ME^.T#FO0<#N15=7-.W+,NJ'NM7YJQX5:HIWU]ME$<]3%)Q8V<7!T#H?&FFG?
MEVC #0WX.0,'&>]=PJJ&@X"XIX<NE'-)Q#4U-6!3]"YSZN21Y,4K-NL-V;]F
ME>WX'<$P.X*77OU%5L]N3/'+E)5\*WRDJ[7<FU5\J8J*FN-H? 9#4Z0&=(QX
MW;@$G/P>_?92W#]RH>'>*N+1Q'FEK*RM$\%3+&[3/3]&T,8QV,'20X:>>_)>
MFX'<$P.X*KJW5FBRHM.Z9X)4-FI:N"=T\M UG%]PD-3T.OHVECL.TD;@\OE4
MQQ7:)^)N*K');ZU\]9!:)JBCN'1]&WQADK"TD 8&<$$=Q*]CP.Y,#N5M^[W2
M*K9\FFS7ZT355PM!O-SM52VB9Q8ZMKZ3HG/,;>@8-9:!ES6/WY=F>Q6SPA7F
MBN=7PM66FY!D--<G"6LBBZ40GH7\P1@\\?*O5<#N"8'<CK)N]B50:5KD!:;_
M $+Y;=;O9 UM=54[IXWB$MZ1C2 YYP,-W.-\>9>9^$BDEGK?""T022,EI[2T
M ,)#\3[@=^W->R"CIA7>.^+Q>-]'T73Z!KT9SIU<\9WQRRN_ [E6%10=TO5[
MEITG.-F_5K'A;;;>+?QM3\-PLF+*"VW!MLJSG!BE8WHFEW])CFEOH 5O\'_$
M=BM?!MMH9 ZAK*&D_A-&Z!XE8^-F9'%F,G)#CGM]*]%P.Y?-([@IG5QJS1$*
M.!W3.%+.RIIXIXLF.1H>TD$'!&1L>2[$18FX1$0!$1 $*(48-.>(OR@N?ZU+
M^^5'J0XB_*"Y_K4O[Y4>OMX?"C\VJ_&^\(B*QF7?P+_SCVKT3?Y3UL^%K!X%
M_P"<>U>B;_*>MGPOF_:_SUW?D^Q]@?XS[W]D$1%Y1[@1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M. -BX[[D*1=80[A:NLW3D-JHYXS+IW;TI<2<9[-?[%VT-_I*Z>*&G$CI)'.
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M+4F5I93F8,:88XRUS&D$@]$TY&,''9E9_!U'44-ACBK=0J'S3SN#L:ATDSY
M#C;.'#.-LJ:11B;5BR@D[H(B*I<(B( B(@"(B (40HP:<\1?E!<_UJ7]\J/4
MAQ%^4%S_ %J7]\J/7V\/A1^;5?C?>$1%8S+OX%_YQ[5Z)O\ *>MGPM8/ O\
MSCVKT3?Y3UL^%\W[7^>N[\GV/L#_ !GWO[((B+RCW B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( OCFAP(< 0=B"OJ("'AX?I:>W4M)3R3Q>+/,D4P<
M#(''.2200<AQ&X/[ N,G#=&Z+HP^=C#&(W .!U%KB]KR2"=0<2[/:2<Y4TBF
M[*X41TEHBEM3J&:69['$.,@+6/)#@X?!  W Y!1\_#HDK:%[GF5D-3XW-+*_
M\9(\,TM&  W&S3V? &QYC.OTU53PTTE))&QOC,,<NIFHN8Z1K2!OL>MSW_U7
MQ\]6SB&* R1FEDII)&QAN'!S71C)=G^^=L?.I39#2Y6.VZ6JGN0/3EX/0OA#
MF.P6AQ:<CN<"QI![,+$=PW18AZ$S0&$-:PQN'5:&:,#(/YNV>?<0NB6KK8KO
MFK=504AT,CT"-T)>1\%QQK^$< [#EWKAPU=:FIK'4U89GS&G9/()*<Q")Y)#
MF-R!D9&W,\]SLF=LB+Q;S1D6:QMM]UJ*O#0TP14T30\N.E@^$=@ X]4''8QN
M_8)4TK#6BJWZ41F(;[8)!_T5/J+O=W15IH9I'/$[H6F:#3'&[QIL3&M.!J!:
M79W.".Q25/?9*Z\VME&<4<C,SAS>MJ=&Y[6^8M#=Q_>"EIO,A2CR)2EMOB<5
M#!23O9!3N)D#NLZ;(/PCWEQU$]I7&6T!]X]D6U=2R30(^C&@LT@Y(&6DC)YX
M(S@=P6&RHFJKY<*7QVNAZ)XCC;% #&!T3'9+RPC5EQV)[MEE<-FHDMXFJJN6
MI>]SA^,:P:<.(VTM'=VJ'=9EE9Y'1+PW324\L(J:MC'1]%'I>/Q,9<"6-VY'
M2 <YV&.2S66UOB,=+--+,R-[)&N<&-(T.#FC#6@8RT=BST479.%!$106"(B
M(B( B(@"(B (40HP:<\1?E!<_P!:E_?*CU(<1?E!<_UJ7]\J/7V\/A1^;5?C
M?>$1%8S+OX%_YQ[5Z)O\IZV?"U@\"_\ ./:O1-_E/6SX7S?M?YZ[OR?8^P/\
M9][^R"(B\H]P(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M$10-TL!) SGF<G_%=B)<601$0D(B( B(@"(B (B( B(@"%$*,&G/$7Y07/\
M6I?WRH]2'$7Y07/]:E_?*CU]O#X4?FU7XWWA$16,R[^!?^<>U>B;_*>MGPM8
M/ O_ #CVKT3?Y3UL^%\W[7^>N[\GV/L#_&?>_L@B(O*/<"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( JK4<33Q3R1BGC(8XMSD]A5J7F];_VR?_:._P 4!-^VF?\ L\?S
ME>?^%#PE\9<+4_LC9;/;+A:FC\=K$AEA_O'#@"WS@;=O>I]?"T.:0X @[$%
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M(!<3W>=8WN(7?RI0?,_U+WQ%WKVGM"5D_)'E/V-LC=W'S9X'[B%W\J4'S/\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M&WGRKBWP:V=P::R6KJ' ;@O#&_,!_JK74UELL5#&RHJ*:BIHVAK&O>&  <@
MNNTWNW7F-S[;5QSAO,-V(^0[KLA1IQR?,\Z>TU9YK)$!2\!\/4DHD%")G-^"
M)GE[1\AV^=3[@ ,#D%ER+&>MHQ4>2.><Y3SD[F+(%CR!93PL=ZL5,21O-8SP
MLQXYK&>$!BO"Z7!9+PNAZ R+'_*]-^E_HKVJ+9!_Z7IOTO\ 17I $*(4!H5Q
M5^5%X_7)OWRHM2G%7Y47C]<F_?*BU]/'X4?*3^)A$16*GHGX/W\[%F_1G_R7
MK<5:=?@_?SL6;]&?_)>MQ5XOM'YJ[CW/9ORGW_@(B+@/1"(B (B( B(@"(B
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M5W'N>S?E/O\ P$1%P'HA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M(N ]$(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@!Y*'D_C'^DJ84-(?QC_ -(H#XB(@"!$
M0'"HJ(J6%TU1(V.)HR7.. %0N(^+YJMKZ>TN=!#R,W)[O1W#]OH49>[R^ON$
MK:Z-SV12.:V,.PUF#CEW^==E%66=@!FMA>.W\85K&-LS-R*RVAC/6?N2<DD[
ME<FV^,G() 5P==+ T9%C?C_;+I?>+!C^0Y,#NJ"K7*E:\2:T;:<^=?&0$D_
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M]SV;\I]_X"(BX#T0B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M8LWZ,_\ DO6XJ\7VC\U=Q[GLWY3[_P !$1<!Z(1$0!$1 $1$ 1$0!$1 $1$
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MEWOSK9?Q!+%-+2BB=4OZ)F2P-< 7$YY 'ES/8"N$?"<-/T<5)52P4;)X*CH
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M%%##%)/(RH%,&RNCF,?5FZ,.<X-WYX:XC.,@$C(79PY8(+'$8X>B<-+8VN;
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MRQ3QW21[J7QVJGCI<-TXD=(T;C?&EY..8)] !*-@W.^1GR<4T<437S054;I
MQT#'QAKI@YS6 MR<#K/:#J((R,XRLR:\105%+%4P3PBH+6->_3@/(V8<'.>S
M(!&>U89X=<X!TU<ZHD9 ::,SPL<T1DM+@YH U%VAN3YA@#?.%!P7303TKQ63
M/,$D,@=(QKGDQ-#0W5C(:<9TCM)(YX3W2;S,GA3B W6BM[)8WOJWT<$]1(T
M,:Z1FH#!.=]^0(\Z^,XA,%]NE+5QRFFIYH8VRM9U(^D:W&HYWRX]@.!SP-UV
M6[AIE'):#XRYS+9"V&+\6T.<!'H(<[F6G8Z>\ ]@7VIX;%1<*V=]9,(*N2&2
M6G#6Z3T>, '&1G2,^;N3W;D>_9:G&LXFIA3S&%TL1;DQROAU-D#9&L>6C(S@
MN WQG.1D+NIN):*:4M>R>&/I9H&S2LTL>^(N#P#G.VAQSC! 6%'P=1Q0U,,+
MF,CE)+2VG8'L!>'XU@9(V &>SGE93^&Z=]-!#*]\D4554U180.OT_2ZFGS#I
MC\P1X L9D6N_07"M-*R"IADZ!M2TS,TAT;B0"-_-R.".T!=%/Q/1S22-Z*I8
MQLTT#9'QX:^2(NUM;OO\!Q!Y'!WSLL/ANV5\-YEK*YU0(FTD=+"R?H]> YQ)
M.@D=V^=SG88WZ[1PW.Z.7V1J) UM;6U$,.&D,Z624!V1N>I(2 >1<<]@"T0G
M-F=%Q31O@AF,%6R.2)L[BZ/'1Q..&O?OL#@[<Q@D@ %=L7$5-+2FHC@J',,Q
MIX<-!,SP2"&C.V"TYU8P!D[+%DX3I734<Q,;WP4\=*XRT[)-;&$EOPAU3N[E
M_2Y<L<*KA*GJYJBHJIP^:22.4?B&: YFL EI!#G%KRTD[X QC *>Z/?.Z7BR
MACZ0]%5.9# :F=[8]H6!SVNU;\VF-P(&3MME?8N)/X9<X)Z&H9XK5-I(BTM>
M:ASHV/& #ML_.^  ,DC<#X_A>G?15].)>C;64'B+NBB:QK1F0ES6C8',IV\R
M7#A:&MFJGRS9;-4,JPU\37ADK8VQYPX$$%C<8([200<8>X/?,6_\6Q06.OGM
MK)Y*F"F=*3T61"[+F@/&?Z3' XSC!)P-U8KC5FBIQ*()9M\%L>G(\_6(&/E4
M!6<(1ST51305CJ1E53BGG%/"QK7@%QR&XPWX;LXY@]^ZE+[9H[LZE<^0L-.Y
MS@"QKVG(P3I<,9 Y'L\XR$>'J)6/.YT6F_BYWB6EIZ:1U(*."LBJ]3=,C92_
M&V<CX'=W\MLQ=7Q35,N0@;;YV,BN@H78TO,P-.9!I /5.2WGL!N2-\2MDL#+
M1)3.@J'N;%004+FN:.NV'5H=YCUW9^3EC?X; PW<UOC+])K!6]%I'\8(#"=^
M[3@^D)>*;(M.R/C^**!L+9 VH<T-D?-B/^(;&\L>7^AP(VR3@D9 )67?:U]%
M0:Z5K'54KVPP-=R+W' ) W('PCCL!43)P=2.G$Q<Q\FN8OZ:G9*'-DF=*1AP
MV(+W $=^X.V):Y6>GN512/K1TL5-J<V(_!UD8#O2 7#_ (BH>&^1*QM.Y@4O
M$C)**UN=2SOJZQC_ ,1$ 2Q[-I&DD@#2<C?N7P<6V]Y#HF5#X.AAG?.(\,C9
M*2&DY.>PY !([5V4'#=-0W)M32R/9$Q\LC( .JPR-8'8]):7>EQ6/#PG!!;)
MZ,5,I9+2PTI<0,@1ZL'TG4I]TCWR0COE+(VF+1)_"*J:C8-/_P"9%TFKY/Q+
M\?(L*;B#I;A04L#'0S.K&PU$4H:7!CHI7 ]4D;EG?G8KA4<*LG<QOC]3'2LG
MGJ61, !:^9LC7D.QGG*XCN/?MCC;^$8**OBJQ4;QR12!C(FQMZC)& 8 [1(2
M?..[9/='OG?67J>FXPI[:Z./Q&6G:XR;ZFRN<_3G?&G$9'I(6+1<4NDNMRAF
MAU0,?%'1MB:3),XF0.SDXYQ.(.PTC)4C=[#'<IJJ;QB2&6:G9"Q[ "8G,>7L
MD;GM#B#OMLL&JX.H9>CP_ B9 V%KXVR-9T37M&0X$'+9' _LP=U*PV#4[Y&8
M>): ]'H$[FEK72.$>! '/+!KSRZS7 \\8). ,J.CXLZU1+5TTU)#3.JM32&R
M&1L(R2"';'S$;YYKO/"=%XY3U ;3"1D;(G@TD9:X-<7#2,=4Y<[EW]^"/E7P
ME'4FK:ZLE$4XJ &A@RPS-P\Y[>\(L!#QF6WB6EZ['P5,=2.BT4[F /D$A<&$
M#.-]#N9&-)SC"S;-<XKM2R30QRQ]',^![)6Z7![#@CY^U1=WL>JI?<(.GDJV
ML@9$V(,RPQ.DPX:B <B5P()&W+==G"EMK;?2.\=J'F26>>:1C@TDE[\M)(&
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MV4L3GU0 D>-1( &W/F0,C*^T7$5UL7$W$$K64U102\04]'*'E_2#I8V-RS?
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MNS10QQ16RD9'' ^F8T1 !L3]W,']T]H7!_"]D?5TE4ZV4OC%(UC87A@!8&?
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M7AD62S0P3VJXQU[K;'4#&!TFIC7G )S)G)VYJUP\14;YQ#,V:FEPYQ;.S3I
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M&,C=1&4DDK$RC!MMLC;';KO<N,G<17J@;;&041HJ:E,S99':GASWO+>J/@@
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M+#0X!Y.<C!P78&#V'.W3Q'<ZRTW:ROJI8)991/&'LC='#'GHP'29<[8'._G
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M>%\\L+9&F6, O8#NT'.,^G!50EX5K:FT4]MFFIXXZ2ADHX9F:BZ74P,#GC;
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MC6M#0&^;9';J)CBOF92(BJ7"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MW,E3(6- ?H!+C(.;AA1?A+M?&7!MNH[I3<<W6YVFK>&1SQULK2"07-VUD$$
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MZG(^.XH?#.R^,<&VB.848:-VBD Z/EW8ZV.]2UPXSX?LG'O"$=EE\:X;LC'
MO##N^4NUO (R2,M/I"JYU;]^?]?8LH4;<^67]_<HUX\'W$=HIFSUE'$8NE;
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M?*=W'SE51=]",E#WWFSSZ\HN?N+)'L=+_P#ADK/]YC]YJ\<7L=+_ /ADK/\
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MW>^>6;;]&3U)[W>^>6;;]&3U+8KAZY2W6U0U53;ZJW3NV?35+</81^PCN/\
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M5#"VAK*%U133[ASI6.Z[#OC9IU*N^#[@:JL5UHIKE;K>'T,#HF5L-?42OE)
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M>LED3&EY;G8DO>&[[ ,=S7?:[U<#>8[95OAE?%4S4\DK&:>D#8F2L<!G8XD
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MN,-#=ACELNQ0W<LHVS"(B@L$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1% <;<66S@ZRNN5X?((M0CCCB;J?(\[Z6C(&<
MG<@;*4G)V1$I**N^1/HO*['X=.$+@0VKEK+<\[?PB'+<^EA=^W"] LW$-HO;
M-=HN5)6 #)Z"5KR/2 <CY5>=*</B5BD*T)_"[DHB919F@6)[&T>:L^*P'QP8
MJ,L'X[JZ>MW[;;]BRT0AJY%T=@M='!40TU# R.H;HF&G/2-P1I.>8P3MRW*X
M3<-VB=D#9J&%X@;HC+ADAN<Z<\R,]AV4NOC]FG"F[(PK0Z:NF@K*26EJHHYJ
M>1I8^-[0YKFD8((/,+@*&D-13S^+P]-3L='%)H&J-KL9#3V Z1\P5#CJ6'A&
M:["XU(NTC VM<*EY-+F1HGQ'G2WHQJQU=M/G.>-YD;0R5=+8+I5]#)1MDF<*
MITQ@>9F-C<USB2"YIDVS@Z.2NH=5S-U%SL7>HMMM;%#+-!!''2/,T;]FB(DY
M)SV9.Y7>RAI(XZ5C*>)K*4 0-#0!%U2WJ]W5)&W8J'Q/;XX:+BBWMJ*XT<=M
MAJVM=62DM>73AQU%V<$,;D9QMR79=&2027ZHI*ZN+:"CA\6Q4R2"(.:_7)@D
MZW:=^MGX(3#?K]>F,=GR]>D68VVR6"*IN<='!3B*-Q?)''NUG,@ <@< X'/
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MK9KP:^%JS\7QQ4E46V^\$!IIY'=64_\ LW=OHY^GFK/QEP99>+Z$T]ZI1(X
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M!')YRX?*1D]ZEM:!1EJ5ZHXBK*8QP3T\?C4QC<PQ-DD:UKVO=@AH+B1T9&<
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"X5$39H)(GYTO:6G'<1A<T0&!16\P2PRR2!\S8WMD<&XU.<X.)'
)<-CLL]$0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ballot_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ballot_02.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" ./ L # 2(  A$! Q$!_\0
M'  !  (# 0$!              0% P8' 0((_\0 5!   0,# @($"0D& P8"
M"@(# 0 " P0%$1(A!C$3%$%1(E1587&3E-'2!Q46&#-2@9'3%R,R5I*C0F*A
M)#1R=+&S@O F-3=D<X2BP>'Q1&,E4[+_Q  : 0$! 0$! 0$
M 0(#! 4&_\0 ,!$!  $# @8! P0" P$! 0    $"$5$#$A,4(3%!4F&!D;$$
M(G'PH=$RP>$S0J+_V@ , P$  A$#$0 _ /U0B(HHB+S*#U$3* B(@(B("(B
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MSNOLUS,;KC7]+-.\'+>F<=0.?,0W\E01<!<0?12226:!W$XN+*UDI?D'0T,
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M*KH^%N+*?A&7@^&GH'T#W.:VY.F_AB+]1!CQG5N?,ND:>CN\6Z>?'F?Y^/\
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M;1P/Y6?[)-\*?MHX'\K/]DF^%.#J>LG&T_:/O#I*+FW[:.!_*S_9)OA3]M'
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M[.GP2=S_ $K,:4S3N:G5B*MCK"+0OD6OMQXCX#I[C>*CK%6^61ADTANP=@;
M +4[?>[_ 'KC+BF@?QG%9:6W5(B@8^G@=J:=7(NP=L>?FG"F\Q?LG&BU,Q'=
MVE%'M[)(Z"G9/4=:E;&T/GTAO2'&[L#89Y[+\_2\:\4?-G$=T'%E/!);;C)3
M06Z6GB)G:#L =G$[_P"BE&E-=[+J:L4=X?HE%S_C+C"HLGR7-O<T9I;I/31A
MD+AO'/(WE@_=.3@_=43Y(^);Q<77BR\5RA]]M\P+R&M;JC< 6D!H _\ V$X5
M6V:CBT[HI=+1<\^3/B"YWKB+C&GN-5TT%ON#H*9NAK=#,N&,@;\ASRO+1Q!<
MZCY8;]8YJDNME-11S10Z6C2XZ,G.,]IYE)TYB9C!&I$Q$YZ.B(N8\9<07RX\
M=4?"/"U4RAEZOUNMK2P2.CCSC2UIVSR_,*&Z[\0\%\9V:VWFZNO%DN[S!%--
M&UDT$NV 2T $$D?_ (QO8TIF._5)U8B>W3M=UI%Q?BJ?C.S<8<-V9G&$DC+Q
M)*WI#;X1T(;@C QOS76+#2UM%:XH+G<77*K:7:ZET38B_))'@MV&!@?@I5I[
M8B;]VJ:]TS%IZ?Q_M8(B+FV(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/E_P#"?0N9?(9;
MZRV\/7F.XTD]+))=9I&-FC+"YI:S#@#S&Q73B,KS2.Y:BJU,TY9FF]458<=^
M2[@JAJCQ1-Q+P_#+.^Z3.@?6T@),9W!:7#EG/):?]';R/D'K;:VT5XKC=>D;
M3"G=K+,CP@W&<>=?I(-PO.C&<X!*ZQ^HF]_X_P .4_IZ9BW\_P"7+_E2?8:T
M?-M^X?NE?+T DIJBEI7.\,Y&AKV[@Y R#MN%=?(]076V_)];J6^B1E6QKL1R
M?Q1LU'2T_ACT<NQ;L(P.P+Z QR6)U+T[72-/]^]RSA>BK:+Y4^.KC-050I)H
MH##)T1TS:6#(83LX[8V6INM])=OE X?N/!EAN=JK65(DN4DM,Z")D?\ B:0=
MM1&1X/\ JN_:!W! P 8P%J-:TWMXLQ.C$Q:_F_\ F[5?E6I:BN^3N^TU'!+/
M42TY:R*)I<YQR-@!S7*^-.$;RW@#AZZV6CG-S9:([;74C8B9)(GQ@8+>>6N_
M\[+OY&1@KS0/,IIZLT1:%KT8KO,N%BR7JSV[Y/\ B6BME343VFEZM6T38R)@
MQPP2&GM&7;<^7X3N,JJN^4FIM%EL]JN$-M95,J:VLJZ=T+6!G^!NH;G!/+S?
MAV8, &$:P-.0%KC=;VZIP>FV_27-?E5MU;6\3\!24=)45$=-<A).^*,N$;<L
MW<1R&QYKI,SM,;CW+W2.X;<EZ1D87*:KQ$8=(IM,SEQ6Q<+W[BCC._\ %#JR
MML$CI#24K9:-KG/@  SID&P.!R',E6/R/6ZZ<+7V_P##==!4R6^.7K%)6.@+
M8WYQJ (& >6V>PKJX8!R 'H7N@972=:9B8MT8IT8IF)B>K0?EJX=DO\ P14]
M2CDDN-&]M53",$N+F\P -\D$_CA4GR36.ON5'Q1>>):2>DN-ZD=$Z.5A8YD0
M;@  [XW/Y!=9+<\]T#<!2-68HV+.E$U[W&^ K[<. ["[AR_62YRS4<D@I):2
ME=+'4M<XN&' ;')//S*^^1^RW*D;?[Y?*8TE=>JLU'5B?"BC&=(/G\(_Z?AT
M4QM/,+T- 2K5O$].Z4Z6V8Z]NSC/!8NW#E@X^JQ:JXUDERGEHXNKO+IB[9A:
M,9+<D'([,JMMGR4WF3Y.9*:2]3POKH^N3V]])&<SX! +SX0.0 N[F,$Y(&R^
M@T8P5KCS>\)P*;1$OSUQ#%>KUP!P6+E8+G/4V^O8VMINJ/<]\3!C46XW#F_A
MG*V'@6W5?TYNMPL]CK+#PV^A,3J6HB,73S]CQ'_AVVV[O.NQZ!W!>&,'L2=>
M\6LD:%IB;N+_ ".7JKX:X4HK)<^&^(VU/6'9D%O=T;0]VQ+CC ':JRAH*2AX
MYXOJ.(^#;G=H*JL#J25EK-0T-&K403WY'+N7?- 0,&,8&$XW69MW(T?VQ3?L
MCVN1DMLI9(H9*>-T37-BD9H=&,;-+>PCEA?F^.S21V_BNEJ>#+K5WNKN$S[?
M6-HW-$0)\%PEVP <NQR/XK]-#DOC0,8  "SIZNR[6II17:[A]]X=XDXHN'"7
M#MPZU%';J055;<>AUL,X;AK07>"]PVSWY*DS</<0<)_*=9[VZIK;Y%<&FDKI
MF48:8V>#I+A&,8!P<_Y5VAK0#GM*.:'<UKCSVMT3@1>]^O\ IQ7@ZYUG"G%/
M&3ZWAWB">.ON3Y8)*6A=(QS=3M\[=X7K*^LM'RN7F^RV"^U%!6T,,<;J:A=(
M0[2PD'L!&"#OS7:= QC 33V*<:+S-NYPIB(B_:;_ )_VX[<Y;C;N/+?QS0V>
MY2VVLHS1UE-T!ZS!AVSC'SQX+>7=YU[<37?*%QUP]+16VMIK':)>MR557"Z'
MI7@C#6-< 3@M'YGN&>P:!G. O6MP<[)Q?-NJ\+Q?IW<U^4*VUM5\IG -534E
M1-34TLYGE9&7-BR&XU$;#..U=,"\+0>80# 7.JJ\1&&XIM,SG_5GJ(BRT(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B(,<LK(@#(]K >UQPOF*JAE>6,EC<\#46AV3CO_P!"
MJ7C^"*?@R^&6-CRRAG<TN&=)Z-VX6N<0/FM=SO5;;)13.I+,R<,9&W2]S73$
M Y'+;L_-;IHW0S-=I=!#@<X(..::AJ#21DC.%SV.\UM-6/FDJ<4@N,D+X8!&
MV0DO:&G!'A-W.<8=Z>RVXKJ:V.]4T=!414\AHI9 ^0-&XFA& X@XR"X<B,D$
M@X5X<WLF^+7;<BUF.^QNX3I[BZ:IC$FF/6\,UZB[3N<:.?;_  XWY+7*"^7>
MOJV0-N4D<<4=<XO:R)QDZ-\09DZ<;"0\L94C3F5FN(=)1:I->*Q]CLE2'] *
MTQ=8J T8A#HR[.#MN[2WS:E5_/MV$_0-JF.;5R.IJ28M:"XMD&9 ,8)T.<<<
MOW1.,%(TYDWPW]>.(:,GDN;5_$-]=1U%1!4,IW,GDBDB<8RZ)HDTM+6XR3C&
M<[$.SW*QO-QN5/5U-L%5TCBSK39'L9J$+6.UC&,'PVM!..4GF5X<IOAO#2'#
M(.0O5SBU7:]5T#8:6H92S-Z*-K7B,-+'1-)>&XR3ESB,;>#CO66/B.YU+&31
MU!8RNZ.CA:V,$13 MZ5[<C<C5+D';]SZ4X4D:D.A+&Z>-LK8G2,$K@2&YW('
MF6N7NY5,-S9 ZKZA2]6?*)RUIUO!'@^$#C WQS.?,5!X8?557%%565IDBJ);
M71O? [&(G.,V6\L[$%2*.EUW=;-O=41L<T22,:7.TM!.,G&<>G 68;KFE4R9
MW$D\)KIA*;[&6:@TEK.I Y:,<MR.[;ORLS>(+O(QE.*@1O'6VLJ'=&T2/BG=
M&T'4,;!H) P3G;&%>%/A.)#HJ+4KW<ZRGJK#%-7"B%27BH<P-()$9. 7 XW[
M524_$%YF:^1U2\-CI8)#B)@;I?/(QTQR,X$;0_'+9(TYF+K-<1-G2$6@5]]K
MH;A34S+D11NKV0&LTQDN:8)'%G+&SFMWQVX["L</$5SEBKC-6="RGBD?2RZ&
MXK"V61H&,;[-9_#C.O;L3A2F^'0UC,S.E$6MO2$%P;G<@8R<?B/S6C5'$570
MW.2*YU,K.L,!A9!T3FPG+ 6ORW+2"XC43I._+8*MH[E<*VXQRLK&-JHJ:X0Q
MU$FC&&ST^"2!IY;9QCD<'D4:4DZD0Z7+-'"S5*]K&Y RXX&2<!?><\EH-YN)
MK^ WU+I9FN951-=),&N+7-J&@GP1I<-MB.86-]_N3;P^@AJB^C#W!E;^[:7.
M$<;A'DC3S>XYQGP<=Z1IS)-<0Z$'!Q."#CFO5SBFN5W?6PT\E9'3U$]?##.^
MFC8X$&CZ1V"6G.7#8G_ILO#Q!<WT=R=4W0T;:6GGZ&81QYFD9/-'D@C<@1Q[
M#&2Y.%)Q(=(1:?=+M5Q4/"KC7FEZ]*UE1+I:=0-/(_&XP,N:-\*F=Q%>C#+,
MR=[Q#2S2,#8V_O0VH,;9#MRT .P, I&G,DUQ#I*+GU;>KK2025DM>U]!"_66
MQ20NG>W2W./!TG!WTC!.H;[8."X\0WLVN[5=-.RGDIV5FJ)^@F(1M?T;FMQJ
M)R&'?8AQ\R1I3).I$.C/=I[E]=BYU>:JN%=U2IN4SH::KHI#+I8TX>YP(.&X
MQEHQZ4J^(;X8J^HHWL#X):EAIWZ#AC \1N:T#62<,=N<$./F3AR37'9T$2LZ
M;HM;>D#=1;G?'?C\U]N(;SV6DV*?7QI7EEQZ^!;X#KPS;+Y#C+0!OS_%4W$-
M]J+A2W."BKJAU--:JJH;LP.:Z-S , #+<ZR"';[#D<I&G,S8G4B(NZ<YX;S(
M"\BD9*TNC>UX!+26G.X."%J7%KW2</4<D%;*UK*RD#IF%OA-Z>,$DXQCF>[\
M%1,NMQL]O?4V^1U4)KC<&LI=#2'Z1/(,$#.2Z,=N,'DD:=XN37:;.FHM<X6K
M*ZJEG=45+*BE,<3HW:F%X<=6K(8,!I&DC._-;&L3%ILW$WBXB(H"(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B(/B5T8;IE+0'^#AW;YEB=+2D^$^$DC3N1OOR_-5G%%'454=!)2
MQ&5U-5LG<P$ EHR#C.V=\_@M%IK?4B]:*ZT]+//35TC8"]A+!)4Y;DYQR(S@
MDA=*:(F+W9FJTVLZ<XTPD8'&$/));G&<]N$<^F>"YSH7#=A)(/I'_P"%I5/8
M[I#0UE--F6MJ*=L<->TM_<D0!F#DZAX8<[;/\?I6.X6*IK,]%;VTU(Z2B#J7
M+,.Z.8.>[8XP&[=YQRV";(RFZ;=F[35-,R!V\;VAA=H;@Y;Y@O89*5^-/1!Y
M&=.V1G'9^2T*Z\-U1I*WJ=$P3RUTLC2US6DQ.@<T8WV!<>7GSA?3.'*L">5E
M,(ZIUPIY6S!PU")M/$QQSGL(>,=N_>KLIR;IPWX/IWDQ!T3B!@L!!_#'XA1;
MC7T-N@=+5RPQLB\(Y(\$<LX_T6E</T@IN)[!3MHV12TUKE;+,QS7!Y)B\+;<
M@D..3@G?SK)Q%8*VJK;F+?2-?%4Q.?+TVC)D&G'1NSJ&0W!#MMAC':V1>TR;
MIM>(;UJIGN!S"7/;D<LN'_W"BW&X4E&Z 2!KWS2M@ ;@D%V<9\VRUFJM5=/5
M5/1TSFRU,\$L%22P&E8P-!8=\[%KS@9!UD=ZA5EBN4UDH[?'"Z"O@J(W35[2
MW]Z079DYAV3S(V(SL=LJ11&2:I\0V\7"C-UZFUK.F9"V4.P,:7.<W /?EIV4
MQSJ>,:1T61EP8,9]./Q_U6AW"PU5937-[+6VGF^:#2TT?2-(;,'2$:3G;?20
M3CGV'(4^HM%<^LF_<AT[ZV*I96$M\")NG+.>1L',P-B'Y[2K-,96*IPN)+_0
M'A]EWD;FF= *EK' :].-7+//!5LR6#PGET;2&Y=D@$#S_P"JYBSAFXQ<)U5'
M-:VU59/24\<3B]G[DLC:TL))VPX.<,9!U=BEW'AFNJ+?=8Y&3R5SV5AA?&8A
M',)&/:QCG;.P YHP=@6#? 5FBG+,5U6[.B$TWVA,//&HXY\N?XKP/I7Z6ZH7
M9\)HV.?.%2<26EM58H**FIV%@JJ5SHQAHT-GC<__ .D.*UZY\.5KHKFZV0-I
MJR6XB2GG:0#'&86MU#N&HNV\YVW6::8GRU55,>&Y5=)15-53U4KV%U*7EOA#
M2,C!ROFJN=#35+H'/8ZI;"Z;HVC+RQO/_JM-/#=9IIIJ>*IC,;H6U-.>ATR-
M8V3&D 8<0YS3EV,Z1VKXN'#-2RAJXJ&DFF-1;*NG:9'1AS))'%S6G!  WTC'
M( 96MD>99FJ;=(;K44E#6S4QD+-5+*9F,:0,'2YFX[L.<IC7TTA#=<3W-W R
M"1WK0J[ARK=%*^FA;35,MPJI75 < 61/AE:QV<YQJ<S;\5DM#&4W%T/5+6(>
M@M6AS8BS+LO9I&QQCP78)QG?N4FB\=UBJWAM=VN%-0U,$,D#I9:D.P(X]1(:
M,G/H!Y+':KM;[H)S2B,QQ%HUD -<'L:\8\Q#@L%^M<EPO=J>TR-AB;,)7QOT
MN;J: //W\EKL_#E53W>5U+ 6VN.<%D#-!):*>-C7 /VV+7#!QSRI$4S'=9JF
M);YJIFAD1,0S_"S;L[@O-=*^-PU0&-IPX9& >XK1*BQW&,6^FBI9#'25%*8I
MRZ(O,;7-+];LY! UMPT8([3G PPV&Y12PP14[VVFFERR-PBZ9P+"-]RU^DXP
M3@G)SD@$W9&4W3AO%WN%%:Z-]95:!&TC) &2XX QY]PHM=1TMSIP)Y)8F/C)
M= R0-)!YYQZ3N"JVOL<GT-CML$;YGM,>ALSFZ@!(TD9&VPR-NY1Y+-6]9?'T
M Z9U:*@5H+=HLCP/O9TYCQRP<^92(CQ*WF_6$VUUEJX@AI)F1NCBH&QU$6L!
MK0)(3C(Y8T/.RV(R4XR\OB&D;NR-@N>6&P7.DHJ+K5-J;#U1TM/K:>E$=-H(
MYX\%^';\]/H6;Z.5DDL<4T+NHUSGBIC$@Q!$V0R1,'XN<#C;?'(!:JIIOW9I
MJFW9O,CJ6.-Q(ATQG61MX/G\RK::]6VMJ*9M.8Y!5TW6(Y<#2Z/(&,_^(;*/
MPW;ZME'62W2)HJZF0ES2X. #6AC1G?8Z=7_B[UK=/PY5/M5'3U-O;TE+8Y*(
M:G,(Z;# ,8/;I._YX4BFGS*S55TM#H1Z!Q+7=$21N#C<+ :BF%7*R0,8YC&D
MO=@ @DX&?P*T^TV"N-Q9+<34&9L[9V31F/&!&!I<3X7>"!D'.>U9;_8ZBOXF
MZ=U,V6CS1ZM3FX/1OG+]L]FMGISZ5-L7M==TX;>7TL0#@86ZN7(:NW\5@H*Z
MW5L GII:=['.<T.&-R#I/^H'^BTZ"Q5U/5034U&34-K)01)T;HA3NJ'.[3EI
M#3D:>W /FD</V">"[6\U5 QL=)#6M+R6$:I)XW,+<'.[0[?&V-TVQ;NFZ<-R
M#J9\;6 PNC<W(;L01Z.Y0IKG;XJL4X?"Z?HW3M:W!):-B1^?^JT9ECO#X+32
MFB+&V^W-II"Z1FF<MD@+F#!.SFQN&3W[JTN=KJ)ZET]-:S&U]NJ:4-_=@L>X
M@MS@XP0#N,\]\*[(RF^<-Q@E@(;HZ-CWC7IV!].%]LJ(7M+F31N:.9#@<+1Z
M6RU\;8XGP8J>LP3=<RW]W&T,U,[^0<S V(=GM*C4'##XK;::>>B<QC;2:>K$
M+F!QFU1$=N'$8DYY',=N\V1E=TX=#9-&]@>R1CF'DX'(*^34P!C7F:,,=R<7
M#!6JMMMTJ.%F05,4;9VRASHFAK.EB$N=+@"6@N9L0-LD]BBNL4U3<Z.:>D:V
MC%P=4]7>6D1-ZNYFK .,EYS@9YY[U-L97=/3HWAI#@"T@@]H7JI^$J6>AX>I
M*:J9HDB#FZ<@Z6ZCI QV8PKA9F+39J)O B(H"(B B(@(B("(B B(@(B("(B
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MG!@9+32NE'0TXCUYC<S#M]_XB4_8G[GM#?;>:9M11TDC&U4G[H-C =.2,EP
M\P.=6.6ZE2<043+4RO;K=#(X1M ;AQ>7:0T@\CJVWQCM51+P='+725KY(^G,
MK96L$(Z(N#7-)<PDY<X/W(()TMY85R^UCYH-#$RE:"TM<TP QG)R069Y')[>
MU)VK&[RAR<1017$T\L<HE(BZ.G$?AESP\XSG')A[@,;E0[;Q= ^"MFK62-$$
MLQ?IB=F*)CRT.>.SD?3@D; KYH>#&T<D$T-;.:B 1]$][00"T2#!&=VXE(QL
M0 ,%?-+P5'#53U,TT=5/4%W3&JIV/:X%[G[#L(+W#T'<' 6OV,_O75XNKK?7
M6F%E*Z9M;.82\.: S$;WYW._\'_G8'[MU[I:Z=D<37MZ5ADA>]F!*T$ EOFW
M'X'/+=+U;'5[Z!S).CDI9C,TEN6G+'QD$9^Z]WXX]"CVBPBBGI"^=TD5%"Z"
MFC+0-#3CF1S.&@9VV\^ZQ^VS?6[[EXAH8=72ZF:9)8WY'\'1@EQ/FQC'_$.]
M1+EQ0RFB9T5%4/G=-!&Z)^&.:V5X:UVYY<_Q&#A9:KAFGJZZXSU$KS%5PF+H
MAL&$@!S@>\AK/Z?.L-1PV^IU2U%67U>J LDZ, #HGZV@MSODYSOZ,*QL9G<L
M(+[235<=,!)KD>^.-[F$,>]G\30>\8/IP<<BJ:^<43TM360PT3VBEFHV&0X?
MT@FF##AH.<X)QYU-LO#<5LJ"^-L+V](^5KGPMZ1KGDDX>-\;GS[\RO;IPYUN
MX33LJ',9,^FE>S3GPH90]N#GD<8*1LB2=TPRQ\0T;V!K(YG3](^)T C\-I:
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$#"(B F$1!Y@+U$0,;HB(&$1$'F
MO41 3"(@81$0>8"]PB(&$PB(&$1$!,(B!A$1!Y@=R]PB(/,!>X1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%\O
M) V[N:#Z1:A:>-8*^\FA?25, =+4Q1S/+"Q[H'Z9.1R!GED*UCXFLTE++4,N
MM$^&(@2/;,TAF>6=^WL6IHJCPD51/E=(J9W$UF::8&Z48-2W7!^];^]'>W?=
M8+#Q-27N]7"CH'LFAI(H9.GC>',?TFK88[M/^J;9M>QNCM=L"(BRHB(@(B(*
M^[7:CM;Z-M;-T1JYA3PY:2'2'.&Y VS@\U\VR\T5RFK(Z.7I'4DQIYMB V0
M$MR>9P1R5=Q_:*F]<-3T]OT"OC<R>E<_8-E8X.;OZ1C\5H[>![TRWPFH@IJZ
MJGIIS.Q]06-AJY7Z^E:0#G&=.1N T8YKK333,=9ZN=5543:(Z.D5=XHZ62:.
M6;,D6@OCC!>]H>[2TEK<G!(.^.P]Q5EJ![0N5W;@BYR7*IGBIJ:IFJ::@C=6
M%P9('P3!TA.V?":!V_X0#V+Z@X-NM'535<&FEGEEN;Y:ADA+M,SB83@<\;'
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MNC*9E5&'!S:=H:P#4=( &V<8S@8SG&RO5SF+39UB;Q<1$4!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6.HFCIX))IGMCBC:7.>XX#0.9)614O
M&L4E3PA>J>G8Z6>:BFCCC:,ESBP@ >=6(O-DF;1=86^OI+A )J&IAJ(LXUQ/
M#A^86=YVV*XQ!;>)K9#71TL<[7S3TCYJB& M+J80EI:UK<'4UXP[3X1!VWPK
MFC^DK9X1<)+A-)U+%#)'"8XWSZI,FH:,X\'HOXL#&3L5UG2CQ+G3JSYAFIOD
MZ>+E63S5=+%'/)6O,E-"6SRMJ"[P7OSN&Z@0.]H.V%]R\"W*1H>;Q!'4QP4]
M*SH('Q-?%$XN(=A^H%V>PC'GRJIPXH=9:P4AO37.HX&R.G $K:KI!KZ/ Y:<
MYQX/+':LE92\24TU2^EJKO*&7&:")KO"'5NJN<U_+?\ >X =V8 "Z?N]F/VQ
M_P#F4ZW_ ";]#0FDK*]D[3;ZNB,G1G4#/+KUC)., XY_BK[@_AVLM-VN-=7U
M5),^J@IX0VGA,0:(@X9P2>>?PY+3HZ3BB"!TC*N\22PP6V5C'X(?*]^*@'P=
M\- R.0R3S4=C>-'6RZ"HJJ]M:8R'1Q0$:)#,W!B?G!&C5LT';G@\TQ55>]4$
M333:U,_WH['(YK6.<2  ,DK%05<%=2155+,R:"5H?'(PY:YIY$'M"YC5Q\0P
M3SPRR7F6UQ5U0QKH&AT[VF&,Q;D;LUF09Y9QG8%?'"]-?;>_A"$15SZ=E!%!
M44I8Z-E.X,.J1SN3CG TNWVR.U<^%TO=TXG6UG647C/X1GGA>KBZ"QU!Q$XK
M(L53]@Y($,.?L 3^:\#W$9U%1ZN'IX7,Z1\>PW8<%5G!<ADX1LCGO<^1U%"Y
MSG'))T-SE=+=+K?K9>:W?>*:W=KCZ,KYYA:O:@9>)+ZY]/T@CJ&ALSG_ &8Z
MO%L!Z23^*1%R9M9M <1G#CZ5]![C_B..]<[X6O=RDLUNBHJ9TS*6"CBD:0,N
M:Z*-SWY+@=@[;8_PNYYVG55=75=FM%<VNZ#KE53DQQ- T-<[=I.=\<CZ#Z%N
M=.TV8BN)B[=>D=]XKW6_[QQZ5IE%=ZN:LK*6*6"F$4E3)TLC26O#9"T#GV<S
MZ1R6&W\0W*J#JMS8HJ;K=+3]6=&=8$T<3CEV?X@9.[L/I$X<KOAO.M_82O-;
M\XU'\UKUYN-1'75%/!)%3LIZ0U)?,TD2'+AI&XV&G?\ XF_C%X<=)5\1W&JJ
M'/&:>G<R%[0#%J:26^;SJ;>EUW=;-KUOS@./YITCOO%:$QPI[35UK)7MN N4
MT41UD&0]8($9[""-O,.6%Y0<05L=-<)W!AAHJ-]7T36^%(X2SC&2=MHQ^*UP
M\,\2.TM^Z1WWBFMWWBM1BNUV%92TM0QD4=6]C8JMS6X)+'N< T//W!@D_P"+
MMP<XI+A74=YKX^M&77-301F1HT1![=W8_P!/20IL7>W/I'??*]UN^\5J4-WK
MY;S3V]LD8:VHEBDF$>>D#6,<-.^Q\/2?.T\N2VL=O>LS398F[ZUN^\4UN^\5
M\HHKZUN^\4UN^\5\H@^M;OO%-;OO%?*(/K6[[Q36[[Q7RB#ZUN^\4UN^\5\H
M@^M;OO%-;OO%?*(/K6[[Q36[[Q7RB#ZUN^\4UN^\5\H@^M;OO%-;OO%?*(/K
M6[[Q36[[Q7RB#ZUN^\4UN^\5\H@^M;OO%-;OO%?*(/K6[[Q36[[Q7RB#ZUN^
M\4UN^\5\H@^M;OO%-;OO%?*(/K6[[Q36[[Q7RB#ZUN^\4UN^\5\H@^M;OO%-
M;OO%?*(/K6[[Q36[[Q7RB#ZUN^\4UN^\5\H@^M;OO%-;OO%?*(/K6[[Q36[[
MQ7RB#ZUN^\4UN^\5\H@^M;OO%-;OO%?*(/K6[[Q36[[Q7RB#ZUN^\4UN^\5\
MH@^M;OO%-;OO%?*(/K6[[Q36[[Q7RB#ZUN^\4UN^\5\H@^M;OO%0+A(\5EM#
M7N =4$'?F.BD*FJ!<?\ ?;9_S)_[4BL$I^^.;OS7I+B -3L#SKQ%![J=N,G'
MI7@)[S^:(@9/WG?FF^V[OS1$#)[W?FO02.3G?FO$06$)S&WT+[6.#[-OH618
M06*I^P<LJQ5/V#D@0?<L$%'3P=#T,$;.ACZ*/2T#0S;P1W#P1MY@LZ+HHH1H
M:$53JCJT'620YTI8-1. -SSY#"FKA?&IEH.+>-[M"7OABI(:2HB;VQS0. =_
MX7AA]&5O3HW3:[GJ5[(B;.T16VA;T#HZ6 &)H;$6L'@-&P [L=B\=:J!PF#J
M.G(F(,F8QX9!R">_?=<?9Q5=;?9Z>*GN+*%U#:Z)]#1NB:\W)SHQJ SX1W\'
M#=QS*FUO$7$3[G4.BNKJ:-M]AM;:?H(WAC)&-R<XR2TDXW].5OA598X].'4)
M**VZVT\D%*7/<9&Q.:W+CS<X#_J5(-%3$O)IXLOD;*XZ1N]N-+CYQI;OY@N'
MW+B>\13.E?5LEKK:+Q!'5/@CUGH=&@_PX![\;'M5G6<5\2VVCN\ K.O2QP44
M[:AT3&&G$V=9QLT@8V+MAG?9.#5DYBG']M=UZIHZ:J+#4P1REG\)>T'"^V01
M,E?*R-@DDP'O W=CED]JXQ4\:\2-M-#_ +33MADK)877*.HIG M:QKFM<[/1
M-<23D_Y< 9*WG@*[U=U$<MQN-/)5NI&/DHH-+FQG4X=*'C.0_'+.!A9JTJJ8
MO+5.K35-H;/%;:*&=TT5) R9SB\O;& XN/,Y[ROJ&@I(7.,-/$PN&EQ:P#(R
M3CT9<X^DGO4E%SO+K9#;:Z%L+XFTD B><N8(Q@GSA/FN@SGJ=/\ 9B+[,?P#
MDWT>93$2\EH1HZ&ECZ+HX(V]$"(]+0-&>>.[*DHB B(H"(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B H%Q_WVV?\ ,G_M2*>H%Q_WVV?\R?\ M2*P2GHO4Y*#
MQ$1 1$0$1$$^#[-OH618X/LV^A9%A!8JG[!RRK%4_8.2!!1$6U%A-/$2[5$P
M]( '9;_$.S/>LRTFNGEZ>YU!E+:V"XT\-.T2'9CNB\'&>3M3L]_X#&J8NE4V
MAMY@I\QY8S]WLS(&6>CN7O5H#DB)N[M62T9SW^GSK7(*</XDOT$LTCHGTD#O
M">?!+G39QW; <NY6_#55+6V"W5-1@S2T\;WD=I+>:3%B)NE&CISL88CDGFT;
MYY]G:O6PPZCAC<D $AHW'<5K'%M3/45HI*+IW34D8JP(FN(,N?W378[#A^1Z
M%%BN\=3?:F>EG<P5M%2=" T%[B3.[ !. [ //88*U%$S%TWQ>S<>JT_0]#T3
M#$#]G@8SSY+Z9%%$[4UC&NQIR!OCN6A0<37:>@K*P20,;16\5;V=']J\/F:1
MG.P(C[S@XW/;?<3M,EPL49A;4-?-)JC>[#7?NG'?8I-$Q-I(KB8O#9,C![@O
M X'DM#XHN%3-;;[")Z>EBHW10-B<W)>'!CB<Y',NTMQVM//D/F:_5U/2TU?,
M8I7.%80&QX#!&[2"=^7:?,.Q.',PG$B);\2 0"=RO5I'$E95VV[V60S,F>^*
MH:9W,Q'""8LO< <Z1_\ <9.,N6YP9Z)H+M9Q_%WK,TVB):B;S,89$1%E1$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0% N6U9;/^8/_:D4]5]S_P![MO\
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M&Y[X6I86"*!U:N\H?V6KPP5H&3</[+4L+!%7]7KMO_\ (#?E^Y:O>K5WC_\
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M/E*H_HC^%+%UANJ^XC-9; >76#_VI$ZC4^4JC^B/X5!N%%4"LMN;C4'-0?\
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M*GIW1M:\ENYERX#L.P'_ (0M;H;_ %\%LH)JF2IQ44397&5S?WLG21C5&1G
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ME56Y=U.&&/71L-.""UPBG:]Q.V,!H('F[E$OMFJ([9<Y6PL875LM47 @'HS
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M>;#3D_Y7)MG";HRMNDN7BM%[2[X%YTER\5HO:7? OF:\P0SU$;FR%E.-51*
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MO:7? OG7<@[4*6B!Y$]9=O\ VU$MMYD=PO;;E40232STK)Y&PM&Q+ YQW/\
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MBJ?L'+*L53]@Y($%$1;41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$^#[-OH618X/LV^A9%A!8JG[
M!RRK%4_8.2!!1$6U$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!/@^S;Z%D6.#[-OH61806*I^P<LJ
MQ5/V#D@041%M1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$03X/LV^A9%C@^S;Z%D6$%BJ?L'+*L53]
M@Y($%$1;41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$$^#[-OH618X/LV^A9%A!8JG[!RRK%4_8.2!
M!1$6U$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1!/@^S;Z%D6.#[-OH61806*I^P<LJQ5/V#D@041%
MM1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$03X/LV^A9%C@^S;Z%D6$%BJ?L'+*L53]@Y($%$1;41$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$$^#[-OH618X/LV^A9%A!8JG[!RRK%4_8.2!!1$6U$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1!/@^S;Z%D6.#[-OH61806*I^P<LJQ5/V#D@041%M1$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$03X/LV^A9%C@^S;Z%D6$%BJ?L'+*L53]@Y($%$1;41$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$$^#[-OH618X/LV^A9%A!8JG[!RRK%4_8.2!!1$6U$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!
M/@^S;Z%D6.#[-OH61806*I^P<LJQ5/V#D@041%M1$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$03X/L
MV^A9%C@^S;Z%D6$%BJ?L'+*L53]@Y($%$1;41$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$^#[-OH6
M18X/LV^A9%A!8JG[!RRK%4_8.2!!1$6U$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!/@^S;Z%D6.#
M[-OH61806*I^P<LJQ5/V#D@041%M1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$03X/LV^A9%C@^S;Z
M%D6$%BJ?L'+*L53]@Y($%$1;41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$^#[-OH618X/LV^A9%A
M!8JG[!RRK%4_8.2!!1$6U$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!/@^S;Z%D6.#[-OH61806*I
M^P<LJQ5/V#D@041%M1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$03X/LV^A9%C@^S;Z%D6$%BJ?L'+
M*L53]@Y($%$1;41$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$$^#[-OH618X/LV^A9%A!8JG[!RRK%4
M_8.2!!1$6U$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1!/@^S;Z%D6.#[-OH61806*I^P<LJQ5/V#D
M@041%M1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MU?Q+\<(B+[3X O0O%Z.80;/=.#*^DFJX*26*XU-)4"FGAI&O<]CR'$;%HR/
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M1 6 M#'$NU' W P-^\CS96]UG&ELEO/6HXJD1=?N-4 6 '1/"UC!SY@@Y_\
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M9DW&"[5G(SC&-TW58791'E23</7-M;/34U'553H9.B<Z*GDQJQG&"T$'&^"
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MBFD87N:&N>6M<&O:>3P?XMBT;'F&ZK"[*+]_[U:U8;)7WVO-';:=\TX8Z0@
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M+NTX062(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
HB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>green.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 green.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ] *\# 2(  A$! Q$!_\0
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M-?AG9J9)X48YCDC@//F,2N'?IG<?F,:KX_X$\*_%3_@IU^U1<_\ "R([K0_
M_A"Z/]IZ1'NCATQ-Y'V)!U-Q(4*LY^;",>-JK7;?\*[\2ZY\<KGP?X4\2_\
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MA-P&6. >J_:V_;&\'?LF>$8[K6)$U/Q1J"D:3X?BE"2W+=/,D;GRH0>KD>H
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2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ": 9T# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7-*%MCMA6YMU8]41MU&[WJ"'[J@9P/E.[J*GK(Z0W>]&[WHHI@&[WHW>]%%
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M]H^9[(\W&8CV4>5;LP/%GBO7OB#XFNM;UVZGUC7+Z;.YOG9B3PL8K[9_9?\
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M[5^8G[:*[?C_ *K_ ->\?]:^3S9OV5S]Q\.XP_M:TND6>'!5S@C'^Z!FN[^
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M&QG'2OU">Q_#\7JF^Y]<6Z1BUC)13\@_A'I6'XVT.SU3P]?+<0)E8BZM@##
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MK'ZXK6_X*$_%"_\ B1^T3<>'8I6?2M ,=A;68.4,[8R2.^<XKZ\_X)E?"-?
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M7?LRZ3;B0M<Z3-):3(3DI@\#^=?3^H:=;W]K/;7$8E@GC:*2-N0RD8(KX<^
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M.U/V!>,&EC_U2T^OT4_B5[E#5U']EW9(X\I^OT-?CIXJS_PE&M\@_P"GS?\
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L,"C:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHI:* "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>proxy_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_01.jpg
M_]C_X  02D9)1@ ! 0$!+@$M  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" ./ L,# 2(  A$! Q$!_\0
M'  !  (# 0$!              0% P8' @$(_\0 5Q   0,# @,#!0D," 0%
M! $% 0 " P0%$1(A!A,Q(D%1!Q0R87$5%B-4@9&4L=$7-#="4U=T=9*3TN$S
M4E5B<H*5H216<[,F0V.BP34VLO (&+33X_'_Q  4 0$
M    _\0 %!$!                     /_:  P# 0 "$0,1 #\ _5*(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+@=P_\ Y%0TU?4P1<.2
M2,BD<QKW5@:7 '&2-!Q\Y7?#T7"_))Y/.%N).%Y[A>K4VJK'5U0PR&:1NP?L
M,-< @D4GEKN=7'*^GX.+VQ/,;S[I,&'#J-VJG_\ ZD6?\L.^G?\ ^M=%^X]P
M'_8#/I$W\:'R/<!_V!'](F_C07GD]XHCXQX5I;U%3.I1,7M,3G:M):XM.^V>
MG@MC7.O($QL7DWIHV##&U52T#P E<NBH"(B BJO?'9?/S1>ZUO\ / =)@\Y9
MS,^&G.<J;7UU);Z<SU]3#30 X,DSPQH/M.R"0B@6N]6R[!QM=QI*P-&7>;S-
MDQ[<$KU/=K=3U\=#/7TL=;)@LIWS-$CL],-SD]"@FHHMQN-%;(6RW&LIZ2)S
MM#7SRMC:7;G )/78[>I>ZNLIJ.D=55E1#3TS "Z65X8QN3@9)V&Y"#.BQ,J(
M7THJ6RQFG+.8)0X:2W&=6>F,;Y53[[N'/^8+1]-C_B07:*#37BVU=%+64MPI
M)Z2(D231S-<QA !(+@<#8CYUXME]M-UD?';+G15CV>DV"=LA'M *"Q1$0$10
M3=[>+Q[E.JX6W'E"84[G8>YA)&H#O&6GITP@G(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B(!Z+F_D!_\ L27]85/_ .:Z0>BYOY ?
M_L27]85/_P":#I"%$*#GGD&_!Y!^EU/_ 'G+H:YYY!OP>0?I=3_WG+H)D8)
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MNG;_ 'G=(@? 9=ZUM7#O#]KX=H126:CBIHNKM(RYY\7..[CZR5:H@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("PUW-\SF\V_IM!T?XL;+,L%<
M^2.DE=",RAITC&=T%3)[LN>=(:!E[-0([\Z7:? =GOSN[;HO+FWHPEL>.8&@
MASG-&^D9'0_C9 ]IWV&<E'4W)_/,L+VB.'+-0&)''./ ]W3 ZY('0>FRU;N:
M#)4!H:70N$8U2'!R'9;@;]-AU08\74U#B[F:'.>6:2W2W<:=6^2,$Y \%Z>;
MHZNJ' /;3:AH:"W) P#C?OW<.GK6*IGN<46B)TLDV=))8,#?(.0W&XSW8&1G
M'59H)[@^HCSJY7->'ES<8:#V=BT'<9[_ %Y[D!HN <01.6$[D.9J#=\ ;]>F
M3[<9V*P 7AO->T/+FR!S&N+<.9IR6]>N=N[IUPLIJ[D*F/FQED+CG+&EY U9
MP1C;L[>WO61]37/HZ%\#'&0@.F#FZ#W C!&W4_-\X>!Y^R:#F"I<QKSS"W1A
MV-FX /0YW]F^ OM:;KYW(ZEQR@6AC7$8(."2>_;!'KU>I8Y*RX,+3%#-,P%K
MGDL#2=\%H!WQWCJ=N_(*LK4Z=].34N<XYPUSFZ21@9V[M\_(@R4(>(?A.=J.
MYYI;G_;;_P#ZI"(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(H-[N+;3:YZZ6-TD4 #Y TX(9D:G?(,GY$$Y%J3^-Z9L=7*VBJ7PTC'332-+
M<-B$KXP\9(SDQ/< /Q1XD ^6\9N\_9226_ER/K7T37&<:=;&:R>G3!&/7X(-
MO1:A=N.(+=?*RV.H:B:2F9S'.C(.6A@>[ ]3<G'4D87NY<:T]#8*2[/HYW4]
M4V>2%N0'.CCAEF#O5J;%D#^\,XW0;8BTJBX]BKZN&&CM\CA)4>:DOD#2R04_
M/<",?BC4T_WACUK!2^4>EF]RM5#*/=&*.:(,D#G!KR  1MN,Y=CH 3N@WQ%S
M^W^4ZBN$5&::BF;)4^;]F9X9RS*V=P#NO= 3Z];2MIL5WDNE1<HGTG(\RJ/-
MG'F:M3M#7[;#;#V_[H+=$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!8:V1\-'-)"W7*UA+6XSDXV"S(@HJBY
MUK(Y'-A#'C.F-\9)/:(R2#@ 8!^7N63W2J'G,36Z0]S7?!.)]+#<>)(!/S*Y
MP/ )@> 04DM;<8FR99&]XU%C1"X:P'$=<]P /KR%E;7U3[=4O9$TU;#RVLTG
M =L,D=XSD^S'CE6V!X)@> 04E/<ZV:K#?-7"FYN"\L((86 MZGKJZ[;# Z[K
M+%75;G-<YC6PZ\.^"=D#2XXZ]00T9Z9)"ML#P3 \ @U^6YW&*5L3H6%Q87.>
M87AHR1CIGN., G)\ -Y=36U4<;7MA<T<IQ+3'DEV6XQAV-\NVS_.UP/!,#P0
M5D4]>YPSRM+GL8,1N[O3.<].X''=WY5FF$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!1+LZ!MLJC5QMEIS&X/C<,AX(P6_+T4M8JF".IA,4H
M)82#LXM.0<C<;]0$&I>=<-BA8P6^G=)31"&.F;%J.EKP&,&V[<EC@#T!!P%*
M-3PX9&3%K63![JH/8V1IU.:P%X( .X>P9[\X5U':J.-I:R'#"6DMR<$MQI)'
MCV1OUV"\MLU UFEM. , 9!.1C3C![L:6X\-(\$%37"T<Z"YMHJ>H\Z:YSIR[
M&EHC.78Q_5!;GKOCH2C)>'[I3T5LJ*>'4V,LCI)6$&,&)["W! QV-8]8RKVH
MH:>H8&SLUCENBW)W:[&1\N OD-OIH9WS1,+)'^D03VMR=QW[N/SH-8CJN'J>
M6*H;;HX7RU<DCGZ0"UW*<WFG_'&,#O(=[4B/"9;%!3PQ3F+EPQL:USS&&O9I
M:,] UQ8<#HM@%DMX;@4[?Q=\G(TM#6D'N( &#W+VZU4C@X.8XAS@X]MV[@,9
MZ]<=_>@URDBX4'(DIZ..&4B/ENBBD8X\J,M;I< "=#'.;MT!(*OHJBW45%55
MM.&-9*SSV72,.>-([1!WSI:!OX+Q6\/4%53" L?$P!P!B.D@'5D ]V=;NGBK
M)\,;X#"]C71%NDM(V(\$$$WFECRVI>V.1N2Y@=K+ -.2['HXU-SG89ZKY)>Z
M**KGIYGOCDA/:)8<8PTEV0,8&MN3W97OW&H<DF'4XG)+G$D[ 8))W'9;L=M@
MO<UJHYIW320ATCMG')[0VV/B-AGQP,] @@5O%=FHJU])55?+J&/<PLY;R=08
MUY P-SI>TC'7.!D@XCLXWX?D&65^=HW$<I^0'MU-)&G88ZD[#H<%2*_A>W5U
MQ=73L)J2Z-^K2S8QDEGXO<25'9P9:6&8LC<WG1RPR8:SM,D=J>#V>\_R098^
M,+))1RU<=87P1F,.<V)Y(+Y#$S8#.[P0/GZ$%8F<;V"1DKF5KW")YC>&T\I+
M7!I<6XT]0 21W8.<8*CU? 5HJ8'Q U$#7NB<XPEC">68RT>CT^"8/GZ9)6=G
M!=HC@DA9&X1R/YKQAG:=I+22=.<EI(/B"<YR4'N3C.Q1RU$;Z[#H#B0\I^&G
M0Z0;Z<;L8YP\1C&<C/J3C"R1M>759[#G-<!"\N!:9 X8#<[<J3/@&Y.Q!4:H
MX'M4TFO,['&:.>30&#FN8XO;J[.X#C\VW3929N$[;,*@2-<[GS&>3LLRYY;H
M)]'O;D'Q!/B4&*DXWL536,I?/.5/)4.IHFR,(YCFD-RTXP02X 'ORI-7Q79Z
M1TPGJRWDO=&]PB>X M&I^X&,-&[CT;WX6(<)6X3/E89HWO+BXQEK,ZL:N@Z'
M ..F0#U&5\?P?:WM>UXE<Q[M3FG2026Z2<:>\;'^L.N4'NV<862Y5D5+1UA?
M-*[0P&&1H<<..Q+0.D;R-]]+O!???;9O/XZ)M6754LQ@CC;"\\QX+@=)#<$
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M5\43YK?RQ(&X^%)PYS&N )+1@=L#/B$GKKS!/.V.CYCWS,;'EKG1AA;&"=0
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M34^*>4TTD3)W2;=ECHY7YQGJ.5_N@K'< 4;KI+7\_$TDAETAATM<1(#@:O\
MU7GY1X+%1^3\4ERBJ(+B64T4+HF4[8B 0X1!^IVO)U"%@P,#KXK8_?!2.8YT
M<<\F).4-+1VCEPVR<?BGU]/$*,.+;;DM//#FB,N!9N-8RSO[]O9G?""IJ/)_
M1U-$:6>H,D)IQ38+7>@UCV,Z.ZM;(\ ^O)R0"I5'P9!2W6.X1SM,[)'R %A+
M=3W.<<C5XN)'R>"ELXH@?5/B%-/M)RV],N.8AMOCK,W?/=D94VU7NENCAYH)
M"QT?-9(YN X:BW;?/4'J$&L.\FUN\VB@9*V-L;(HP6Q;D1LE8TG)()Q/)D]>
MG3"DQ\!T<<,\4<NF*=KV3M&OX:-[BXL=V]VY)]>"1G<JQ9Q1 &!]1#)&SD&9
MQ )( )!P"!J  )R,J32\0T535BFB$W-[.H%GHZAD9_W!\"#E!3>\6G>UHJ*D
MU!%0ZH+I(SJ<7$%S7$.!+26LV/<T ;#"DT7"?FM-3PFM,P@K#7-?+'EYE.K)
M<01J](]<GY  LE)Q7!(U[ZJ"6!A>UD><'47!N =]CEWLQWJ2_B.E96QT[V3?
M"0,J [3Z+'.T]K/KQTR@NT6NTG%,#Z.&6H@F;)+*V$,8 >V[!:S.>NEP.>GU
M+/'Q+1O#"8ZAG,(#-36]HD.+0-^I#78^;O""[1:U#Q=22S-:(9N6\%T9P,O
MB;+G&=NR[OWV5K:[M3W-\S:<2 QYSK &1K>S(WZ9C=\R"P1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 4.\U;J&UU-2R-LCHF:M+C@'VE3$0:='>:*"*H;5T%-S&
M/<P!K1VXA+)&W&W4"(;=.GL65UTIXK;:ZB:W4P$U."YC0"V%K0 1G&<-#W#
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M(B("(B B(@(B("(B#Q+%',PLEC8]AZM< 05Z:QK6AK6@- P !T7U$# \ OA
M(P0"%]1 P/ (B(& B(@81$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$05O$$U53
MV\2T,L4<@EC:3)&7@AS@WH"/'/R*NIKI6&LAYLU,Z)]6ZD,+8R),M#NUG4>N
MG5C'HD;^.PR,;(W3(T.;D'!&>FX6(4E,*LU0@B%26Z3+H&LCPSUP@H+C?:FF
MDJ8&B$34[WN>]X.@18&AQWV&7MR>_ER8]7PU]T]U8*)M72.^'$<DC:<D8,3W
MXQKV<-'KV>TK8^1$97R&-FM[0QSL;N:,X!]6Y^<K'3T5+31L93T\,3&$N:UC
M T-)V) '0[GYT%?PQ5UM?:XZFO9H=*UKVX8&@@@';#G;;]^#ZE5#B.KW@+8/
M.?=$PG8@>;><<O7C/7<-Z]=\8V6Q06RBIY1)3TL,+AJ/P;0T9.,D@;$[#=9#
M1TSLY@B.=SV1OOJ^O?VH-.]]M1/!-YEHEE,K7PB.+470N+@, N;J=V,]1L]H
MQGK:6&\U-RKYH9C QD;8W!S 2)M44;CH/@"\Y/7!;MWF^-+ 3&3$PF,882T=
MGV>'0?,O+**ECT:*>)N@ZFX8!I.-.1X;;>Q!K-)?K@^\-IIV1MADJ98F$LQE
MC)',V(<<^B,Y#=^@.=LE9?:NF9-5!U.^$330MI@TB0&-KSDNSOG1G&/1</#>
M]?:;<\3!]!2N$SM<@=$TZW>+MMSOWK*RAI8Z@SLIH6SEN@R-8 [3X9ZX]2"D
MN-RKK>VB#YJ:?SF0M,K8RUD3=&0X]HY QU]?<,D2:>OJ6U5=!5.8)(V&2!H9
MLY@VU:LG.^,C (]8P58PV^C@:YL-+!&UQ+B&Q@ DC!/M(7VGH:2GYGF]-#%S
M  _0P-U8V&<=4&IVB^WBLFI(7PM$CB72AL3<ANF)V<<W 'PAW!)Z;=58MNE9
M4TEIY4U+3355$:J226,N:" S( U#;MYSG8#UY%LVT6YL<4;:"D#(G:XVB%N&
M.\0,;'UKX+1;A#R104O*U\S1R6Z=7];&.OK0:U%Q56&F$\D$89#$Z6H SD:V
MAT &_4YTGUCN4Z[W>X4-PH::..*8O#'3!K3EPT2.?HWZ]C8;^'?D; ^E@D+R
M^&-Q?IU9:#G2<C/L/1?7P1/D;(Z-ID;T<1N.O?\ *?G*#5[G?ZUEAH:Z@$<K
MIII6DM8' QM;*X$9>W\F-\^. K"CNL\T%O>_E#SBLG@>6@XTLYN,>OX,?[JR
MFMU'-!'#-24\D,;M3&.C!:T[[@8V.Y^=>'VFW2"8/H:5PG(,N8FGF$;@NVW^
M5!46*ZW"X5K.8QOFOFT<KG,8,:G GJ7Y^9I]JB7"_P!?!22U4+J9^MU1'% &
M$OC=&'8+CJP?0P1MNX;^.SBAI14BI%-"*@-T"70-8;X9ZX7PT%(9I9O-H>;*
M-,C] U/'@3WH*&6\7%UDH9H6-=635,D#VMB&0&\S;27@!W8&>UCKC.R\MXBE
M-A?5/?!'4221PPD-<YNI[&.R1L2!J<[&VS>Y;!/04E1"89Z6"6(NUECXPX%W
MC@]_K7QENHF51J64D#:@]91& X[8Z]>FR"HM%WFN[XGP30PQMBCDD8YA>XDE
MP<T'(Q@M+<X.X/@L5!?*NIX;K+D\1,FBI#*V(M.=087:COZ)[AX=^=A>R6^D
MD?&^2FA>^-Q>QSF EKB<D@]QSWKT*2G ($$6#'RCV!NS^K[-SL@U*NXGKJ6*
M8.BB=,)Z@1-:W^DCC+P,9/I L /=VATSM;UEW=2\/^>R2P\Z9PCCPTEK'N=I
M (V)TD]KH>R=@K9U'3/QK@B=@N(RT'&>OS]Z^LIH&.U-B8':^9D-'I8QGVXV
MR@HK=>YJR2V2NT,I:EG+=I9J^'&K4PG/9 TG!P0<'<;9Q"ZW)]0]F8H62UKJ
M6&1\0+0&Z]]GY)[&-PW=VV5L H:45(J13P^< $"70-0SUWZKU+2T\T#X98(G
MPO.7,<T%KCG.X]NZ#7:2^5<L<^KDN=#-##J:T@/U5#HG. SMLW('=ZU[N5UK
MF5%6*66E:V">*E;%)&2Y[I S#LAPP 7],;Z3OOM<26BW2%IDH*5Y:P1@NA:<
M,'1O3IZE[9;J)DL4C*2!LD+=$;FQ@%C? 'N'J"#7*7B*MJW1\B*$"J<T4NO.
M#I9JEU'.V""T>OQ5W8ZN:KI?^( Y\;G,F&C06/&#IQEPZ'J"0I?F=-AHY$79
MU8[(VU;N^?O\5]IJ2GI6-93011,8"&M8T-#03DX Z;H,R(B B(@(B("(B B(
M@(B("(B B(@(B@7*ZTMNDC94F7+V/D&B)[P&MQJ)T@X U#J@GHH3[I1LJ)X3
M,-<$0FDP"0&G/?T)VZ=>GB%X;>:-_FG+D<\U4)GB:V-Q+F8!SC&QP>AW/R(+
M!%4Q\06]\L47,D:][@S#HG@M)=I =MV<NV&<97JX7V@H*B2&J?(U\<9D=B)[
MAC2YV,@8)PQQQUV06B*"VZ4YEIHW-G8ZHR(]<+VC."<$D;' .Q6#W=HQ$Z1W
M/:QC]#]4#QRS@'M;=D8(.3L@M44:EKH*JIJ8(7ETE.0V08. 2,]>A^124!$1
M 1$0$1$!$0D $DX [T!%%FN5#"UIFK*:,.(#2^5HR2,@#?O"\>Z]M_M"D_I.
M5_3-]/\ J]>OJ034426YT$-3YO-6TS*C&KE.E:'8QG.,YQC=9)JRFAU\ZHAC
MT-+G:G@:0,9)\!N/G"#.BCR5U)&(#)50,$^!"72 <S/33X]>Y>'7*A89PZMI
MFF#'-S*T<O/35OM\J"6B@^Z]MYK8O="CYKFZPSG-R6XSG&>F-\^"RFX48DDC
M-73\R+',;S!EF=AD9VR@DHL$]930122SU$,<<9#7O>\ ,)Q@$GIU'SA>6W"B
M=*V-M73F1[.8UHD;DM_K 9Z>M!)11X:^DG@;/#5020N<&"1D@+22<  C;.=E
M\EN%'$YK9:NG8YS^6 Z0 EW]7V[C;UH)*+!)64T43I)*B%D;0XESG@ :?2W]
M7?X+Q)<:*.D9525E.VF?LV5TK0QWL.<()2**+A1&66(5=.9(6ZI&<QN6#&<D
M9V&X7P7.@,<,@K:;ESG3$[FMQ(?!ISO\B"6BA27:W1\WF5](WE.T2:IFC0[?
M8[['8[>I9A64SI8XA40F25NMC \9>WQ [P@SHB("(B B(@@W:\6VSQ,EN]PH
MZ&*1VECZF=L37'K@%Q&2JOW\<)_\SV/_ %"'^)7E524U6UK:NGAG:TY D8'
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MI7\D]_WE!_-S+])_D@ZXBY'[_O*#^;F7Z3_)/?\ >4'\W,OTG^2#KB+D?O\
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M*#^;F7Z3_)/?]Y0?S<R_2?Y(.GQVJWQPF&.BIFQ%KF%@B:&EKL:AC'0X&?'
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M(@BSVZCGEGEGIHI'SPBGE+V@ZXQGL'Q':=MZRL%ML=LMD@?;Z&GIWAKFZHV
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MDDX=MC&W4;+$+#;A40SMA<V6+&ES9'#8!HP=]QAC=CX*356^"JF9-)S6RL&
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MI6M;!#*T-_\ 7D.1I:W2<NW;AC>R=MNBRBP4 +"YDS]&D8DG>X.#3EH=D]H
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M1ZE&FL%NGCT31/?VM>ITK]6KLX=G.<]AN_J0?*Z]PPVFGKZ1IJHZB2*./2'
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MX%HQWCY2L3^*:)EH=72-E8\,>X0.:=?9 .^,X!!;N=NTWQ4M]]MS,YJ#G6&
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MK=)<#DXP/1=@'K@XZ(+-%72WFCC(!D<"0PG5&YH9J< -1([)WZ'!7@7^V$Q
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MZ=;B2YQQW#).R"S7+/*K^$GR9_IE1]42ZFN6>57\)/DS_3*CZHD'4T1$!$1
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MH."+A^LGN+YWS4$[87:9:0,#8I#@%K7X;DZ6D$:M70';. &XLJH'SF%DK'2
M$X!ST)!_W!"S9'BM-J.&ZFGBD]SQ%!*Z9W*= ,<L22.<YQ&W1KW#OZ#Y)-UL
MLUTJ*:2AJ(11PMY;0!APP7->T/ U $8&Q&-/?G8-HR/$+[D+5Y;74OH[;1L>
MS7%(8ZAT0#6B$C)CP,=1H&0!XX&5XBX>KX(AR)H&RL+1WZ92(Y&&5_\ ?=S
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$1!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>proxy_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_02.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              0% P8' @$(_\0
M4!   00" 0("!04," ,'! (# 0 " P0%$1(&(1,Q!Q0B05$R87&!T@@5%A@C
M,U)7D9*4E39"5'5VH;+"4U:Q)&)R@J+!\#1CT?$E0W,71__:  @! 0  /P#]
M4HB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B)M$7ELC'/>QKVE[-<F@]QOR
MVO2(B+R][8V.?(YK6-&RYQT OC)8WN<UDC'.;K8!WK?<+VB\^(SQ#'S;X@'+
MCOOKXZ7I$18X[$,A:(YHW%P) :X'8!T2/K7I\C(^/B/:WD>+=G6S\ OCY8XW
M!LDC&D@D N V!YKY'-%(=1RL>>(=IK@>Q\C]"R(O#I8V2,C=(QKW[XM) +M>
M>A[U[1$VB(B\OD8PM#WM:7'BW9UL_ ))(R*,OE>UC&^;G'0'UKUM>#+&)1$9
M&>*1R#-C>OCI>T7EDC'EP8]KBTZ< =Z/P*](B(O,DC(V\I'M8W8&W'0V5Z1$
M7F.1DK>4;VO;O6VG87I$1$1$1$1$1$1$1$1$1$6A^DHD=0]!Z)&\SKM__@E6
M@X+JKJ_(T<!++GVL=E,;=MOU1BW&Z!PUQ[>9]^]CX >:KZ?I-Z@G9<MG,4VV
MJ[,6^OB#79RMF>*,RM!^5YN<>WE]"VJCUKF)>IJT;KM=T\V:DQLN"$;?%@KM
MY:GY?*\FAQ)]D@]@M=M97J?*=(='=19'JA].K=RD$4K(J\<<< 'B-,DCC\H$
ML!T=-V1V[!7UOKV\_JZ[6QM_G5:V]":\L40=#)!$YP< "7ZY-(V\:=[@%2S=
M0]57NFK]:?,R.EM=)LSC)8*S(Y(WG8=&TM'D1[_,'RTMBZWF=-]SO;E.0^^#
MS0B/K+2WVSS;L;;V[>7U=^ZU3[]Y3IKJW,5H(Y+F3Z>Z<EKQNE:7"6/UF,QR
MG7RM1/!/SL<I/6'4&:N]+]35J'4GK]/'BE,,I3C8SEXDFI(7%O;31IVQHZV'
M=BI&0ZGNXOJS,PU,E5A@L6,7!/G37C<&1NKO=XKB/9/(@ %WLCEV'DI&?ZYZ
MAH]5^I8VW4LU*\-5T#YIZL3<D'CVW[<YI/O \/L".^]Z4OTZ59;?4G2D<&-@
MR;VT\G+ZK-(6!W&.([! /M#S [=_>/-:_9ZYSN*QV K8:_%+3CPL-J*U>F@C
M]>D/9S7NE>#IO'1#"7 GN3V5I#UUFY^H*39LK!6EEZB.,FPHAC=)%7#7:<7?
M*/+0]KR.QK7??RMZ0\E<BZGL8_(^-79A;61J>)%$)*\D;N+06M)U\H'B_P!K
ML-^>E3]=]39Q^&S>/S6>J5X)\&+T,+JK6&T9M@PM).SP'8$=R3L[&PK#[^Y/
M'9/*18B:&I--?P=+QA78YQ9+  [EL>U\VSV\AI2XNMLXVS3Q>0S5>C&W,7Z$
M^7EKQM!; UKHVD'V&N?R(_\ +V[JP.8S6>^Y\LY<Y*:/+.IV973UXVM<\,=(
M-  >SL- V.X6K9+)93'Y*SF</FV36:725>RZQX+)18XSR>P==@/,$COV\QWW
M>6.O.I#UYZG$RK#598JPLIS301^/'(UI=(.;Q(YVWGCP!'LZ()VIWIQL.R]O
M%=*P17YFSLENV_4(W221M8TMB):WW&4M/_D*IX_2'G!@L-+"7&UE:+L=#&^(
M.,&5CD;&>7;>B'%VCO7'Z5>7^LK<'I$I8BKDC+''<AH6ZTT43"\OBY&1HWXG
MF6GEH,[Z&_-:=TEG68TX/,VP(65^G<E*[U:N/9U< !$8T/<#[A\2.Y7W-=37
M<GC<5]\<O7XT>J*C(LBX1.:QCJ[W$N,9\,\27=QV[=_(J2_J2]FI<:+TE:ZV
M,9VK%?9 T&S%' WC(T@>SO9!XZ!XJAR%G(LZ2/WNNNH^K]-X2222&-HD>QSP
MUP<_7(- ._/78@]B5T)W4^>BZSK]*PWVW'WY:ENI?$,>G4>!,[O9''9=&0#_
M /<&O<K7TA=17,7U%4QS<M7P5!U":YZ_/&QXFF8YH$(Y=O(EQUW/NTM:Z2=D
ML_Z5L%E\S(8ISTXRZ*CH&:@+WECFL)')N_E;WR[\2==E'ZSP%[J+THYZKB:\
M(NLI4719"28QNH'F\E[  2XD C7;Y^RECJWJ3[TR9";*P0TY<Y)B'3.K,U2B
M$[QX[G;T3H,8-CB.Q.^ZAY?T@=14\ +.+LP9.U#DK-.#C "W)UXX^1G'$=O#
M.]ENFG7SA2W]7=00Y7&X2ME69*?.UZ<V.R#:[ UK=GUIV@T Z:TN ([<@%F]
M.]6S:S_1[J'+UVHR]>KM&_:E@CCE:TCW[+-?6M7PG4+'==6^N;!L15;V)O6(
M0V,O<R"%T4;"&=MG;7.\QY^8'E+SG46<RWH_Z@>W.O'WNO5 +=?P=R12.CY!
MSX_9TTN=LM/D"#VVK6YUQU'#UP,?5GJS4X9:D$39IJT8O1R!O*8<G!Y<[D>/
MA@MV-:*CX_.YG)4>BLSF+=>U'=S/@QP>ILW#X3;#7.#NY+G<1Y : T/,DTO5
M765OJ+I#JV#UWUO&RXL6X6O9$V2$BPUO$B,GCV(/%_M#W^:Z/TSU/>G])^5P
ME^]%8A#))*D-3PGQQQL+ ?%(_*,D!.M.['?;R6IY>?)X/KKTC9ZM+Z_<Q]&H
M*[):['>$R4O/8@<@U@!<0".6MG9TL]OK?-UO7*N-S%7+P17J$,659"PL)G<6
MOB<&^R[C[)[:(!T3ONKGTK1YBATMTX]W4$U=T.3J1W;C(F1M>#(T>(\>36@]
M^/R3OOM:YC\KE,-U5E+5&\QU.UU9!0L0F%I$K98HP7\_,$=B-=O/>_=9^CSK
M;J3,=8,JY%M9M>>2RR:H^:NV2IX9/#BP/\4_)T[FWW[&@J7TM96[=ZRL3XRM
MD9_P5ACGC=5C>^+UDO;(\2$#0'@MUW_2*G=1]=9LV.H,IA,G&W%8ZOC+<%8U
MF/$S;!TX%WRAV[]N^Q[O?+=U7U%'U++(<BQ^/9U2S">IFLS\T^-KN7,>UL$]
MO\]^[#@O2-=DN]/PW\A')+XV6^^E=D33*QD >8@6 ;:=-&O(N^=4.0ZJN]0X
M"]#9O-O58KF)LP2<8@]GBV#MCO"):".#>Q.QO1VMH]/%&QDLMT?!2)%MK[MB
M#6^\L5<RL_\ 4QJTZIU!<O\ 6@ZXH4Y)9;F.R#J55P/M1P1Q-:-#S)?XA[=S
MY*RJ^D/JMO2]^=LE2X]OJ@%UL]5SJWBN+7N<V-Y8&C7LE^M=^6P%[J9[J#*=
M0]&V<EG&U*0R5BIXD,M=\<P$!<PR&,N9S=R+.._=MH!*^83/YPT,12P]^'&-
MG;F+$OA4XW!SH9SPT"-#S._CL^_NL>7])&>DP<EP9>IB+$.!K9""%T#'>O32
M \^//W-UK0^)WM=AZ3MOMLO.DR\>1<V< L9&UIJG@T^$=>9&][/?VE?HB(B(
MB(B(B(B(B(B(B+Q)%'(YCI(V/+#R:7#?$_$?!8VTJK P,K0M#&EK0& <0?,#
MYBJK%],8[&YO*92O&?'ONB<]K@WC'X<8C;P 'L^R._=9+^1I8_(5VR5)G6;3
MO CDCBV7D-<_COZ&./?MV63&38_)T9(H:S!7CE?$Z%\8 #F/+3[/E\H%3/5J
MKWR/\&)SR?;=Q!).M=_J.OH5/C\W@[=.*W3X&)TYQS2(M%KPXMX$:V!L?1K1
M]ZGW9,90Q=AUMM>*A787R@M'!C0.1V/\UEB?5DL2RLB;XK&AIF+/-I[Z#O>%
M[C@J^"8&0Q")P)\,-'%P/GV^M5N8O8?#L<R["QL;X3+(&0<@(H];<[0^2W84
MC)R8_'4H;-FNSPX7LBA#8@2USWM8T-'NVXM"]U;E&\_Q&!IF@>8B)&Z?$[0V
MWOW&P6_2"#W!"R>KT3'$SP("R-VXV\!IKM^[X'S5!+TGCK/4C<S9M6K,D4PE
MBKR2-,,4G'B' !H)(!.N1.M]M=E;SRXZ*Z:7J[)+$C><C&1<M,>=<G_ .+3Y
M^?$_ Z]12XN_$YS!6FC@<Z$DM!##\ES?F^"^L?C);\U5C*[K<0CFD9P'(#9#
M'']TZ^&E ZAP=;,5(X&6[% >+X_.F6-<YWEWY-<#Y^>M[UW4W!8K'X?#5\7C
MH6QTZK/#:S?+0\SLGS)WLD^>UF%:@!P%>L YG#B&-[M[GCKX>9TO,$N.MWI&
M1"&2U3(8[3071;&];]W8^Y9P*S9GR!L8ET ]V@#KW;/P7@5J(9XH@KAH>9.7
M$=G^]WT_.L6.FI9*-]N"$$LED@+GL =RBD<P]_AR:=+%B+.+R%0V:$<7A1N=
M #X7#7?N!L#V3V(([.!!&]J2:U 0Q@P5O"[%@XMUV&AKZCI>W5ZC0QKH(=1-
M(:.(]AI&B!\ =*)D9<=CL;<LSUX_ KUG.E:R,$F)K2>.O>- Z'DJ>3&8W$=1
MP9J9]RQ<N-]2J0Z#F0-XF0LC: .((C).R?DZ'P5]6GHY:I#.P,G@>=LYL_K
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M;VWLZ>YAT1KV/H4V_@+5OU1M?&BM68ZHV>L2PB3A88\N\]$-:U_SGEY=E?\
M3N/?C\OGB:HBAM6F3Q2-#0'-$$4>M#N#R8X^6N_SK5<I@\OD;(D.+$/BUG,L
M1L,087^L0/ V#MXXME.W >_L"[2MF8"R<]-+.V5L0MQSUI8&Q@1QM8T>&2?:
M:-AX( ((>?>3K[UE1R5]SHJ= 2<&Q20SM\/D'MDY$$N(+=:!!&]G?EI81BLC
M!+;U1]9@KN\&HQY8=Q22>)(X-)T>/L,:'$?FR??WJ6=.9CC /4G!K)9B&ET8
MXM=>AE:- Z'L,<=#X:\]+UG<)F<E)8D;BO#=+0L0R1,?&QCWF:%S!R#MN]EL
MAY. UL]AO2F7<#E)LL;&-KFA$7N\)I+/R+_596>+H$CNYS!H;^3M772F(DI/
M?/+%8KR&O%"Z)WA^&2WD=CCYGVB-G6QI:W=P66R N228ID#YL>6/A:8@PS"1
MK@T$';NW/3G:\SY;TMIZGJW)\=4LXNN_UZN[<</)K=<V&,@G>M-Y\O\ R=E2
M'INQ ;$=>J_U;&Q-.- D ,CO%$SF]SV&XV,[Z[;]WGBDZ8NVFMK2PF&&6-^0
MDD$@)9?<WCV'P'(N^&P/JDT\3D7W:=JQ1?$+DPO7XS*UQ8^/D8F'1TYW>$;'
M;\CW/EN)DJ<^3SW4#*U!XN2P5/"G<Y@-9WM'9[[!'G[.]ZU\%+HX*S6L"Q8H
M">(V[SY*X#"7^),712[)T=,Y#1/_ /9\RB?@[D3=QDEFFV>"LQC+3"\?]H!<
MXL;YZ<(.0(+O,DD=P%@QE#)RT)<A4W8R-*<X^J00/%ABYP\G$D#Y3WR'7O8!
MW5G)T]9KLGJ5H72$NKBE;/$FI'&UC>)V=G1:]_;S\31]ZBP]/WX9(HS2)IQ6
M;\DD<;8G"0S3<XG@..CQ87-.]$<NVPKFUC;3,7BJ<45BU#1=#XS+#F%UI@86
MZ)WHN:XM>=Z!+=>]0[6)NS/N&*FZ.:Q)"^I.0P&DQH;MA )\G![]#8//7Q6"
MITU*)L=)/082,Q=M6"2T[B>;!C)^(VZ(Z]QT==E?])06J6(@IW*\D;X@=.+F
MENB]VFC1]S0WYM$ >_5VB(B(B(B(B(B(B(B(B(B(B(B(B(B(B+PV&-DKY6L:
M)'@!S@.YUY;/UKVB(B(B(B(B(O,<;(P1&QK027$-&NY.R?K))7I$1$1$1$1$
M7EL;&R.>UC0]VN3@.YUY;7I?' .:0X;![$+S#%'!&V.%C8XVC36M&@!\ %[1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%!R^9QF&A9+F,C3H
M1/=Q8^U,V)KCYZ!<1LJJ_#KI+_FC!?S"+[2LK^<Q..HP7,AE*-6G/KPIY[#&
M,DV-CBXG1V._;W*M_#OI'_FG!?S"+[2M+F9Q=+'19"YD:=>A*&EEF6=K(W<A
MMNG$Z.QY?%5?X==(_P#-."_F$7VE939W$P8IF3GRE&/&OUPMOL,;$[?EIY.C
MOZ56_AWTC_S3@OYA%]I6,F>Q$6*;DY<I19C7:+;;IV"$[.AI^]>?;S5=^'72
M/_-."_F$7VE9_?O%?>G[Z??*E][-<O6_';X.MZWSWK6^WGYJL_#KI'_FG!?S
M"+[2L8L]B)<2[*192B_&-WRMMG881HZ.W[UY]O-5WX==(_\ -."_F$7VE8PY
M[$3XM^3@RE&3&Q[YVV3L,+=>>W@Z&OI5=^'72/\ S3@OYA%]I6=3-XJYCI,A
M3R5.Q0C#B^S%,U\30T;=MX.AH>??LJS\.ND?^:<%_,(OM*QH9[$9&E-<Q^4H
MVJ<&Q+/!.U\<>AL\G Z&AW[^Y5WX=](_\TX+^81?:5CC\]B,E4FM8[*4;=:'
M?BS5[#)&,T-GD02!V[]U7?AWTC_S3@OYA%]I66,SN)RM::QB\I1NP0_G9*]A
MDC6=M]RTD#MW5;^'72/_ #3@OYA%]I6>(S6+S+)'X?)4K[(B ]U6=LH:3Y \
M2=*M/7720)!ZHP0([$'(1=O_ %*PQ&>P^:=*,/E:%\Q &05;#)>&]ZWQ)UO1
M_8J]W7'2;'%K^I\&UP.B#?B!'_J4_$=08;-/D9A\MC[[H@"\5;#)2P'RWQ)T
MH,G6_2D<CF2=38-CVDM<UU^($$>8(Y*;B.H<+FI)(\/E\??DC')[:MEDI:/B
M>).E%L]9]+U;,M>SU)A89XGF.2.2]$US' Z+2"[8(/;2D8KJ;!9BRZOB<UC;
MT[6>(Z.K:9*X-V!LAI)ULCO\X4>UUETQ4LRU[74>&@L1.+)(I+T37,</,$%V
MP?F6?%=3X'+V36Q.;QEZP&EYBK6F2O#1H$Z:2==QW^=8;?6/3-.S+6N=18>O
M8B<6212W8V/8X>8(+M@K+C.J,!EK7JV*S>,NV>)=X5:U'*_0\SII)UW"\7^K
M>G,=;DJ9#/XFK:CT'PSW(XWMV-C;2=CL05]Q_5G3N2MLJX[/8JW:?OA#7N1R
M/=H;.F@DGL"5\R'5O3F-N25,CG\34M1ZYPSW(XWMV 1MI((V"#]:8_JWIS)7
M(ZF.S^)MVI-\(8+D<CW:!)TT$D]@3]2^Y'JSIW&7'U,EGL54M,T7PV+D<;V[
M&QMI((V#M?*'5W3F1MQU<?G\1:M2;X0P7(WO=H;.F@[/8$KUDNJ^GL7;=5R>
M=Q5.RT NAL6XXW@'N/9<05YH]7=-Y"W'5H=08BU:E.F0PW8WO>?/LT'963*]
M38'$6A6RV:QE&P6\Q%9M,B<6^6].(.NQ[_,L%7K+IBW9BKU>H\-/8E<&1Q1W
MHG.>XG0  =LD_!2,MU+@L/9;7R^9QM"=S ]L=JTR)Q:21L!Q!UL'O\Q4:MUG
MTO:L105NI,+-/*\1QQQWHG.>XG0  =LDGMI2LMU'A,/.V#+YC&T)G-YMCM6F
M1.+=D; <0=;![_,HL'6O2UB>.&OU)A99I'!C(V7HG.<XG0  =LDGW*;E\_A\
M*^)N8RV/H.E!,8M6&1%X'GKD1OS"KV]<])N<&MZGP;G$Z %^(DG]Y6&7SV'P
MIB&8RM#'F;9C%JPR+GK6]<B-ZV/VJN'7721( ZHP1)]PR$7VE8Y?/8C#>%]^
M,I1Q_B[\/UJPR+GK6]<B-ZV/VA5WX=](_P#-."_F$7VE9Y;-8O#Q,ER^2I4(
MY#Q8^U.V(./P!<1LJL_#OI'_ )IP7\PB^TK+(YW$8VI#:R.4HU*L^A%-/.V-
MDFQL<7$Z/;OV5;^'72/_ #3@OYA%]I6-_/8C'TH+F0RE&K3GT(IYYVLCDV-C
MBXG1V 3V]RKOPZZ1_P":<%_,(OM*QNY[$4,?!?O92C6HS\?"L33M9')R&V\7
M$Z.P"1KW*N_#KI'_ )IP7\PB^TK.UF\54QC,E:R5*#'2!KF6I)VMB<'?)(>3
MH@[[=^ZK/PZZ1_YIP7\PB^TK&7/8B+%-RDN4HLQCM$6W6&"$[.A[>^/GV\U7
M?AUTC_S3@OYA%]I63\[B68@95^4HMQ9UJX;#/!/?C\O?'S[>?FJW\.NDO^:<
M%_,(OM*T;FL6_$'*LR--V, +O6Q.TPZ!T3SWQUL:\_-5?X==(_\ -."_F$7V
ME909S$V,7)DX,G1EQL>^=IEAAB;KSV\'0U]*K?PZZ2_YHP7\PB^TK*MG<3:Q
MDN2K92C-CHM^):CL,=$S7GMX.AKW]U6_AUTC_P TX+^81?:5I0S6+R-"2]0R
M-.U2BWSL0SM?&W0V=N!T-#N55_AUTC_S3@OYA%]I6..SV(R=6:SC<I1N5H21
M++7G9(QFAL\G Z';OW5=^'72/_-."_F$7VE8XS/8C*UYI\7E*-V"'M+)6G;*
MUG;?M%I.NRKOP[Z1_P":<%_,(OM*SQ&<Q6:;([#Y.E?;&0'NJSME#"?($M)T
MK!$1-)H?!-#X)I-#6M=DTF@FDT/@FDT/@$TFA\ FDT$TFA\ FDT/@$TFA\$T
MFDTFA\$T/@FA\$T/@F@FD1-#X)H?!-#X)H?!-!-#X)I-)H?!-#X)H?!-(B)H
M)H?!-#X)H?!-!-#X(FDT/@FDT/@$TFA\ FDT$TFA\ FDT/@$TFA\$TFDT$T-
M>2:3L!KLOG;YD[?,G;YE][)V^9.WS)V^9-#X!-!$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1574+&OK0A\;Y8Q,TR,:POVWO[AY^Y
M5#H<O'9H/9 ]T,3Y"UKI_<YLG$2>>]?DQ[_?Y]E@;#F15@8Z*8\;HDD/C^VX
M>(P_N:+CKY@/)?98;+XYI((IG->X^#"8I(QR(^41YAS2/E$@$GW$ JPN4\A:
MLT18,3!%')N2/;R3N/1'R>+CIWQ'FH->N(L=#6?7DV'\668ZTC7#36[D+>Y#
M][ )^&_+SSRM+IK[C#+X$I:T;JR.',$[);O;_=[0T/+X++C8LHS-TW6XY!7;
M4,9)FY ._)G;OBXGD-_ ?2MD1$1$6M]?]88[HCIV7+97FY@(CBBCUSE>?)HW
M]9/P *T&CZ1NO[M6.Q5]&EET$@VPR7A&XC_PN:"/V+/^'GI%_5E-_,F?93\/
M/2+^K*;^9,^RGX>>D7]64W\R9]E/P\](OZLIOYDS[*?AYZ1?U93?S)GV4_#S
MTB_JRF_F3/LI^'GI%_5E-_,F?93\//2+^K*;^9,^RGX>>D7]64W\R9]E/P\]
M(OZLIOYDS[*?AYZ1?U93?S)GV4_#STB_JRF_F3/LI^'GI%_5E-_,F?93\//2
M+^K*;^9,^RGX>>D7]64W\R9]E/P\](OZLIOYDS[*?AYZ1?U93?S)GV4_#STB
M_JRF_F3/LI^'GI%_5E-_,F?93\//2+^K*;^9,^RGX>>D7]64W\R9]E/P\](O
MZLIOYDS[*?AYZ1?U93?S)GV4_#STB_JRF_F3/LI^'GI%_5E-_,F?93\//2+^
MK*;^9,^RGX>>D7]64W\R9]E/P\](OZLIOYDS[*?AYZ1?U93?S)GV4_#STB_J
MRF_F3/LI^'GI%_5E-_,F?93\//2+^K*;^9,^RGX>>D7]64W\R9]E/P\](OZL
MIOYDS[*?AYZ1?U93?S)GV4_#STB_JRF_F3/LI^'GI%_5E-_,F?93\//2+^K*
M;^9,^RGX>>D7]64W\R9]E/P\](OZLIOYDS[*?AYZ1?U93?S)GV4_#STB_JRF
M_F3/LI^'GI%_5E-_,F?93\//2+^K*;^9,^RGX>>D7]64W\R9]E/P\](OZLIO
MYDS[*?AYZ1?U93?S)GV4_#STB_JRF_F3/LI^'GI%_5E-_,F?93\//2+^K*;^
M9,^RGX>>D7]64W\R9]E/P\](OZLIOYDS[*?AYZ1?U93?S)GV4_#STB_JRF_F
M3/LI^'GI%_5E-_,F?93\//2+^K*;^9,^RGX>>D7]64W\R9]E/P\](OZLIOYD
MS[*?AYZ1?U93?S)GV4_#STB_JRF_F3/LI^'GI%_5E-_,F?93\//2+^K*;^9,
M^RGX>>D7]64W\R9]E/P\](OZLIOYDS[*?AYZ1?U93?S)GV4_#STB_JRF_F3/
MLI^'GI%_5E-_,F?93\//2+^K*;^9,^RGX>>D7]64W\R9]E/P\](OZLIOYDS[
M*?AYZ1?U93?S)GV5\/7?I%/_ /S*7^9,^RGX=^D7]64O\R9]E/P[](GZL9?Y
MBS[*?AWZ1/U8R_S%GV4_#OTB_JRE_F3/LI^'?I$_5C+_ #%GV4_#OTB?JQE_
MF3/LK[^'GI%_5E+_ #)GV4_#STB_JRF_F3/LJ/>])'7M"K)9N>C2RV",<GF.
M\)' >\@-:25T#H'J_'=:]/0Y;%%XC>2R2*37.)X\VNT3\Q'S$%;&B(N+?=$G
MQ<SZ/*<K6OK3YAOB,< 0[3HQW^;3CV^==H: T:"^HB(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(A&P0?>N0_<ZQ,AJ=9Q1,:R-F?L-
M:UHT  &@ !=>1$7%?NA?Z3^C7^^!_KB7:D1$1$1$1$1$1$1$1$1$7QV]=EPJ
M3TRRM]$EK+_?'#_A7'*6,I;&RT3AOYOER^1L_P":V3TJ=?Y7IO*4:>!@@LR0
MUG9/),D:2YE5KVM);KR))=W/P7KKGK:_2ZEZ=I8K*XK'X_)4IK9N7HN;-- <
MW^NW0=O7UJ)T_P"D3-VY^BK66IUZF/SIGJ3 ,<.$[2?#<TD]FO [ IE?2)EH
M\7U/=I-JGAEF87"QOC),T^PUY=H^T-EQ&M?)*QY+TCY:+T0OS\0J19RI;;0N
M,?&3'',)0Q_L[WK1#AW]X66KU[FQC.N Z7'9$X*IX]7)U(BV"=YC<[B6\G#;
M2-'3EZH]:]28F/I&YU#][KN)ZA,$0FK0NADJS3,#F-(+G!S?,;['L3V\E;>E
MGJR]TQ/T[%2NT,?#D;;H)[=R/FR%H;OEKDW_ *J@PWI#Z@LW>F8+,5,PY#+6
M:)M1Q.$=N"-H+9H@7'0<=]^X^"LHNK>J,Y3S^9Z<CQ3,7B9YH(:]ECG27C%\
MMW,. C'Z/8[/GH=U!S'I.L3R])C'VJ.%I9JJ;+LAD8C+&QXT/!&G-'+?F20/
M)7N5ZGSDW5-#IC C'.R#J(O7;T[7&&%A/$<(PX%Q)[CVNPUOSV(V2ZGZ@P_6
M%'!W9Z%GGB;-V26*NZ/D^/?#0+W:[ ;&SW6LX7TC9BYZ/K_4 ZCP-G)08^2T
M[$PU=2P$. !>?%)UW']4?*"EX_TG9:WA>DW20UH<K;S,.,R<)82&M>WD',[]
MN32UP/?S*O\ !=1=3=77<I+@'XK'XBC:DJ12VH7V)+3XSIQTU[ QA.OB>WSJ
MKJ];Y*YZ0\WA)^H\)B8J5R&O6K6*W.:V'@$AI,K>^SKL#YCZ^LG>NWFN!W_2
MQU/7QN+M5ZM2U)+EKM::%D1!?!!Q=IOM=G<>7?Z.RV>YZ4/4LUU%.?!L8.AA
MX,E6+!Q?*Z37$%WP)('EVVMJZ2?U9=BJY#.S8F""Q'S=0KP/+XMC8_*E^B>X
M!]G7P*VM$1$1$1$1$1$1$1$1$1$7)/N>_P UUM_B&S_M76T1%Q7[H7^D_HU_
MO@?ZXEVI$1$1$1$1$1$1$1$1$1$=Y+DCO1A>=Z&;71WK5/[X33&06>+N 'K
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MHV9^HHXX+$EJ4PUV%I\*#EJ,.()!=H;)!]ZT+!^C+(X_(8&>6Y4>S'9:YD)
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M(9(N/LCE[1.^6M#XJ[Z3P?4O2%&IC*D5*QZ[FI[5NP"7,@JNV[R/$\R= :!
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MPFU")90#&TO&W ^1 ]^UCPF1;E,/4OL8YC;$8D#"=D;]R\87,09?UGP(Y8_
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M[K&[(U!/) ;,/C1@ES.8Y- &^X\_(@_6HF#S,.5Q R<9:RH_;FDO!(:/>[W
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M3/T:-*&SX\4K)7P!G"1IVR65D8D'_=!>#M279;',ACE?>JMB>[@UYE:&N=\
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M2!WBRGEMS"6GCOF7D.V.8!&N[CXM=*6'5,ZVLQHDOXN:M&97[<)I'RO.R
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MO(>$1]86OOZ5O^!C&P/BA]3HU('-:0 ]T+^1;W:1KW@Z/?796UO!23=*9*C
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M#?E$#^L1H]_+S]WGV7B[F:,%2S,VQ'.8"&.CA<'OYD\6LT#\HN[ 'WK*W)4
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M<V0.?X;&!D9#GM(T=.<X:V.9UL^<#%]*9"+ MJSMKFR*^-:0Y^VR.K\2]CB
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M+1*6N ([;\QONK9URNSQ!)/$TQ-YR O X-^)^ 7QEZI)*V)EJ!TK@2&"0$D
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M^C4FQ\0FCEDOR^% &/;[1XEQ.R?+33]>A[U(NY:G3N4ZMBQ$RQ:<61,<>[B
M3_[+SA,Q4R^*K7Z[PV.:!D_![ARC:YH< [1['14Z*:*:,20R,D8X;#FG8/UK
M$;U0,D>;,(;&>+SS&FGX'X+T;==LK8S/$)' %K2\;._+0^H_L6-V0I-@\9UN
MN(=EO,R#CL;)&_J/[%[DNU8V1ODLPL9(0&.<\ .)\@/BL=K(005_&\1CVZ)
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MC+->20Q"6(R ;='R!(^D+U'8@?(8XYHG/&]M:X$C6M]OFV/VA?731-D8Q\C
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MM=M]OCV!4>S?KPUW3"1DC02W37M[N&]M'?S&CV^8J%C,_6R-\U(8IFO'C]W
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M'_4C]J\3V60R,;)L<@X\CY  ;.RLD;V2-Y1N:YNR-M.QV[%&R,<XM:]I</,
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M.&-S6E\9I&$\02 #S<3WUY%5<^$SDN"GJ'&MCF?)-/&^.2(N:]UJ20!SG'L
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M1\HO"#:]ZY9-SVQVB-J26,@;[\FO+3[].'P42#I6_)5C@OML"N^B*O&JZ'G
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MY987!PT>4<CHW?5R8[2EL<'C;3L;TO+IF-#B7#3>Q._)?#-&'AA<.1\AOO\
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MX=_9: )!K?<=NZPY'!Y?(V6RNQ;8!)6X6(FF(,+_ %F!X (=MX#1*07 >9[
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M];^"BY/,4L;!9EM2\17KOLO:!MPC;YG2G<Q\5CG=%$'6'L)<QNN38RYVO@
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M4V'U>7PS$ S@SQGDQMDV>)>._?6M+W8Z.R57)=92=/8>W3=DHJDU5['^&70
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MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(N2?<]_FNMO\
M$-G_ &KK:(BXK]T+_2?T:_WP/]<2[4B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(N2?<]_FNMO\ $-G_ &KK:(BXK]T+_2?T:_WP
M/]<2[4B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MN2?<]_FNMO\ $-G_ &KK:(BXK]T+_2?T:_WP/]<2[4B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(N2?<]_FNMO\ $-G_ &KK:(BX
MK]T+_2?T:_WP/]<2[4B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(N2?<]_FNMO\ $-G_ &KK:(BXK]T+_2?T:_WP/]<2[4B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(N2?<]_FNMO\
M$-G_ &KK:(BXK]T+_2?T:_WP/]<2[4B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(N2?<]_FNMO\ $-G_ &KK:(BXK]T+_2?T:_WP
M/]<2[4B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MN2?<]_FNMO\ $-G_ &KK:(BXK]T+_2?T:_WP/]<2[4B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(N2?<]_FNMO\ $-G_ &KK:(BX
MK]T+_2?T:_WP/]<2[4B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(N2?<]_FNMO\ $-G_ &KK:(BXK]T+_2?T:_WP/]<2[4B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(N2?<]_FNMO\
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M6[$4+K,HAA$CPWQ'D$AK=^9T"=?,I.Q\0BBMR%1V1?0;8B-UD0F="'CFUA)
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M.8<9(I&[:X>?_71W[B%R^W]S[T//+SCBR-=NM<(K/;_U G_-8?Q=NBOT\O\
MQ+?LI^+MT5^GE_XEOV4_%VZ*_3R_\2W[*?B[=%?IY?\ B6_93\7;HK]/+_Q+
M?LI^+MT5^GE_XEOV4_%VZ*_3R_\ $M^RGXNW17Z>7_B6_93\7;HK]/+_ ,2W
M[*?B[=%?IY?^);]E/Q=NBOT\O_$M^RGXNW17Z>7_ (EOV4_%VZ*_3R_\2W[*
M?B[=%?IY?^);]E/Q=NBOT\O_ !+?LI^+MT5^GE_XEOV4_%VZ*_3R_P#$M^RG
MXNW17Z>7_B6_93\7;HK]/+_Q+?LI^+MT5^GE_P");]E/Q=NBOT\O_$M^RGXN
MW17Z>7_B6_93\7;HK]/+_P 2W[*?B[=%?IY?^);]E/Q=NBOT\O\ Q+?LI^+M
MT5^GE_XEOV4_%VZ*_3R_\2W[*?B[=%?IY?\ B6_93\7;HK]/+_Q+?LI^+MT5
M^GE_XEOV4_%VZ*_3R_\ $M^RGXNW17Z>7_B6_93\7;HK]/+_ ,2W[*?B[=%?
MIY?^);]E/Q=NBOT\O_$M^RGXNW17Z>7_ (EOV4_%VZ*_3R_\2W[*?B[=%?IY
M?^);]E/Q=NBOT\O_ !+?LI^+MT5^GE_XEOV4_%VZ*_3R_P#$M^RGXNW17Z>7
M_B6_93\7;HK]/+_Q+?LI^+MT5^GE_P");]E/Q=NBOT\O_$M^RGXNW17Z>7_B
M6_93\7;HK]/+_P 2W[*?B[=%?IY?^);]E/Q=NBOT\O\ Q+?LI^+MT5^GE_XE
MOV4_%VZ*_3R_\2W[*?B[=%?IY?\ B6_93\7;HK]/+_Q+?LI^+MT5^GE_XEOV
M4_%VZ*_3R_\ $M^RGXNW17Z>7_B6_93\7;HK]/+_ ,2W[*?B[=%?IY?^);]E
M/Q=NBOT\O_$M^RGXNW17Z>7_ (EOV4_%VZ*_3R_\2W[*?B[=%?IY?^);]E/Q
M=NBOT\O_ !+?LI^+MT5^GE_XEOV4_%VZ*_3R_P#$M^RGXNW17Z>7_B6_93\7
M;HK]/+_Q+?LI^+MT5^GE_P");]E/Q=NBOT\O_$M^RGXNW17Z>7_B6_93\7;H
MK]/+_P 2W[*?B[=%?IY?^);]E/Q=NBOT\O\ Q+?LI^+MT5^GE_XEOV4_%VZ*
M_3R_\2W[*?B[=%?IY?\ B6_93\7;HK]/+_Q+?LI^+MT5^GE_XEOV4_%VZ*_3
MR_\ $M^RGXNW17Z>7_B6_96:I]S[T/!+SDBR-@?H2VCK_P!(!_S74<3C:>(Q
MT%#&5HJM.!O&.*)O%K1O?E]))^M2T1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
7$1$1$1$1$1$1$1$1$1$1$1$1$1%__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
